Document:

exv10w1

 

      Confidential
Materials omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote omissions.

Exhibit 10.1

STRATEGIC ALLIANCE & COLLABORATION AGREEMENT

by and between

Adnexus Therapeutics, Inc.

and

Bristol-Myers Squibb Company

February 14, 2007

 

 

Strategic Alliance and Collaboration Agreement

Table of Contents

	 	 	 	 	 
	 	 	Page
	ARTICLE — 1 DEFINITIONS
	 	 	1	 
	 
	 	 	 	 
	ARTICLE — 2 PROGRAM AND TARGET SELECTION
	 	 	13	 
	 
	 	 	 	 
	2.1 Programs Generally
	 	 	13	 
	2.2 Initial Programs
	 	 	14	 
	2.3 Substitution With Respect to [**]
	 	 	14	 
	2.4 Selection of [**]
	 	 	15	 
	2.5 Selection of [**]
	 	 	15	 
	2.6 Guidelines Applicable to all Programs
	 	 	16	 
	 
	 	 	 	 
	ARTICLE — 3 GOVERNANCE AND COMMITTEES
	 	 	16	 
	 
	 	 	 	 
	3.1 Joint Research Committee
	 	 	16	 
	3.2 Meetings of JRC and DWG
	 	 	17	 
	3.3 Alliance Managers
	 	 	18	 
	 
	 	 	 	 
	ARTICLE — 4 DEVELOPMENT
	 	 	18	 
	 
	 	 	 	 
	4.1 Research Plans
	 	 	18	 
	4.2 Annual Reports
	 	 	19	 
	4.3 Obligations Relating to the Programs and the Research Plans
	 	 	19	 
	4.4 Commencement of a [**]
	 	 	20	 
	4.5 Compliance with Applicable Laws
	 	 	20	 
	4.6 Records
	 	 	20	 
	4.7 Subcontracting
	 	 	21	 
	 
	 	 	 	 
	ARTICLE — 5 REGULATORY MATTERS
	 	 	21	 
	 
	 	 	 	 
	5.1 Overview of Regulatory Responsibilities
	 	 	21	 
	5.2 Ownership of Regulatory Materials
	 	 	21	 
	5.3 Communications with Regulatory Authorities
	 	 	21	 
	 
	 	 	 	 
	ARTICLE — 6 MANUFACTURE AND SUPPLY
	 	 	21	 
	 
	 	 	 	 
	6.1 Pre-Clinical Research Supply
	 	 	21	 
	6.2 Clinical and Commercial Supply
	 	 	22	 
	6.3 Transfer of Manufacturing
	 	 	22	 
	 
	 	 	 	 
	ARTICLE
— 7 COMMERCIALIZATION
	 	 	23	 
	 
	 	 	 	 
	7.1 Commercialization of Licensed Product
	 	 	23	 
	7.2 ATI’s Co-Promotion Option
	 	 	23	 

i

 

Strategic Alliance and Collaboration Agreement

	 	 	 	 	 
	 	 	Page
	7.3 Promotional Materials and Activities
	 	 	26	 
	7.4 Statements and Compliance with Applicable Law
	 	 	26	 
	7.5 Sales and Distribution
	 	 	27	 
	7.6 Reporting
	 	 	27	 
	 
	 	 	 	 
	ARTICLE — 8 LICENSE GRANTS AND EXCLUSIVITY
	 	 	27	 
	 
	 	 	 	 
	8.1 License Grants
	 	 	27	 
	8.2 Grant-Back to ATI for Adnectin Core Manufacturing and Formulation Technology
	 	 	27	 
	8.3 Exclusivity for BMS
	 	 	28	 
	8.4 License to Certain Regulatory Data
	 	 	30	 
	8.5 PROfusion License Grant
	 	 	30	 
	8.6 License Agreement Between [**]
	 	 	30	 
	8.7 Sublicensing Rights
	 	 	31	 
	8.8 Transfer and Use of Materials
	 	 	31	 
	8.9 No Other Licenses
	 	 	32	 
	 
	 	 	 	 
	ARTICLE — 9 BMS PAYMENTS AND ROYALTIES
	 	 	32	 
	 
	 	 	 	 
	9.1 Up-Front Payment
	 	 	32	 
	9.2 R&D Support and Expense Payments
	 	 	32	 
	9.3 Milestone Payments
	 	 	33	 
	9.4 Royalties
	 	 	36	 
	9.5 Payment Terms
	 	 	38	 
	9.6 Mutual Convenience of the Parties
	 	 	40	 
	 
	 	 	 	 
	ARTICLE — 10 INTELLECTUAL PROPERTY; PATENT PROSECUTION AND MAINTENANCE
	 	 	40	 
	 
	 	 	 	 
	10.1 Ownership
	 	 	40	 
	10.2 Disclosure
	 	 	41	 
	10.3 Patent Prosecution and Maintenance; Abandonment
	 	 	41	 
	 
	 	 	 	 
	ARTICLE — 11 ENFORCEMENT OF IP RIGHTS; DEFENSE OF THIRD PARTY INFRINGEMENT CLAIMS
	 	 	45	 
	 
	 	 	 	 
	11.1 Enforcement of Patent Rights
	 	 	45	 
	11.2 Defense of Third Party Claims
	 	 	49	 
	11.3 Copyright Registrations
	 	 	49	 
	11.4 Patent Marking
	 	 	49	 
	 
	 	 	 	 
	ARTICLE — 12 Complaints and Adverse Event Reporting
	 	 	49	 
	 
	 	 	 	 
	12.1 Adverse Event Reporting
	 	 	49	 
	12.2 Pharmacovigilance Agreement
	 	 	50	 

ii

 

Strategic Alliance and Collaboration Agreement

	 	 	 	 	 
	 	 	Page
	ARTICLE — 13 PRODUCT RECALLS
	 	 	50	 
	 
	 	 	 	 
	ARTICLE — 14 CONFIDENTIAL INFORMATION AND PUBLICITY
	 	 	51	 
	 
	 	 	 	 
	14.1 Confidentiality
	 	 	51	 
	14.2 Terms of this Agreement; Publicity
	 	 	52	 
	14.3 Publications
	 	 	53	 
	14.4 Relationship to the Confidentiality Agreement
	 	 	54	 
	 
	 	 	 	 
	ARTICLE — 15 WARRANTIES; LIMITATIONS OF LIABILITY: INDEMNIFICATION
	 	 	54	 
	 
	 	 	 	 
	15.1 Representations and Warranties
	 	 	54	 
	15.2 Disclaimers
	 	 	55	 
	15.3 No Consequential Damages
	 	 	55	 
	15.4 Performance by Affiliates
	 	 	55	 
	15.5 Indemnification
	 	 	55	 
	15.6 Insurance
	 	 	58	 
	 
	 	 	 	 
	ARTICLE — 16 REVERSION RIGHTS FOR DILIGENCE FAILURES
	 	 	58	 
	 
	 	 	 	 
	16.1 General
	 	 	58	 
	16.2 Reversion
	 	 	58	 
	 
	 	 	 	 
	ARTICLE — 17 TERM, TERMINATION AND SURVIVAL
	 	 	59	 
	 
	 	 	 	 
	17.1 Term
	 	 	59	 
	17.2 Termination by ATI
	 	 	59	 
	17.3 Termination by BMS
	 	 	60	 
	17.4 Termination by Either Party
	 	 	60	 
	17.5 Effects of Termination
	 	 	61	 
	17.6 Survival
	 	 	63	 
	 
	 	 	 	 
	ARTICLE — 18 GENERAL PROVISIONS
	 	 	64	 
	 
	 	 	 	 
	18.1 Assignment
	 	 	64	 
	18.2 Change of Control of ATI
	 	 	64	 
	18.3 Force Majeure
	 	 	65	 
	18.4 Severability
	 	 	65	 
	18.5 Amendment; Waiver
	 	 	65	 
	18.6 Notices
	 	 	66	 
	18.7 Dispute Resolution
	 	 	66	 
	18.8 Governing Law
	 	 	67	 
	18.9 Jurisdiction
	 	 	67	 
	18.10 Further Assurances
	 	 	68	 
	18.11 Cumulative Remedies; Irreparable Harm
	 	 	68	 
	18.12 Relationship of the Parties
	 	 	68	 

iii

 

Strategic Alliance and Collaboration Agreement

	 	 	 	 	 
	 	 	Page
	18.13 Entire Agreement
	 	 	68	 
	18.14 Headings
	 	 	68	 
	18.15 Waiver of Rule of Construction
	 	 	68	 
	18.16 Interpretation
	 	 	69	 
	18.17 Counterparts; Facsimiles
	 	 	69	 

iv

 

Strategic Alliance and Collaboration Agreement

List of Exhibits

	 	 	 	 	 
	Exhibit A (Exhibits A-1, A-2, A-3)
	 	 	 	 
	 
	 	 	 	 
	Exhibit A-1
	 	Program One
	 
	 	 	 	 
	Exhibit A-2
	 	Program Two
	 
	 	 	 	 
	Exhibit A-3
	 	Program Three
	 
	 	 	 	 
	Exhibit B Production Form Definition
	 	 	 	 
	 
	 	 	 	 
	Exhibit C PROfusion Patents
	 	 	 	 
	 
	 	 	 	 
	Exhibit D ATI Foundation Patents
	 	 	 	 
	 
	 	 	 	 
	Exhibit E ATI Target Patents
	 	 	 	 
	 
	 	 	 	 
	Exhibit F Research Plan
	 	 	 	 
	 
	 	 	 	 
	Exhibit G Press Release
	 	 	 	 
	 
	 	 	 	 
	Schedule 2.3(b)
	 	 	 	 

a

 

STRATEGIC ALLIANCE & COLLABORATION AGREEMENT

     This Strategic Alliance & Collaboration Agreement (this “Agreement”), dated as of February 14,
2007 (the “Effective Date”), is made by and between Adnexus Therapeutics, Inc., a Delaware
corporation (“ATI”), and Bristol-Myers Squibb Company, a Delaware corporation (“BMS”). ATI and BMS
are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”

     WHEREAS, ATI has developed and owns or has rights to certain patents and technology relating
to a new class of protein therapeutics named “Adnectins” (as defined below), and methods of making
and using the same, and is the leader in the discovery, development and commercialization of
Adnectins;

     WHEREAS, BMS has specialized experience in, among other things, clinical development and
commercialization of pharmaceutical products, and desires to collaborate with ATI in the research,
development and commercialization of pharmaceutical products containing Adnectins; and

     WHEREAS, ATI and BMS each desire to collaborate to develop and commercialize pharmaceutical
products containing one or more Adnectins against certain specified protein targets in certain
specified product forms, all in accordance with the terms and conditions set forth below.

     NOW, THEREFORE, the Parties hereby agree as follows:

ARTICLE — 1DEFINITIONS.

     The following terms and their correlatives shall have the following meanings:

     1.1 “Adnectin” shall mean a protein based [**] human fibronectin [**]. For clarity,
references to an Adnectin do not include [**].

     1.2 “Adnectin Core Manufacturing and Formulation Technology” shall mean Patents and Know-How,
in each case invented or discovered in connection with a Program and [**] (or claiming Inventions so invented or discovered) that cover (i) [**] or (ii) the [**] of Adnectins (and methods of making and using any such [**]), but
shall not include Patents and Know-How that cover [**] (or methods of
making and using any such [**]) of a product comprising both (x) [**] and (y) another [**],
provided however that [**] shall be included in the definition of Adnectin Core Manufacturing and
Formulation Technology.

     1.3 “Affiliate” of a person or entity shall mean any other entity which (directly or
indirectly) is controlled by, controls or is under common control with such person or entity. For
the purposes of this definition, the term “control” (including, with correlative meanings, the
terms “controlled by” and “under common control with”) as used with respect to an entity shall mean
(i) in the case of a corporate entity, direct or indirect ownership of voting securities entitled
to cast more than fifty percent (50%) of the votes in the election of directors or (ii) in the
case of a non-corporate entity, direct or indirect ownership of more than fifty percent (50%) of
the equity

 

 

Strategic Alliance and Collaboration Agreement

interests with the power to direct the management and policies of such entity, provided
that if local law restricts foreign ownership, control shall be established by direct or indirect
ownership of the maximum ownership percentage that may, under such local law, be owned by foreign
interests.

     1.4 “Applicable Law” shall mean applicable laws, rules and regulations, including any rules,
regulations, guidelines or other requirements of the Regulatory Authorities, that may be in effect
from time to time.

     1.5 “ATI” shall have the meaning set forth in the preamble to this Agreement, and shall
include its successors and permitted assigns.

     1.6
“ATI Foundation Patents” shall mean those ATI
Patents covering [**] generally, but excluding [**]. For the avoidance of doubt and
without limitation, Exhibit D lists those Patents that are “ATI Foundation Patents” as of
the Effective Date, which Exhibit shall be updated as provided in Section 10.3(j).

     1.7 “ATI Know-How” means all Know-How Controlled by ATI and its Affiliates, including Know-How
Controlled jointly with BMS, as of the Effective Date and during the Term that is necessary or
reasonably useful for BMS to exercise the rights licensed to it under this Agreement or to perform
its obligations under the Research Plans.

     1.8 “ATI Patents” shall mean all Patents Controlled by ATI and its Affiliates, including
Patents Controlled jointly with BMS, but not the [**] and the [**], as of the
Effective Date and during the Term that are necessary or reasonably useful for BMS to exercise the
rights licensed to it under this Agreement or to perform its obligations under the Research Plans.
For clarity, “ATI Patents” shall include, without limitation, ATI Collaboration Patents and ATI’s
interest in Joint Collaboration Patents to the extent any such Patents satisfy the foregoing
description.

     1.9 “ATI Target Patents” shall mean those ATI Patents with claims specifically covering
Adnectins (including such claims specifically directed to compounds and formulations thereof)
directed against [**], and their Manufacture and use.
For the avoidance of doubt and without limitation, Exhibit E lists those Patents that are
“ATI Target Patents” as of the Effective Date, which Exhibit shall be updated as provided in
Section 10.3(j).

     1.10 “BMS” shall have the meaning set forth in the preamble to this Agreement, and shall
include its successors and permitted assigns.

     1.11 “BMS Regulatory Data” shall mean (i) all Clinical Data arising from Clinical Studies for
Licensed Compounds and Licensed Products, and (ii) all Non-Clinical Data submitted by BMS and its
Affiliates and Sublicensees for Licensed Compounds and Licensed Products to a Regulatory Authority.

     1.12 “Clinical Data” shall mean all information generated and collected in connection
with Clinical Studies, including any data and results with respect to any of the foregoing.

2

 

Strategic Alliance and Collaboration Agreement

     1.13 “Clinical Studies” shall mean (i) Phase 1 Studies, Phase 2 Studies, and Phase 3 Studies,
and such other tests and studies in humans that are required by Applicable Law, or otherwise
recommended by the Regulatory Authorities, to obtain or maintain Regulatory Approvals, and (ii)
Post Approval Studies.

     1.14 “Collaboration Patents” shall mean Patents arising from and covering Inventions first
invented or discovered during the Discovery Term with respect to any Program in connection with
this Agreement, with “ATI Collaboration Patents” and “BMS Collaboration Patents” being solely owned
by each such Party and “Joint Collaboration Patents” being jointly owned by both the Parties in
each case by operation of the terms of this Agreement.

     1.15
“Collaboration Target” shall mean [**] on a Program-by-Program basis. As of the Effective Date, the
Collaboration Targets are listed in Exhibit A for each Program.

     1.16 “Commercialization” shall mean any and all activities directed to the marketing,
detailing, promotion, and securing of reimbursement of any Licensed Product after Regulatory
Approval has been obtained (including using, importing, selling and offering for sale any Licensed
Product), and shall include post-launch marketing, promoting, detailing, marketing research,
distributing, customer service, and commercially selling Licensed Product, importing, exporting or
transporting Licensed Product for commercial sale and regulatory compliance with respect to the
foregoing, including Post Approval Studies but shall not include Manufacturing.

     1.17 “Commercially Reasonable Efforts” shall mean, with respect to the Development or
Commercialization of Licensed Compound or Licensed Product, that level of efforts and resources
commonly dedicated by a Party to the development or commercialization, as the case may be, of an
internally-developed product of similar commercial potential at a similar stage in its lifecycle,
in each case taking into account issues of safety and efficacy, product profile, the proprietary
position, the then current competitive environment for such product and the likely timing of such
product’s entry into the market, the regulatory environment and status of such product, and other
relevant scientific, technical and commercial factors.

     1.18 “Confidentiality Agreements” shall mean (i) that certain confidentiality agreement
between the Parties dated May 1, 2006 and (ii) that certain Consultant’s Confidential Disclosure
Agreement among BMS, ATI and [**] dated January 17, 2007.

     1.19 “Control” shall mean, with respect to any particular Know-How, Materials, Clinical Data,
Non-Clinical Data, Patents or other intellectual property rights, possession by a person or entity
of the right, whether directly or indirectly, and whether by ownership, license or otherwise (other
than by operation of the license and other grants in Article 8), to assign or grant a license,
sublicense or other right to or under, or grant access to, such Know-How, Materials, Clinical Data,
Non-Clinical Data, Patents or other intellectual property rights, to another person or entity as
provided for herein without violating the terms of any written agreement or other binding
arrangement with any Third Party, or be obligated to pay any monies or other consideration
therefor, at the time such assignment or grant is first required hereunder.

     1.20 “Development” shall mean any and all activities related to research, identification,

3

 

Strategic Alliance and Collaboration Agreement

preclinical and other non-clinical testing, test method development and stability testing,
toxicology, formulation, process development, qualification and validation, quality
assurance/quality control, Clinical Studies, statistical analysis and report writing, the
preparation and submission of Drug Approval Applications, regulatory affairs with respect to the
foregoing and all other activities necessary or reasonably useful or otherwise requested or
required by a Regulatory Authority as a condition or in support of obtaining or maintaining a
Regulatory Approval, plus pre-launch marketing, promoting, detailing, marketing research,
distributing, and commercial sales, in each case with respect to Licensed Compound or Licensed
Product (including using, importing and offering for sale Licensed Compound and Licensed Product).

     1.21 “Development Supplies” shall mean supplies of Licensed Compound and Licensed Product (in
bulk, vialed, finished product or other appropriate form, as the case may be) Manufactured in
compliance with Applicable Law for their intended used, ready to be used for the Development of
Licensed Compound and Licensed Product in the Field by the Parties as contemplated hereunder.

     1.22 “Discovery Term” shall mean, with respect to each Program, the period commencing on (a)
the Effective Date for the Initial Programs and (b) the payment of the applicable expansion fee
under Section 2.5 and Section 2.4(c) (if applicable) for all other Programs, and continuing through
the end of the R&D Period with respect to such Program, plus
[**] years.

     1.23 “Discovery Working Group” or “DWG” shall mean the committee described in Section 3.1(c).

     1.24 “Distributor” shall mean any person or entity, other than a Sublicensee or an Affiliate
of BMS, in one or more countries in the Territory that (i) purchases Licensed Compound or Licensed
Product from BMS, its Affiliates or Sublicensees for such country(ies), (ii) assumes responsibility
from BMS for all or a portion of the Commercialization of such Licensed Product in such
country(ies), and (iii) sells Licensed Product in such country(ies).

     1.25 “Drug Approval Application” shall mean a Biological License Application (or supplement
thereof or other application for regulatory approval) as defined in the FDCA and the regulations
promulgated thereunder, or any corresponding foreign application, including, with respect to the
European Union, a Marketing Authorization Application filed with the EMEA pursuant to the
centralized approval procedure or with the applicable Regulatory Authority of a country in Europe
with respect to the mutual recognition or any other national approval procedure.

     1.26 “Drug Master File” shall mean any drug master files filed with the FDA with respect to a
product and any equivalent filing in other countries or regulatory jurisdictions.

     1.27
“ECN” or “Early Candidate Nomination” means a compound or other substance that has
been [**]. This decision point is known within BMS as “Decision Point 3.0” or “DP3”. This
decision point is typically made about [**] prior to the
anticipated filing of the IND for such compound. For such a transition to be considered, the
[**]

4

 

Strategic Alliance and Collaboration Agreement

shall generally need to include[**] based upon [**]; and [**], including [**]. For clarity,
[**] shall be necessarily [**]; however, [**].

     1.28 “EMEA” shall mean the European Medicines Agency and any successor agency thereto.

     1.29 “European Union” shall mean the organization of member states as it may be constituted
from time to time, which, as of the date hereof, consists of Austria, Belgium, Bulgaria, Czech
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia,
Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia,
Spain, Sweden and the United Kingdom and a portion of Cyprus.

     1.30 “FDA” shall mean the United States Food and Drug Administration and any successor agency
thereto.

     1.31 “FDCA” shall mean the United States Food, Drug, and Cosmetic Act, as amended or any
replacement thereof.

     1.32 “Field” shall mean the diagnosis, treatment, prophylaxis and/or control of human or
animal disease.

     1.33 “First Commercial Sale”, with respect to a Licensed Product, shall mean the first sale
for use or consumption by the general public of such Licensed Product in a country after all
required Regulatory Approvals for commercial sale of such Licensed Product have been obtained in
such country.

     1.34 “FTE” shall mean a full-time person, or more than one person working the equivalent of a
full-time person, where “full-time” is determined by the standard practices in the
biopharmaceutical industry in the geographic area in which such personnel are working.

     1.35 “GAAP” shall mean generally accepted accounting principles in the United States,
consistently applied.

     1.36 “Generic Product” means, with respect to a particular Licensed Product in a country, a
pharmaceutical product that: (a) contains the same Adnectin(s), and in the same Product Form, as
such Licensed Product (or equivalent as determined by the relevant Regulatory Authority); and (b)
is approved for use in such country as a generic equivalent to such Licensed Product (pursuant to
21 U.S.C. 355(b)(2), an Abbreviated New Drug Application, a separate Drug Approval Application,
compendia listing or otherwise), whether for use as monotherapy or for use in combination with any
other vaccine, biologic or compound.

     1.37 “HSR Act” means the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended
from time to time, and the rules, regulations, guidance and requirements promulgated thereunder as
may be in effect from time to time.

     1.38 “IND” shall mean an investigational new drug application filed with the FDA for
authorization to commence Clinical Studies and its equivalent in other countries or regulatory
jurisdictions, or first use in humans.

5

 

Strategic Alliance and Collaboration Agreement

     1.39 “Invention” means any invention that arises out of the activities contemplated by this
Agreement and that is invented or discovered by employee(s) or agent(s) of a Party (or their
respective Affiliates).

     1.40 “Joint Invention” means any Invention invented or discovered jointly by employee(s) or
agent(s) of both Parties (or their respective Affiliates).

     1.41 “Know-How” shall mean all commercial, technical, scientific and other know-how and
information, trade secrets, knowledge, technology, methods, processes, practices, formulae,
instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs,
drawings, assembly procedures, computer programs, specifications, data and results (including
biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical,
pre-clinical, clinical, safety, manufacturing and quality control data and know-how, including
study designs and protocols); in all cases, whether or not confidential, proprietary, patented or
patentable, in written, electronic or any other form now known or hereafter developed. Know-How
shall not include Patents or BMS Regulatory Data.

     1.42 “Knowledge” means, with respect of a Party, the good faith understanding of the facts and
information in the possession of an officer of such Party, or any in-house legal counsel of, or
in-house Patent agents employed by, such Party or its Affiliates, without any duty to conduct any
additional investigation with respect to such facts and information by reason of the execution of
this Agreement. For purposes of this definition, an “officer” means any person in the position of
vice president, senior vice president, president or chief executive officer of a Party.

     1.43 “Koseisho” shall mean the Japanese Ministry of Health and Welfare and any successor
agency thereto.

     1.44 “Licensed Compound” shall mean a specific molecule [**] Adnectins,
[**]; provided however, in no case [**].

     1.45 “Licensed Product” shall mean a pharmaceutical composition or preparation, which may be
in finished form labeled and packaged for sale by prescription, over-the-counter or any other
method that contains Licensed Compound as an active ingredient.

     1.46 “Major Market Country” means each of Germany, the United Kingdom, France, Spain and
Italy.

     1.47 “Manufacture” and “Manufacturing” shall mean all activities related to the production,
manufacture, processing, filling, finishing, packaging, labeling, shipping and holding of Licensed
Compound or Licensed Product (or any clone, cell or other biological or chemical materials used for
the foregoing) for Development or Commercialization, including process development, process
qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and
analytic development, product characterization, stability testing, formulation, quality assurance
and quality control.

     1.48 “Net Sales” shall mean the gross amount invoiced or otherwise billed by BMS or its
Affiliate or Sublicensee for sales or other commercial disposition of a Licensed Product to a

6

 

Strategic Alliance and Collaboration Agreement

Third
Party purchaser, less the following to the extent included in such billing or otherwise actually
allowed or incurred with respect to such sales: (a) discounts, including cash, trade and quantity
discounts, price reduction programs, retroactive price adjustments with respect to sales of a
product, charge-back payments and rebates granted to managed health care organizations or to
federal, state and local governments (or their respective agencies, purchasers and reimbursers) or
to trade customers, including but not limited to, wholesalers and chain and pharmacy buying groups;
(b) credits or allowances actually granted upon rejections or returns of Licensed Products,
including for recalls, withdrawals or damaged goods; (c) freight, postage, shipping and insurance
charges actually allowed or paid for delivery of Licensed Products, to the extent billed; (d)
customs duties, surcharges and other governmental charges incurred in connection with the
exportation or importation of a Licensed Product; (e) bad debts relating to sales of Licensed
Products that are actually written off by BMS in accordance with GAAP during the applicable
calculation period; (f) costs due to the factoring of receivables; and (g) taxes, duties or other
governmental charges levied on, absorbed or otherwise imposed on sale of Licensed Products,
including value-added taxes, or other governmental charges otherwise measured by the billing
amount, when included in billing, as adjusted for rebates and refunds, but specifically excluding
taxes based on net income of the seller; provided that all of the foregoing deductions are
calculated in accordance with generally accepted accounting principles consistently applied
throughout BMS’ or its Sublicensee’s organization.

Notwithstanding the foregoing, if any Licensed Product is sold under a bundled or capitated
arrangement with other BMS products, then, solely for the purpose of calculating Net Sales under
this Agreement, any discount on such Licensed Products sold under such an arrangement shall be no
greater, on a percentage basis based on the gross selling price prior to discount, than the largest
percentage discount applied on any other ethical pharmaceutical product sold within such bundled
arrangement for the applicable accounting period. In case of any dispute as to the applicable
discount numbers under the preceding sentence, the determination of same shall be calculated and
certified by BMS’ independent public accountants, whose decision shall be binding.

A sale of a Licensed Product is deemed to occur upon invoicing. In the event that BMS, after
reasonable efforts, cannot calculate accurately the Net Sales of a Sublicensee in a particular
country, the Parties shall meet and negotiate in good faith an appropriate means for calculating
Net Sales in such a situation.

For sake of clarity and avoidance of doubt, sales by BMS, its Affiliates or sublicensees of a
Licensed Product to a Distributor of such Licensed Product in a given country shall be considered a
sale to a Third Party customer. Any Licensed Products used (but not sold for consideration) for
promotional or advertising purposes or used for clinical or other research purposes shall not be
considered in determining Net Sales hereunder except for any payments received for same.

In the event that, in a given country, a Licensed Product is sold as an end-user product consisting
of a combination of active functional elements or as a combined product and/or service, Net Sales,
for purposes of determining royalty payments on such Licensed Product, shall be
calculated in such country by multiplying the Net Sales of the end-user product and/or service by
the fraction A over A+B, in which A is the net selling price of the Licensed Product portion of

7

 

Strategic Alliance and Collaboration Agreement

the
end-user product and/or service when such Licensed Product is sold separately during the applicable
accounting period in which the sales of the end-user product were made, and B is the net selling
price of the other active elements and/or service, as the case may be, of the end-user product
and/or service sold separately during the accounting period in question. All net selling prices of
the elements of such end-user product and/or service shall be calculated as the average net selling
price of the said elements in the applicable country during the applicable accounting period for
which the Net Sales are being calculated. In the event that, in any country or countries, no
separate sale of either such above-designated Licensed Product or such above designated elements of
the end-user product and/or service are made during the accounting period in which the sale was
made or if net retail selling price for an active functional element, component or service, as the
case may be, cannot be determined for an accounting period, Net Sales allocable to the Licensed
Product in each such country shall be determined by mutual agreement reached in good faith by the
Parties prior to the end of the accounting period in question based on an equitable method of
determining same that takes into account, on a country-by-country basis, variations in potency, the
relative contribution of each active agent, component or service, as the case may be, in the
combination, and relative value to the end user of each active agent, component or service, as the
case may be. Notwithstanding the foregoing, the Parties agree that, for purposes of this
paragraph, drug delivery vehicles, adjuvants, and excipients shall not be deemed to be “active
ingredients” or “active functional elements”.

To the extent BMS or its Affiliates or Sublicensees receives consideration other than or in
addition to cash upon the sale or distribution of Licensed Compound or Licensed Product, Net Sales
shall include the fair market value of such additional consideration.

     1.49 “Non-Clinical Data” shall mean all data and results (other than Clinical Data) for a
product (including such data and results for an active agent therein), including biological,
chemical, pharmacological, pharmacokinetic, toxicological, pharmaceutical, physical and analytical,
pre-clinical, safety, manufacturing, stability, and quality-control data, in each case submitted to
a Regulatory Authority in any IND, application for Clinical Studies or Regulatory Approvals
(including any Drug Approval Application).

     1.50 “Party” and “Parties” shall have the meaning set forth in the preamble to this Agreement,
and shall not include any Affiliates of ATI or BMS.

     1.51 “Patent” shall mean a patent or a patent application, including any additions, divisions,
continuations, continuations-in-part, invention certificates, substitutions, reissues,
reexaminations, extensions (including pediatric exclusivity patent term extension), registrations,
patent term extensions, supplementary protection certificates and renewals of any of the foregoing.

     1.52 “Patent Costs” shall mean the out-of-pocket costs and expenses paid to outside legal
counsel and agents and other Third Parties (including Third Party licensors of any Patents),
including translation costs, fees for filing and prosecution and maintenance expenses, in each case
that are incurred in connection with preparing, filing, prosecuting and maintaining Patents.

     1.53 “Phase 1 Study” shall mean a human clinical trial of a product, the principal purpose of
which is a preliminary determination of safety and pharmacokinetics in healthy

8

 

Strategic Alliance and Collaboration Agreement

individuals or
patients, as described in 21 C.F.R. 312.21(a) (as amended or any replacement thereof), or a similar
clinical study prescribed by the Regulatory Authorities in a foreign country, including any
Exploratory IND studies as contemplated by that guidance issued by the FDA on January 1, 2006 (as
amended or any replacement thereof). For purposes of this Agreement, “start of Phase 1 Study” for
a product shall mean the first dosing of such product in a human patient in a Phase 1 Study.

     1.54 “Phase 2 Study” shall mean a human clinical trial of a product, the principal purpose of
which is a determination of safety and efficacy in the target patient population, as described in
21 C.F.R. 312.21(b) (as amended or any replacement thereof), or a similar clinical study prescribed
by the Regulatory Authorities in a foreign country. For purposes of this Agreement, “start of
Phase 2 Study” for a product shall mean the first dosing of such product in a human patient in a
Phase 2 Study. For clarity, a Phase 2 study may be conducted with the intent of supporting
Regulatory Approval.

     1.55 “Phase 3 Study” shall mean a human clinical trial of a product on a sufficient number of
subjects that is designed to establish that a pharmaceutical product is safe and efficacious for
its intended use, and to determine warnings, precautions, and adverse reactions that are associated
with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to
support Regulatory Approval of such product, as described in 21 C.F.R. 312.21(c) (as amended or any
replacement thereof), or a similar clinical study prescribed by the Regulatory Authorities in a
foreign country. For purposes of this Agreement, “start of Phase 3 Study” for a product shall mean
the first dosing of such product in a human patient in a Phase 3 Study.

     1.56 “Post Approval Study” shall mean any human clinical study or other test or study with
respect to a product and an indication that (i) is conducted solely in support of pricing or
reimbursement for such product in a country or (ii) is not required in order to obtain or maintain
Regulatory Approval for such product for such indication. For clarity, any human clinical study
that is intended to expand the Product Labeling for a product after its Regulatory Approval shall
be deemed a Post Approval Study. Subject to the foregoing, Post Approval Studies may include
registrational studies, epidemiological studies, modeling and pharmacoeconomic studies,
post-marketing surveillance studies, post-approval investigator sponsored studies and health
economics studies.

     1.57 “Product Form” shall mean for each Program [**]; provided however, in no case does a Product Form include or
cover [**]. Further aspects of this
“Product Form” definition, which are intended to be generally applicable to all Programs and to
provide guidance with respect to determining [**] as of the Effective Date, are set forth on Exhibit B.

     1.58 “Product Labeling” shall mean, with respect to a country, (i) the full prescribing
information for Licensed Product approved by the relevant Regulatory Authority for such country,
including any required patient information, and (ii) all labels and other written, printed
or graphic matter upon an container, wrapper or any package insert utilized with or for
Licensed Product.

9

 

Strategic Alliance and Collaboration Agreement

     1.59 “PROfusion Patents” shall mean all Patents (other than RCT Patents) Controlled by ATI and
its Affiliates, as of the Effective Date or during the Term that: (a) cover a process or a product
produced by such process by which nucleic acid materials expressing Adnectins are prepared and
identified; and (b) are necessary or reasonably useful for ATI to perform its obligations under the
Research Plan with respect to each Program. For the avoidance of doubt and without limitation,
Exhibit C lists those Patents that are “PROfusion Patents” as of the Effective Date, which
Exhibit shall be updated as provided in Section 10.3(j). For clarity, PROfusion Patents do not
include Patents within the definition of ATI Target Patents.

     1.60 “Program” shall mean any one of the projects that are the subject of this Agreement, each
as described in Exhibit A, and each of which with the specific Product Form as specified on
the applicable sub-exhibit relating to such project within Exhibit A (i.e., Exhibit
A-1, Exhibit A-2, Exhibit A-3, etc.).

     1.61 “Program 1 Target Directed Licensed Product” shall mean a Licensed Compound or Licensed
Product which contains one or more Adnectins directed towards the Collaboration Target of Program
1.

     1.62 “Program 3” shall mean the Program directed against the Target in the Product Form
described in Appendix A-3 hereto.

     1.63 “Promotional Materials” shall mean all sales representative training materials with
respect to Licensed Product and all written, printed, graphic, electronic, audio or video matter,
including journal advertisements, sales visual aids, direct mail, medical information/education
monographs, direct-to-consumer advertising, Internet postings, broadcast advertisements and sales
reminder aids (e.g., scratch pads, pens and other such items) intended for use or used by BMS, its
Sublicensees or Distributors in connection with any promotion of Licensed Product (but excluding
Product Labeling).

     1.64 “R&D Period” shall mean, with respect to each Program, the period commencing on (a) the
Effective Date for the Initial Programs and (b) the payment of the applicable expansion fee under
Section 2.5 and Section 2.4(c) (if applicable) for all other Programs, and concluding upon the
earlier of (x) [**], or (y) the termination of such
Program.

     1.65 “RCT License Agreement” shall mean that License Agreement by and between ATI and Research
Corporation Technologies, Inc., as such agreement may be amended or restated in the future.

     1.66 “RCT Patents” shall mean those Patents licensed to ATI and licensed to BMS pursuant to
the License Agreement between Research Corporation Technologies, Inc. and BMS contemplated by
Section 8.6.

     1.67 “Regulatory Approval” shall mean, with respect to a country, any and all approvals
(including Drug Approval Applications), licenses, registrations or authorizations of
any Regulatory Authority necessary in order to commercially distribute, sell or market a
product in such country, including, where applicable and as required, (i) pricing or reimbursement
approval in such country, (ii) pre- and post-approval marketing authorizations (including any

10

 

Strategic Alliance and Collaboration Agreement

prerequisite Manufacturing approval or authorization related thereto), (iii) labeling approval and
(iv) technical, medical and scientific licenses.

     1.68 “Regulatory Authority” shall mean any supra-national, federal, national, regional, state,
provincial or local governmental regulatory agencies, departments, bureaus, commissions, councils
or other government entities regulating or otherwise exercising authority with respect to the
development, manufacture or commercialization of biological drug products, including the FDA, EMEA
and Koseisho.

     1.69 “Regulatory Documentation” shall mean all applications for Clinical Studies and
Regulatory Approvals (including all Drug Approval Applications), all registrations, licenses,
authorizations and approvals (including all Regulatory Approvals), all correspondence submitted to
or received from Regulatory Authorities (including minutes and official contact reports relating to
any communications with any Regulatory Authority), and all Clinical Data and Non-Clinical Data
submitted to Regulatory Authorities, in each case for a particular product, including all INDs,
regulatory drug lists, advertising and promotion documents, Drug Master Files, adverse event files
and complaint files for such product.

     1.70 “Regulatory Exclusivity Period” shall mean any period of data, market or other regulatory
exclusivity (other than supplementary protection certificates, which shall be treated as Patents
hereunder), including any such periods under national implementations in the European Union of
Section 10.1(a)(iii) of Directive 2001/EC/83 and all international equivalents.

     1.71 “Reverted Compound” shall mean an Adnectin, a Licensed Compound or a Licensed Product
with respect to which BMS has granted a license to ATI pursuant to Section 17.5.

     1.72 “Sole Invention” means any Invention invented or discovered solely by employee(s) or
agent(s) of one Party (or its Affiliates).

     1.73 “Sublicensee” shall mean any person or entity, other than an Affiliate of BMS, that is
granted a sublicense by BMS or any of its Affiliates as provided in Section 8.7(b). For clarity,
any Distributor that is granted such a license limited to only those activities contemplated under
the definition of Distributor in Section 1.24 shall not be deemed a “Sublicensee” hereunder by
virtue of such grant.

     1.74 “Target” shall mean [**].

     1.75 “Third Party” shall mean any person or entity other than ATI, BMS and their respective
Affiliates.

     1.76 “Trademark” shall include any word, name, symbol, color, designation or device or any
combination thereof, including any trademark, trade dress, brand mark, service mark, trade name,
brand name, logo or business symbol, whether or not registered.

     1.77 “United States” or “U.S.” shall mean the United States of America, including its
territories and possessions, the District of Columbia and Puerto Rico.

11

 

Strategic Alliance and Collaboration Agreement

     1.78 “Valid Claim” shall mean, (a) a claim in an issued Patent that has not: (i) expired or
been canceled; (ii) been declared invalid by an unreversed and unappealable or unappealed decision
of a court or other appropriate body of competent jurisdiction; (iii) been admitted to be invalid
or unenforceable through reissue, disclaimer or otherwise; or (iv) been abandoned in accordance
with or as permitted by the terms of this Agreement or by mutual written agreement of the Parties;
or (b) a claim under an application for a Patent that has been pending for [**] years or less from
its date of filing for non-Japanese applications, or [**] years or less from its date of filing for
Japanese applications, and, in any case, which has not been canceled, withdrawn from consideration,
finally determined to be unallowable by the applicable governmental authority or court for whatever
reason (and from which no appeal is or can be taken), or abandoned.

   Definitions for each of the following terms are found in the body of this Agreement as
indicated below:

	 	 	 
	Defined Term	 	Location
	“Active Development or Commercialization”

	 	Section 8.3(c)(iv)
	“Adnectin Class Specific Data”

	 	Section 8.4(a)
	“Adnectin Exclusivity Period”

	 	Section 8.3(c)(ii)
	“Adverse Drug Experience”

	 	Section 12.1
	“Agreement”

	 	Introduction
	“Alliance Manager”

	 	Section 3.3(a)
	“ATI Enforcement Patent”

	 	Section 11.1(b)(i)
	“ATI Prosecuted Patents”

	 	Section 10.3(a)(i)
	“ATI Sublicensee”

	 	Section 8.2(b)
	“[**]”

	 	Section [**]
	“BMS Enforcement Patent”

	 	Section 11.1(a)(i)
	“Change of Control”

	 	Section 18.2(c)
	“Co-Promote” or “Co-Promotion”

	 	Section 7.2
	“Co-Promotion Agreement”

	 	Section 7.2 (a)(iii)
	“Co-Promotion Option”

	 	Section 7.2
	“Co-Promotion Plan”

	 	Section 7.2(a)(ii)
	“Co-Promotion Products”

	 	Section 7.2(a)(i)
	“Co-Promotion Target Audience”

	 	Section 7.2(b)(ii)
	“Co-Promotion Territory”

	 	Section 7.2(b)(iii)
	“Confidential Information”

	 	Section 14.1(a)
	“Cost Terminated Patent Right”

	 	Section 10.3(b)(i)
	“Coverage”

	 	Section 15.6
	“Detail”

	 	Section 7.2(b)(iv)
	“Detail Rate”

	 	Section 7.2(a)(iii)(4)
	“Development Milestones”

	 	Section 9.3(a)
	“Disclosing Party”

	 	Section 14.1(b)
	“Drug Company”

	 	Section 18.2(c)
	“Effective Date”

	 	Introduction
	“Exclusive Alliance Adnectin”

	 	Section 8.3(c)(ii)

12

 

Strategic Alliance and Collaboration Agreement

	 	 	 
	Defined Term	 	Location
	“Exclusivity Notice”

	 	Section 8.3(c)(i)
	“Expansion Option Period”

	 	Section 2.4(a)
	“Expansion Program”

	 	Section 2.5(b)
	“Indemnification Claim Notice”

	 	Section 15.5(c)
	“Indemnified Party”

	 	Section 15.5(c)
	“Intellectual Property”

	 	Section 17.4(a)(ii)
	“Issuing Party”

	 	Section 14.2(b)
	“JAMS”

	 	Section 18.7(b)
	“JRC”

	 	Section 3.1(a)
	“Joint Invention Patents”

	 	Section 10.1(b)
	“Listable Patent”

	 	Section 11.1(d)
	“Losses”

	 	Section 15.5(a)
	“Materials”

	 	Section 8.8(a)
	“Milestone Event”

	 	Section 9.3
	“Milestone Payment”

	 	Section 9.3
	“Nominated Expansion Target”

	 	Section 2.4(a)
	“Oncology Related”

	 	Section 2.3(e)
	“Other Joint Patent”

	 	Section 11.1(c)
	“Possible LC Components”

	 	Section 1.44
	“Pharmacovigilance Agreement”

	 	Section 12.2
	“Program 1 Target”,

“Program 2 Target”,

“Program 3 Target”, etc.

	 	The specific Target(s) defined
for each Program on the
applicable Exhibit A
	“R&D Period”

	 	Section 1.63
	“Receiving Party”

	 	Section 14.1(b)
	“Release”

	 	Section 14.2(b)
	“Research Plan”

	 	Section 4.1
	“Reviewing Party”

	 	Section 14.2(b)
	“Safety Reasons”

	 	Section 17.5(a)(vii)
	“Sole Invention Patents”

	 	Section 10.1(b)
	“Substitution Target”

	 	Section 2.3
	“Supplemental Program”

	 	Section 2.5(a)
	“Term”

	 	Section 17.1
	“[**]”

	 	Section [**]
	“Terminated Rights”

	 	Section 17.5(a)
	“Third Party Claims”

	 	Section 15.5(a)

ARTICLE — 2 PROGRAM AND TARGET SELECTION.

   2.1 Programs Generally. Under this Agreement, the Parties shall establish Programs, each of which
shall have the Product Form specified in the applicable Exhibit A for such Program. The
purpose of each Program shall be to Develop and Commercialize in the Field one or more

13

 

Strategic Alliance and Collaboration Agreement

Licensed
Compounds and corresponding Licensed Products in the applicable Product Form for such Program.

   2.2 Initial Programs. The Parties shall initially establish three Programs (the “Initial
Programs). The applicable Product Form for each of the three Initial Programs is set forth on
Exhibit A. The Parties understand and agree that the goal of the Initial Programs and this
Agreement, as of the Effective Date, is to [**].

   2.3 Substitution With Respect to [**].

     (a) In the event that either (i) the Parties are [**]; or (ii) the JRC determines that [**],
then BMS shall have the right to substitute another Oncology Related Target in place of [**] and to commence a Program (and corresponding Product Form) utilizing a Substitution Target
designated by BMS in the manner set forth in clause (b) below. For clarity, (I) such right of
substitution shall only be available once and solely with respect to [**], and (II) no expansion
fees shall be due under Section 2.4(c) with respect to any such substitution.

     (b) BMS may nominate an Oncology Related Target to be the Substitution Target by providing
written notice to ATI, which notice shall contain a reasonably detailed description of the Oncology
Related Target which is being nominated for substitution. Within ten (10) calendar days subsequent
to receipt of such written nomination, ATI will notify BMS as to whether [**] for the discovery
and/or development of Adnectins generated against such Oncology Related Target. If ATI notifies
BMS that such Oncology Related Target is not [**], or if BMS receives no such notice
within such ten (10) day period, BMS may designate such Oncology Related Target as a Collaboration
Target, [**] will be terminated and a new Program directed against such Substitution Target (and
corresponding Product Form) shall be established, and thereafter such Oncology Related Target will
be available to BMS for use in selection of additional Programs (and corresponding Product Forms)
pursuant to Section 2.5 (if applicable). In the event that ATI notifies BMS that such Oncology
Related Target is [**], then BMS will be free to nominate another Substitution Target to be
substituted as described herein, until such time as a new Collaboration Target has been selected.
Any dispute as to whether [**] or as to whether a Target is a Substitution
Target or Oncology Related shall be referred to dispute resolution as set forth in Section 18.7.
For clarity, once a Substitution Target has been accepted by ATI, ATI shall be deemed to have
waived its right to dispute resolution under Section 18.7(b) as to whether [**] or as to whether a Target is a Substitution Target or Oncology Related or an ATI Target. In
addition, ATI may reject any Target nominated by BMS under this Section 2.3 or 2.4 as (i) set forth
on Schedule 2.3(b) or (ii) for which ATI has [**].

     (c) For purposes of this Section 2.3, “Substitution Target” shall mean a Target for which, as
of the date of nomination of such Target as a Collaboration Target to be substituted for the
Target of [**], there are, based on a reasonable review of publicly available information
(including information available through industry databases employed by BMS or ATI at such time),
[**] that comprise an antibody, antibody-based protein, or soluble receptor protein that is
primarily intended to bind to (or act against) such Target.

     (d) For purposes of this Section 2.3, “[**]” shall mean [**].

14

 

Strategic Alliance and Collaboration Agreement

     (e) For purposes of this Agreement, “Oncology Related” with respect to a Target shall mean a
Target [**].

   2.4 Selection of [**].

     (a) At any time during the period commencing on the Effective Date and ending on the second
anniversary of the Effective Date (such period, the “Expansion Option Period”), BMS may, in its
sole discretion, nominate one additional Oncology Related Target for the purpose of creating one or
more additional Programs (and corresponding Product Forms) (such Target, a “Nominated Expansion
Target”) by providing written notice to ATI which notice shall contain a reasonably detailed
description of the Nominated Expansion Target.

     (b) Within ten (10) calendar days subsequent to receipt of such written nomination, ATI will
notify BMS as to whether [**] for the discovery and/or development of Adnectins generated against
such Nominated Expansion Target. In addition, ATI may reject any ATI Target nominated by BMS under
this Section 2.4(b). Any dispute as to whether a Target is an ATI Target shall be referred to
dispute resolution as set forth in Section 18.7. For clarity, once a Nominated Expansion Target
has been accepted by ATI, ATI shall be deemed to have waived its right to dispute resolution under
Section 18.7(b) as to whether a Target is an ATI Target.

     (c) If ATI notifies BMS that such Nominated Expansion Target is [**] nor an ATI Target that
ATI does not desire to be designated as a Collaboration Target, or if BMS receives no such notice
within such ten (10) day period, then (i) such Target will be deemed to be a Collaboration Target,
(ii) BMS will pay an expansion fee of [**] U.S. Dollars (US$[**]) within ten (10) calendar days
subsequent to such event, and (iii) such Collaboration Target will thereafter be available to BMS
for use in selection of additional Programs (and corresponding Product Forms) pursuant to Section
2.5.

     (d) In the event that ATI notifies BMS that such Nominated Expansion Target is either [**] or
an ATI Target that ATI does not desire to be designated as a Collaboration Target, then (i) such
Nominated Expansion Target will not be available to BMS for use in selection of additional Programs
pursuant to Section 2.5, (ii) BMS will be free to nominate another Target for the purpose of
creating one or more additional Programs (and corresponding Product Forms), and (iii) in the event
that the Expansion Period has expired, the duration of the Expansion Option Period shall be deemed
to be extended by thirty (30) calendar days in order to allow BMS a reasonable opportunity to
propose an alternative Nominated Expansion Target.

   2.5 Selection of [**].

     (a) BMS shall have the right, at any time prior to the expiration of the Expansion Option
Period, and regardless of whether a Nominated Expansion Target has been designated as a
Collaboration Target pursuant to Section 2.4(c), to create one (1) additional Program (and
corresponding Product Form) (such Program, the “Supplemental Program”), subject to payment by BMS
of (i) a Supplemental Program milestone fee(s) of [**] U.S. Dollars ($[**]) within ten (10)
calendar days subsequent to such event and (ii) any additional funding obligations of BMS with
respect to such Supplemental Program as described in Section 9.2, by giving written notice to ATI
to such effect.

15

 

Strategic Alliance and Collaboration Agreement

     (b) In the event that a Nominated Expansion Target has been accepted by ATI and BMS has paid
the expansion fee set forth in Section 2.4(c), then BMS shall have the right, at any time prior to
the expiration of the Expansion Option Period, to create up to two (2) additional Programs (and
corresponding Product Forms) (each, an “Expansion Program”), subject to payment by BMS of (i) an
Expansion Program milestone fee(s) of [**] U.S. Dollars ($[**]) within ten (10) calendar days
subsequent to the designation of the second such Program (and only the second such Expansion
Program, and only in the event that a second such Expansion Program is designated) and (ii) any
additional funding obligations of BMS with respect to such Expansion Programs as described in
Section 9.2, by giving written notice to ATI to such effect.

     (c) The Product Form with respect to any such Supplemental Program and/or Expansion Program
shall consist of [**], and shall not consist (in whole or in part) of [**].

   2.6 Guidelines Applicable to all Programs. The Parties are entering into this Agreement with the
following express intentions which, subject to the terms and conditions of this Agreement, shall
establish the framework for making decisions necessary to timely advance the Programs hereunder.
The following intentions shall serve as a general guide for the exercise of reasonable business
judgment by the Parties, but are not intended to and do not create any obligation or impose any
liability upon either Party with respect to the good faith exercise of such judgment:

     (a) the Parties intend that, subject to reasonable business considerations of each Party
respecting its business operations from time to time during the Term, their activities shall be
directed toward optimizing and expediting Development and Commercialization efforts set forth
herein;

     (b) The Parties shall regularly practice clear, prompt, respectful communication, particularly
in regard to experimental and other Development schemes proposed, data, data interpretation and
proposed changes in plans;

     (c) the Parties intend in good faith and in the spirit of collaboration to evaluate critically
the success of their activities under this Agreement and to promptly initiate such corrective
action as may be provided or allowed under this Agreement or as may otherwise be agreed by the
Parties in order to realize, to the extent commercially reasonable, the intent of the Parties for
the Programs as of the Effective Date; and

     (d) the activities and resources of each Party shall be managed by such Party, acting
independently and in its individual capacity, and the Parties shall have a relationship of
independent contractors with respect to each other.

ARTICLE
— 3 GOVERNANCE AND COMMITTEES.

   3.1 Joint Research Committee.

     (a) Formation. Within thirty (30) calendar days after the Effective Date, the Parties
shall establish a Joint Research Committee (the “JRC”), which shall be composed of six (6) members,
with each Party appointing three (3) representatives to the JRC. Each Party may replace its
appointed JRC representatives at any time upon written notice to the other Party. Each Party

16

 

Strategic Alliance and Collaboration Agreement

shall
designate one (1) of its representatives as co-chairperson of the JRC. Each of the co-chairpersons
shall be responsible, on an alternating basis with the BMS co-chairperson having responsibility
with respect to the initial meeting, for working with the Alliance Managers to schedule meetings,
prepare and circulate an agenda in advance of each meeting, and to prepare and issue minutes of
each meeting within thirty (30) calendar days thereafter. Any JRC member may add topics to the
draft agenda. Each Party may invite, with the approval of the other Party (which shall not be
unreasonably withheld, delayed or conditioned), additional employees or consultants (provided such
employees and consultants: (i) have contractual confidentiality obligations to such Party that are
at least as stringent as those set forth in this Agreement; and (ii) are under intellectual
property assignment obligations to such Party in accordance with Section 10.1(c) to attend one (1)
or more meetings of the JRC as ad hoc, non-voting guests.

     (b) Decision-making. The three (3) JRC representatives of each Party shall
collectively have one (1) vote, and the JRC shall operate by unanimous consent of all JRC members
participating in the applicable meeting and in accordance with the principles set forth in this
Article 3. In the event of a dispute between the Parties with regard to the performance of the
Collaboration, the matter shall be first referred to the Alliance Managers for resolution. If
these two (2) individuals are unable to resolve the dispute, then the matter shall be elevated to
the Chief Executive Officer of ATI and the Senior VP for Drug Discovery for BMS. If these two (2)
individuals are unable to resolve the dispute, then, subject to the last sentence of this Section
3.1(b) and to Section 3.1(c), BMS shall have the final decision so long as such decision does not
conflict with the terms of this Agreement. Notwithstanding anything to the contrary, no decision
by a Party shall require the other Party to: (i) breach any obligation or agreement that such other
Party may have with or to a Third Party; or (ii) perform any activities that are materially
different or greater in scope or more costly than those provided for in the then-current Research
Plan.

     (c) Responsibilities of the JRC and DWG. The JRC shall be responsible for the overall
planning and execution of the Research Plans and the approval and oversight of the Research Plan.
The Discovery Working Group (DWG) shall report to the JRC and shall manage the day-to-day
activities and decisions required in connection with the advancement of the Programs. Membership
of the DWG shall be determined by the JRC and shall not be limited with respect to number of
appointees (in total or from either Party). Each Party shall designate one (1) of its
representatives as co-chairperson of the DWG. At its meetings, the DWG shall evaluate the data
generated by the Parties in the course of carrying out the Research Plan, shall recommend project
prioritization within the Research Plan (subject to approval by the JRC), shall perform those
activities specifically described in this Agreement, and may recommend revisions to the Research
Plan to the JRC. At each DWG meeting, the DWG shall summarize the progress in carrying out the
Research Plan since the last DWG meeting, bring to attention of the JRC any overarching issues or
significant changes in the Research Plan, and address any issues raised at its previous meeting.
To the extent necessary to carry out its responsibilities, a Party’s DWG and/or JRC members shall
be granted access to the other Party’s Confidential Information relevant to any decision required
to be made by the DWG or the JRC.

   3.2 Meetings of JRC and DWG. During the R&D Period with respect to each Program: (a) the JRC shall
meet quarterly by audio or video teleconference and, at a minimum, once each calendar year in
person (which in-person meeting shall be held on an alternating basis in New

17

 

Strategic Alliance and Collaboration Agreement

Jersey and in the
greater Boston area); and (b) the DWG shall meet monthly by audio or video teleconference and, at a
minimum, four times each calendar year in person (which in-person meeting shall be held on an
alternating basis in New Jersey and in the greater Boston area). With the consent of the
representatives of each Party serving on a particular committee (such consent not to be
unreasonably withheld, delayed or conditioned), other representatives of each Party may attend
meetings of that committee as nonvoting observers (provided such representatives: (i) have
contractual confidentiality obligations to such Party that are at least as stringent as those set
forth in this Agreement; and (ii) are under intellectual property assignment obligations to such
party in accordance with Section 10.1(d)). Meetings of a committee shall be effective only if at
least one (1) representative of each Party is present or participating. Each Party shall be
responsible for all of its own expenses of participating in the committee meetings. The Parties
shall endeavor to schedule meetings of the JRC and the DWG at least six (6) months in advance. The
JRC and DWG shall meet one time for each Program after the end of the R&D Period for such Program
and thereafter shall not meet with respect to such Program.

   3.3 Alliance Managers.

     (a) Appointment. Each of the Parties shall appoint an individual (each, an “Alliance
Manager”) who possesses a general understanding of the scientific and business issues relevant to
this Agreement. Each Party may change its designated Alliance Manager from time to time upon prior
written notice to the other Party. Any Alliance Manager may designate a substitute to temporarily
perform the functions of that Alliance Manager by prior written notice to the other Party.

     (b) Responsibilities. The Alliance Managers shall use good faith efforts to attend
all committee meetings and support the co-chairpersons of each committee in the discharge of their
responsibilities. Alliance Managers shall be nonvoting participants in such committee meetings.
An Alliance Manager may bring any matter to the attention of any committee if such Alliance Manager
reasonably believes that such matter warrants such attention. Each Alliance Manager shall be
charged with creating and maintaining a collaborative work environment within and among the
committees. In addition, each Alliance Manager: (a) shall be the point of first referral in all
matters of conflict resolution; (b) shall identify and bring disputes to the attention of the
appropriate committee in a timely manner; (c) shall plan and coordinate cooperative efforts and
internal and external communications; and (d) shall take responsibility for ensuring that
governance activities, such as the conduct of required committee meetings and production of meeting
minutes, occur as set forth in this Agreement, and that relevant action items resulting from such
meetings are appropriately carried out or otherwise addressed.

ARTICLE — 4 DEVELOPMENT.

   4.1 Research Plans. The research and pre-clinical Development activities of the Parties with
respect to each of the Programs shall be described in a “Research Plan”, an initial version of
which that applies to the three Initial Programs is attached hereto as Exhibit F. The
Research Plan(s) shall be reviewed as necessary at each meeting of the JRC, and at any other time
upon the request of either Party, and shall be modified as appropriate at the direction of the JRC
to reflect material scientific, commercial and other developments.

18

 

Strategic Alliance and Collaboration Agreement

   4.2 Annual Reports.

     (a) During the R&D Period with respect to a Program, at least once per year, in addition to
the other reporting and meeting requirements hereunder, each Party shall provide to the JRC a
written progress report which shall describe the activities that such Party has performed, or
caused to be performed, during the preceding calendar year under the Research Plan with respect to
such Program, and evaluate such Party’s work performed in relation to such Research Plan.

     (b) Subsequent to the R&D Period and prior to First Commercial Sale with respect to a Program,
at least once every six (6) months, BMS shall submit to ATI a written progress report summarizing
the research and Development performed by BMS with respect to Licensed Compounds or Licensed
Products arising out of such Program. If reasonably necessary or useful for ATI to exercise its
rights under this Agreement, ATI may request that BMS provide more detailed information and data
regarding such reports by BMS, or to meet with appropriate representatives of BMS who are
responsible for such activities, and BMS shall promptly provide ATI with information and data as is
reasonably related to such request, at ATI’s expense, or conduct such a meeting, as applicable;
provided that BMS shall not be required to conduct such meetings more than twice in any given
calendar year. All such reports and/or information provided during any such meeting shall be
considered Confidential Information of BMS.

   4.3 Obligations Relating to the Programs and the Research Plans.

     (a) Programs. Each Party shall use Commercially Reasonable Efforts to perform (itself
or through its Affiliates or by permitted subcontracting hereunder) its respective obligations
under the Research Plan for each Program, and shall cooperate with and provide reasonable
support to the other Party in such other Party’s performance of its responsibilities under
each Research Plan.

     (b) ATI Obligations. As part of and in accordance with the R&D Program, ATI shall use
Commercially Reasonable Efforts (directly or through one or more of its Affiliates or by permitted
subcontracting hereunder), and in a manner consistent with, and subject to, the Research Plan and
the direction of the JRC:

          (i) to generate compositions of matter in the Product Form for each Program, including
molecular drug design and generation of applicable Adnectin chemistry;

          (ii) to conduct certain preclinical development activities including, by way of example,
assays for activity, toxicology, biophysical properties, pharmacokinetics, and in vitro and in vivo
testing of a Licensed Compound.

          (iii) to conduct process development, develop release assay methods, and preclinical and
clinical manufacturing of Licensed Compounds as set forth in Article 6; and

          (iv) to commit at least such number of ATI FTEs to the Programs, in the aggregate, as are
being funded by BMS pursuant to Section 9.2(a) and 9.2(e) to the activities described in clauses
(i) through (iii) above.

19

 

Strategic Alliance and Collaboration Agreement

     (c) BMS Obligations. As part of and in accordance with the R&D Program and thereafter
for the remainder of the Term, BMS shall use Commercially Reasonable Efforts (directly or through
one or more of its Affiliates or Sublicensees or by permitted subcontracting pursuant to Section
4.7):

          (i) to apply its oncology research expertise to conduct preclinical development including, by
way of example, preparation of target protein, assays for activity, toxicology and related safety
studies, biophysical properties, metabolism and pharmacokinetics, in vitro and in vivo testing to
assess binding, mechanism of action and efficacy, process and formulation development and
manufacture of a licensed compound.

          (ii) to apply its oncology clinical Development expertise to Licensed Compounds and Licensed
Products, including IND preparation and filing and the conduct of Clinical Studies of all Phases;
and

          (iii) to Develop Licensed Compounds and corresponding Licensed Products from each Program, to
obtain and thereafter maintain Regulatory Approvals worldwide with respect to Licensed Products
from each Program, and to expand approved indications and Product Labeling for Licensed Products.
BMS shall contract with Third Parties as permitted hereunder to satisfy the diligence obligations
contained in this Section 4.3(c).

   4.4 Commencement of a [ ** ]. The Parties shall determine, via the JRC, whether or not to
commence a [ ** ] program for a Product Form in each Program (a “[ ** ]”) with respect to
some or all of the Programs, as well as the appropriate timing for such [ ** ] Program(s). The
[ ** ]
Program(s) shall be funded solely by BMS and subject to JRC oversight and decision making and to a
[ ** ] Research Plan (which shall be considered to be a component of
the [ ** ] with respect
to the Program to which such [ ** ] relates) to be established by the JRC prior to the
start of [ ** ] work.

   4.5 Compliance with Applicable Laws. Each Party shall perform or cause to be performed any and all
of its Development obligations hereunder in good scientific manner and in compliance with all
Applicable Law.

   4.6 Records.

     (a) Each Party shall maintain, or cause to be maintained, records of its Development
activities with respect to Licensed Compounds in sufficient detail and in good scientific manner
appropriate for patent and regulatory purposes, which shall be reasonably complete and accurate and
shall properly reflect all work done and results achieved in the performance of such Development
activities, and which shall be retained by such Party for at least ten (10) years after the
termination of this Agreement, or for such longer period as may be required by Applicable Law.

     (b) The other Party shall have the right, during normal business hours and upon reasonable
notice, to inspect and copy any such records, except to the extent that such Party reasonably
determines that such records contain Confidential Information that is not licensed to such other
Party hereunder, or to which such other Party does not otherwise have a right hereunder.

20

 

Strategic Alliance and Collaboration Agreement

     (c) Each Party shall provide the other with such additional information regarding such Party’s
Development activities relating to Licensed Compounds as such other Party may reasonably request
from time to time.

   4.7 Subcontracting. As provided in the Research Plan or otherwise with the prior consent of the
other Party, not to be unreasonably withheld, delayed or conditioned, either Party may subcontract
any of its Development activities set forth in the Research Plan to be performed by a Third Party,
provided that any such Third Party must have entered into a written agreement with such Party that
includes terms and conditions protecting and limiting use and disclosure of Confidential
Information and Know-How at least to the same extent as under this Agreement, and requiring the
Third Party and its personnel to assign to such Party all right, title and interest in and to any
intellectual property (and intellectual property rights) created or discovered in connection with
performance of subcontracted activities. Each Party is responsible for compliance by such Third
Party with the applicable terms and conditions of this Agreement. Notwithstanding the foregoing,
BMS may subcontract activities relating to Clinical Studies subsequent to the R&D Period with
respect to a Program, or with respect to Commercialization of Licensed Products, without the
consent of ATI.

ARTICLE — 5 REGULATORY MATTERS.

   5.1 Overview of Regulatory Responsibilities. Subject to Article 5 and except as otherwise provided
in the Research Plan, BMS shall have primary responsibility for preparing and maintaining all
Regulatory Documentation with respect to all Clinical Studies for each Licensed Compound and
corresponding Licensed Products, including Drug Approval Applications and Regulatory Approvals
therefore.

   5.2 Ownership of Regulatory Materials. Subject to Article 17, all BMS Regulatory Data, and
Regulatory Approvals and related Regulatory Documentation for Licensed Compound or Licensed
Product, shall be the sole property of BMS (subject to the license grant by BMS to ATI set forth in
Section 8.4(a)) and held in the name of BMS (or in each such case its Affiliate or Sublicensee),
even if ATI is primarily responsible for them hereunder.

   5.3 Communications with Regulatory Authorities. BMS shall be primarily responsible for all
communications with Regulatory Authorities. ATI shall have the right to attend, but not actively
participate without BMS’ consent (such consent not to be unreasonably withheld, delayed or
conditioned), in any pre-IND meetings with such Regulatory Authorities if the JRC concludes that
any such attendance shall not materially harm the regulatory matter involved. ATI shall provide
reasonable assistance to BMS with respect to communications with any Regulatory Authorities and the
preparation of Regulatory Documentation, including attending any meetings with Regulatory
Authorities, upon the request of BMS, at the expense of BMS.

ARTICLE — 6 MANUFACTURE AND SUPPLY.

   6.1 Pre-Clinical Research Supply. Subject to the Research Plan with respect to each Program, ATI
shall use Commercially Reasonable Efforts to Manufacture, or the Parties (through the JRC) shall
arrange with Third Parties for the Licensed Compounds for the purpose of the Parties’ research and
pre-clinical Development activities to be performed under Article 2

21

 

Strategic Alliance and Collaboration Agreement

with respect to the Programs
described in Exhibit A. All customary and reasonable costs and expenses, including FTEs
but not including fixed assets and capital expenditures, incurred by ATI in carrying out such
Manufacturing shall be reimbursed [**] percent ([**]%) by BMS in accordance with Section 9.2(a).

   6.2 Clinical and Commercial Supply. Subject to the determination of the JRC, prior to the
completion of ATI’s technology transfer under Section 6.3 of the Manufacturing technology for a
Licensed Product, ATI shall use
Commercially Reasonable Efforts to Manufacture, or the Parties (through the JRC) shall arrange with
Third Parties for the Manufacture of, such Licensed Product for the purpose of transitional supply
of Licensed Product for IND toxicology studies and the first Phase 1 Study of such Licensed
Product. As part of such Phase 1 Study supply, ATI will enable BMS’ regulatory function to test
(where applicable) and release all supplies of such Licensed Product for such Phase 1 Study (if
applicable). All customary and reasonable costs and expenses, including FTEs but not including
fixed assets and capital expenditures, incurred by ATI in carrying out such Manufacturing shall be
reimbursed [**] percent ([**]%) by BMS in accordance with Section 9.2(a). After the completion of
ATI’s transfer under Section 6.3 of the Manufacturing technology for Licensed Compounds, BMS shall
use Commercially Reasonable Efforts to Manufacture or, in the sole discretion of BMS, shall arrange
with Third Parties for the Manufacture of, Licensed Compounds and Licensed Products (in bulk and
finished form) for use in Development and for commercial sale.

   6.3 Transfer of Manufacturing.

     (a) At the direction of the JRC, ATI shall transfer any necessary Manufacturing technology for
the manufacture of Licensed Compounds to either (i) BMS or (ii) a Third Party manufacturer selected
by BMS. As soon as is practicable after its receipt of such request, ATI shall transfer to BMS or
such Third Party manufacturer, as the case may be, all ATI Know-How and/or relevant Materials of
ATI that are related to the Manufacturing of Licensed Compounds and Licensed Products and is
reasonably necessary or useful to enable BMS or such Third Party manufacturer (as appropriate) to
Manufacture such Licensed Compounds and Licensed Products. All customary and reasonable costs and
expenses, including FTEs but not including fixed assets and capital expenditures, incurred by ATI
in carrying out such transfer shall be reimbursed [**] percent ([**]%) by BMS upon successful
completion and confirmation of such transfer in accordance with Section 9.2(a).

     (b) BMS and/or its Third Party manufacturer shall use any ATI Know-How and/or relevant
Materials of ATI transferred pursuant to Section 6.3(a) solely for the purpose of Manufacturing
Licensed Compounds and Licensed Products under this Agreement, and for no other purpose.

     (c) BMS acknowledges and agrees that ATI may condition its agreement to transfer of any
Manufacturing technology or Information to a Third Party manufacturer on the execution of a
confidentiality agreement between such Third Party manufacturer and BMS, relating to such
Manufacturing technology or Information, that contains terms substantially equivalent to those of
Article 14. In addition, BMS shall use commercially reasonable efforts to require such Third Party
to assign or license back Patents and Know-How and other intellectual property rights for Adnectins
to the same extent as provided in Section 10.1(c) (with any such Third Party

22

 

Strategic Alliance and Collaboration Agreement

manufacturer treated
as “BMS” hereunder for such purposes); provided, however, that in the event that BMS is
unsuccessful with respect to such efforts, BMS shall consult with Adnexus, and shall require such
Third Party to (i) assign to BMS Patents covering compositions of matter with Adnectins or Product
Forms other than Patents specifically claiming an Adnectin linked to (or used with) another agent
or component Controlled by BMS (and Patents to the extent such Patents specifically claim such
compositions or Product Forms) and (ii) shall require that such Third Party license inventions that
are Adnectin Core Manufacturing and Formulation
Technology to the extent that such inventions do not comprise or contain core technology of
such Third Party.

ARTICLE
— 7 COMMERCIALIZATION.

   7.1 Commercialization of Licensed Product.

     (a) In General. BMS shall have the sole right and obligation to Commercialize
Licensed Products in the Field, in compliance with this Agreement and Applicable Law, subject to
Section 7.2 for Co-Promotion Products in the Co-Promotion Territory.

     (b) Commercialization Obligations. BMS, directly or through one or more of its
Affiliates, Sublicensees or Distributors, shall use Commercially Reasonable Efforts to
Commercialize Licensed Products for each indication for which it receives Regulatory Approval.

   7.2 ATI’s Co-Promotion Option.

     (a) Co-Promote Option.

          (i) For the first Licensed Product for which a Drug Approval Application is filed for in the
United States, ATI shall have an option (the “Co-Promote Option”) to Co-Promote such Licensed
Product, and all other Licensed Products containing the same Licensed Compound as such Licensed
Product (collectively, the “Co-Promotion Products”), to the Co-Promotion Target Audience in the
Co-Promotion Territory.

          (ii) ATI may exercise the Co-Promote Option by providing written notice to BMS at any time
subsequent to the filing of a Drug Approval Application for such first Licensed Product until
thirty (30) calendar days after such Drug Approval Application is accepted by the FDA for such
first Licensed Product. At any time before the end of such thirty (30) calendar day period, BMS
shall meet and discuss with ATI the Co-Promotion plan proposed by BMS (the “Co-Promotion Plan”),
ATI’s obligations thereunder, and the likely compensation to ATI for its Co-Promotion efforts.

          (iii) If ATI exercises the Co-Promote Option before the end of such thirty (30) calendar day
period for such Licensed Product, ATI and BMS shall promptly negotiate in good faith and enter into
an agreement (a “Co-Promotion Agreement”), which agreement shall contain the following material
terms as well as other customary and commercially reasonable terms:

               (1) BMS shall be responsible for [ ** ] ATI’s involvement as specified in this

23

 

Strategic Alliance and Collaboration Agreement

Section 7.2. BMS shall be
solely responsible, and have sole control, [**], including the
preparation of promotional materials.

               (2) ATI shall have the right to use employees and individual representatives of ATI and its
Affiliates (but not a contract sales force) experienced in promotion and Detailing pharmaceutical
products (with qualifications substantially similar to BMS sales representatives who will be
responsible for detailing the Co-Promotion Product) to provide Details under the Co-Promotion Plan
in the Co-Promotion Territory with respect to the Co-Promotion Product. ATI shall have the right
to provide up to a maximum of [**] percent
([**%)] with respect to the Co-Promotion
Product, with the allocation of Detailing responsibilities to be established by good faith
negotiations by the Parties in the Co-Promotion Agreement taking into account the total size of the
sales force, ATI’s capabilities and resources and the strategic and financial needs of the
Co-Promotion Product. Periodically during the term of the Co-Promotion Agreement, BMS shall have
the right to adjust the total number of sales representatives promoting the Co-Promotion Product.
In the case of each such adjustment, the number of sales representatives of ATI shall be adjusted
to maintain the percentage set forth in the Co-Promotion Agreement; provided, however, that in the
event of an increase in the overall size of the sales force, ATI shall have the option to maintain
its current number of sales representatives or increase the number to maintain the current
percentage. In the event of any increase in the number of sales representatives other promotional
personnel of ATI agreed to or required of ATI, ATI shall have a commercially reasonable period of
time to satisfy such increase.

               (3) At any time subsequent to the second anniversary of the First Commercial Sale of a
Co-Promotion Product, ATI shall have the right, upon nine (9) months prior written notice to BMS,
to terminate its Co-Promotion rights and obligations under this Section 7.2 for any Co-Promotion
Product. In such event, ATI shall have no further right to Co-Promote any Licensed Products during
the Term.

               (4) BMS shall compensate ATI, [**], with rates consistent with BMS’
internal cost [**] (which shall be calculated in a manner consistent with
BMS’ internal accounting procedures for determining such costs), for [**] performed by ATI
(which compensation shall take into account whether the [**] of the Co-Promotion Product is in
the [**]).

               (5) ATI shall use Commercially Reasonable Efforts to execute its obligations under each
Co-Promotion Agreement, consistent with the Co-Promotion plan established by BMS and as set forth
in such Co-Promotion Agreement. The Co-Promotion Agreement will set forth remedies for breach of
ATI’s obligations under the Co-Promotion plan.

               (6) ATI shall, and shall cause its sales representatives to make only such statements and
claims regarding the Co-Promotion Product, including as to efficacy and safety, as are consistent
with the applicable FDA-approved product labels and inserts and promotional materials prepared by
BMS. ATI shall not, and ATI shall cause its sales representatives not to make any untrue or
misleading statements or comments about the Co-Promotion Product.

               (7) Prior to the First Commercial Sale of each Co-Promotion Product in the Co-Promotion
Territory and on a regular, at least annual, basis thereafter, BMS shall provide

24

 

Strategic Alliance and Collaboration Agreement

training materials
to, and train by holding in-person meetings or, after the initial training, webcasts for, each
member of ATI’s designated sales force prior to his or her commencement of Co-Promotion of such
Co-Promotion Product to ensure that he or she is properly trained to
promote, Detail and sell the Co-Promotion Product and able to satisfy ATI’s responsibilities
under the Co-Promotion Agreement.

               (8) ATI shall comply with all BMS pharmaceutical marketing and promotion policies, as set
forth in the marketing and promotion guidelines to be included in the Co-Promotion Agreement.

               (9) ATI sales representatives that are Co-Promoting a Co-Promotion Product shall not
simultaneously detail another product containing an Adnectin that is targeted against a Target that
is targeted by an Adnectin contained in such Co-Promotion Product if such other Adnectin-containing
product has an approved label (or compendia listing) for the same indication as the Co-Promotion
Product at the time of launch of the second of such two products.

               (10) ATI shall only have the right under this Section 7.2 [**] has occurred with respect to ATI, and BMS shall have the right to
terminate any Co-Promote arrangement in effect on six (6) months notice in the event of [**].

     (b) Definitions.

          (i) “Co-Promote” or “Co-Promotion” shall mean, with respect to any Co-Promotion Product, the
joint Detailing of such Co-Promotion Product to the Co-Promotion Target Audience in the
Co-Promotion Territory using a coordinated sales force consisting of representatives of both
Parties.

          (ii) “Co-Promotion Target Audience” shall mean, with respect to each Co-Promotion Product, any
or all of those classes of physicians and other medical or administrative professionals that
customarily prescribe or purchase, or that would reasonably be expected to prescribe, purchase or
administer, products to treat or prevent any indication for which the Co-Promotion Product receives
Regulatory Approval in the Co-Promotion Territory as well as patients indicated by Product Labeling
for treatment for Co-Promotion Product. For clarity, Co-Promotion Target Audience shall include
nursing homes, infusion centers, hospitals or comparable facilities if they would reasonably be
expected to purchase a particular Co-Promotion Product.

          (iii) “Co-Promotion Territory” shall mean the United States of America (excluding its
territories and possessions), but including the District of Columbia and Puerto Rico.

          (iv) “Detail” shall mean that part of an in-person, face-to-face sales call during which a
sales representative, who is trained with respect to a Co-Promotion Product, including its labeling
and any promotional materials, makes a presentation of the Co-Promotion Product to the Co-Promotion
Target Audience such that the relevant characteristics of the Co-Promotion Product are described by
the sales representative in a fair and balanced manner consistent with the requirements of the
Co-Promotion Agreement and all Applicable Laws in a manner that is customary in the industry for
the purpose of promoting a prescription pharmaceutical product.

25

 

Strategic Alliance and Collaboration Agreement

   7.3 Promotional Materials and Activities. BMS shall be responsible, at its sole expense, for preparing all Promotional Materials used to
support the Commercialization of Licensed Product. BMS shall ensure that all its Promotional
Materials shall be limited to the Field and consistent with Applicable Law and the approved Product
Labeling for the Licensed Product. BMS shall be responsible for obtaining any appropriate
approvals from the Regulatory Authorities required for the use of any Promotional Materials and
shall submit applicable Promotional Materials to such Regulatory Authorities as required by
Applicable Law.

   7.4 Statements and Compliance with Applicable Law.

     (a) Public Statements Regarding Licensed Product. BMS, and ATI in the event that it
is Co-Promoting a Co-Promotion Product, shall be responsible for disseminating accurate information
regarding the Licensed Product based on Product Labeling and Promotional Materials for the Licensed
Product (and for causing its Affiliates, Sublicensees and Distributors to so disseminate such
accurate information), and limited to the Field. In exercising its rights pursuant to this 7.4(a),
BMS, and ATI in the event that it is Co-Promoting a Co-Promotion Product, shall use Commercially
Reasonable Efforts to prevent claims or representations in respect of Licensed Product or the
characteristics of Licensed Product (e.g., safety or efficacy) being made by or on behalf of it or
its Affiliates, Sublicensees or Distributors (by members of its or their sales force or otherwise)
that do not represent an accurate or fairly balanced summary or explanation of the Product Labeling
for the Licensed Product in the country in question, or that are outside the Field.

     (b) Sales Force Compliance. BMS (directly or through one or more of its Affiliates,
Sublicensees or Distributors), and ATI in the event that it is Co-Promoting a Co-Promotion Product,
shall use Commercially Reasonable Efforts to train and monitor its and its Affiliates’,
Sublicensees’ and Distributors’ sales representatives and other employees, consultants and agents
to (i) use only Promotional Materials (without any material addition, deletion or other
modification) that meet the requirements under Section 7.3 for the promotion of the Licensed
Product, (ii) limit claims of efficacy and safety for the Licensed Product to those that are
consistent with Applicable Law and with approved (by the relevant Regulatory Authority, where
appropriate) promotional claims in Product Labeling and Promotional Materials for Licensed Product,
and not add, delete or otherwise modify claims of efficacy and safety in the promotion of Licensed
Product in any material respect from those claims of efficacy and safety that are contained in such
approved Product Labeling and Promotional Materials, and (iii) Commercialize the Licensed Product
in adherence in all material respects with Applicable Law.

     (c) Medical and Other Inquiries. BMS (directly or through one or more of its
Affiliates, Sublicensees or Distributors) shall be responsible for responding to all medical
questions or inquiries relating to the Licensed Product sold. BMS (and such other entities, as
applicable) shall keep such records and make such reports as are reasonably necessary to document
such communications in compliance with all Applicable Law.

     (d) Compliance with Laws. BMS shall in all material respects conform its practices
and procedures relating to educating the medical community with respect to the Licensed Product to

26

 

Strategic Alliance and Collaboration Agreement

any applicable industry association regulations, policies and guidelines, as amended from time to
time, and other Applicable Law.

   7.5 Sales and Distribution. BMS shall be solely responsible for invoicing and booking sales of the
Licensed Product, establishing all terms of such sales (including pricing and discounts), and
distributing the Licensed Product and shall perform all related services, in each case in a manner
consistent with the terms and conditions of this Agreement. BMS shall also be solely responsible
for handling all returns, recalls or withdrawals in accordance with Article 12, order processing,
invoicing and collection, distribution and inventory and receivables.

   7.6 Reporting. Subsequent to the First Commercial Sale of a Licensed Product, BMS shall prepare
and maintain reasonably complete and accurate records regarding Commercialization of each Licensed
Product and shall provide to ATI a detailed report regarding such Commercialization at least twice
per calendar year. All of the foregoing shall be deemed Confidential Information of BMS hereunder.

ARTICLE
— 8 LICENSE GRANTS AND EXCLUSIVITY.

   8.1 License Grants.

     (a) Subject to the terms and conditions of this Agreement (including the exclusivity provided
to BMS by Section 8.3 and payments by BMS in Article 9), on a Program-by-Program basis, ATI hereby
grants to BMS and its Affiliates, for Licensed Compounds in the Product Form for such Program and
corresponding Licensed Products, a worldwide, nontransferable (except as permitted by Section
8.7(a)) and royalty-bearing license, with the right to sublicense only as provided in Section
8.7(b), under the ATI Patents (including any ATI Patents licensed to ATI by BMS pursuant to Section
8.2) and ATI Know-How, to Develop, Commercialize and Manufacture Licensed Compounds and Licensed
Products in the Field.

     (b) The foregoing license grants in Section 8.1(a) shall be limited such that the license to
Develop, Commercialize and Manufacture does not include the right to Develop, Commercialize or
Manufacture any Adnectin not previously provided to BMS by ATI as part of the Research Plan with
respect to a Program, or any therapeutic or diagnostic product that does not contain an Adnectin.

   8.2 Grant-Back to ATI for Adnectin Core Manufacturing and Formulation Technology.

     (a) Subject to all of the limitations and restrictions set forth in this Section 8.2, BMS
hereby grants to ATI and its Affiliates an exclusive, royalty-free and fully paid-up, perpetual and
irrevocable and worldwide license, with the right to grant sublicenses through multiple tiers
(subject to Section 8.2(b)), to any pending or issued Patent claim Controlled by BMS or any of its
Affiliates that covers an Invention that comprises Adnectin Core Manufacturing and Formulation
Technology, solely for the purpose of making, having made, using, selling, having sold, importing
or exporting Adnectins and products containing same and pharmaceutical compositions thereof.
Subject to and without limiting the other terms and conditions of this Agreement, including but not
limited to ATI’s obligations under clause (b) below and Section 8.3, the foregoing license grant is
subject to the license grant to BMS in Section 8.1, and thus because of this Agreement ATI shall
only have the right to practice the Adnectin Core

27

 

Strategic Alliance and Collaboration Agreement

Manufacturing and Formulation Technology, and to
grant sublicenses to the Adnectin Core Manufacturing and Formulation Technology to Third Parties
who have a license from ATI, to permit ATI or such Third Party to making, having made, using,
selling, having sold, importing or exporting Adnectins and products containing same and
pharmaceutical compositions thereof outside of the exclusive scope of such license to BMS specified
in Section 8.3(a). For clarification, the rights granted to ATI by BMS under this Section 8.2(a)
are limited to the Adnectin Core Manufacturing and Formulation Technology and no rights are granted
under any claims in any Patent that do not cover Adnectin Core Manufacturing and Formulation
Technology.

     (b) ATI’s rights to sublicense a Drug Company (an “ATI Sublicensee”) to all or part of the
rights granted by BMS to ATI under Section 8.2(a) (including any limitations and restrictions with
respect to such rights) shall be further limited as follows. The ATI Sublicensee’s rights with
respect to rights granted by BMS to ATI under Section 8.2(a) shall be conditioned upon and limited
to, and shall not substantially exceed the scope of, the corresponding rights (if any) that such
ATI Sublicensee has granted back to ATI (including any limitations and restrictions with respect to
such rights) and that are effectively sublicensed to BMS hereunder without additional fee.
Accordingly, if the scope of such ATI Sublicensee rights granted back to ATI (and effectively
sublicensed to BMS hereunder) is substantially narrower in whole or in part and/or any restrictions
with respect to such sublicense are substantially more restrictive in whole or in part than the
corresponding scope and restrictions set forth in Section 8.2(a), then the rights granted back to
ATI under Section 8.2(a) that ATI has the right to sublicense to such ATI Sublicensee shall be
limited to be more restrictive and to have a narrower scope so as to correspond to the restrictions
and scope of such rights granted back to ATI by the ATI Sublicense (and effectively sublicensed to
BMS hereunder). The foregoing limitation in this Section 8.2(b) shall not apply to services or
materials provided by CROs, CMOs, other subcontractors or others on a fee-for-service basis.

   8.3 Exclusivity for BMS.

     (a) Product Form Exclusivity.

          (i) The license grants in Section 8.1 shall be exclusive for the ATI Patents and the PROfusion
Patents with respect to each Product Form of a Program on a Program-by-Program basis; thus, ATI
hereby agrees not to research, develop or commercialize, or to grant any license under any ATI
Patents or PROfusion Patents to any Affiliate or non-Affiliated Third Party to research, develop or
commercialize products within any such Product Form for such Program for as long as Active
Development or Commercialization of a Licensed Compound or Licensed Product arising out of such
Program is continuing. The exclusive nature of such license grants shall extend only to the
Product Form of a Program on a Program-by-Program basis and shall not be exclusive as applied to
any Target absent such Product Form.

          (ii) Notwithstanding the foregoing exclusive license grants, ATI shall retain sufficient
rights under the ATI Patents and the PROfusion Patents to perform its obligations under the
Research Plans and otherwise to assist in the Development and Commercialization of Licensed
Compounds and corresponding Licensed Products as contemplated hereunder (including for permitted
subcontracting hereunder).

28

 

Strategic Alliance and Collaboration Agreement

     (b) Target Exclusivity, Subject to Section 17.5:

          (i) Program 1 Target. Until the earlier of (A) the date which is [ ** ] to the filing of the first IND for a Program 1 Target Directed Licensed Product, or (B)
such time as all research and development activities by BMS have ceased with respect to Program 1
Target Directed Licensed Products, and except for permitted subcontracting hereunder, ATI hereby
agrees not to research, develop or commercialize, or to grant any license under any ATI Patents or
the PROfusion Patents to any Affiliate or non-Affiliated Third Party to research, develop or
commercialize, an Adnectin against the Target of Program 1. After such period, there shall be no
further Target-based exclusivity hereunder with respect to the Target of Program 1.

          (ii) All other Collaboration Targets. Until the earlier of (A) the date which is [ ** ] to the filing of the first IND for a Licensed Compound or Licensed Product
containing an Adnectin against a given Target that is identified in a Product Form of a Program, or
(B) such time as all research and development activities by BMS have ceased with respect to
Licensed Products containing Adnectins against such Target, and except for permitted subcontracting
hereunder, ATI hereby agrees not to research, develop or commercialize, or to grant any license
under any ATI Patents or the PROfusion Patents to any Affiliate or non-Affiliated Third Party to
research, develop or commercialize, an Adnectin against such Target. After such period, there
shall be no further Target-based exclusivity hereunder with respect to such Target.

     (c) Adnectin Exclusivity. Subject to Section 17.5, BMS shall have exclusivity for
particular Adnectins as follows:

          (i) The maximum number of Adnectins for which BMS can obtain exclusivity under this Section
8.3(c) for any given Collaboration Target subject to any of the Programs is [**] Adnectins, which
shall be selected by BMS in its sole discretion and identified by written notice
to ATI at any time prior to IND filing with respect to the first Licensed Compound arising out
of any such Program (such notice, the “Exclusivity Notice”); provided that ATI shall provide BMS
with available information regarding all Adnectins generated with respect to a Program in order to
enable BMS to make a reasonable determination with respect to its election hereunder.

          (ii) Subject to Section 8.3(c)(i), upon ATI’s receipt of the Exclusivity Notice as provided
above, for a period of no less than [ ** ] years, and for as long as Active Development or
Commercialization of a Licensed Compound or Licensed Product containing Adnectins against the same
Target as the Adnectins identified in the Exclusivity Notice (the “Adnectin Exclusivity Period”,
with the applicable Adnectin hereinafter being referred to as an “Exclusive Alliance Adnectin” for
its Adnectin Exclusivity Period), for each Exclusive Alliance Adnectin ATI shall not research,
develop or commercialize such Exclusive Alliance Adnectin (either alone or with any other
component), or grant a license to the same or provide materials of the same to any Affiliate or
Third Party, except as part of a Program hereunder. Such exclusivity shall continue for an
Exclusive Alliance Adnectin during its applicable Adnectin Exclusivity Period even if such
Exclusive Alliance Adnectin is no longer being Developed by BMS. Notwithstanding the foregoing,
ATI shall retain the right to use such Exclusive Alliance Adnectins solely for internal, non-in
vivo research purposes.

29

 

Strategic Alliance and Collaboration Agreement

          (iii) By “Active Development or Commercialization” under this Section 8.3, the Parties mean
that at least one Licensed Compound or Licensed Product from the applicable Program (1) continues
to be part of an ongoing Clinical Study (save for any lapses between Clinical Studies not to exceed
six (6) months individually or twelve (12) months in the aggregate during the Adnectin Exclusivity
Period), (2) is subject to a pending Drug Approval Application before the FDA, EMEA or Koseisho, or
(3) is being Commercialized and royalties are being paid to ATI hereunder on a calendar quarterly
basis.

          (iv) If the foregoing Active Development or Commercialization condition is no longer
satisfied, then any extension beyond the initial [ ** ] period of exclusivity of such Adnectin
Exclusivity Period shall not occur or shall immediately terminate, respectively, and any Exclusive
Alliance Adnectins from the applicable Program whose initial [ ** ] period of exclusivity has
expired shall no longer be treated as “Exclusive Alliance Adnectins” hereunder or have the benefit
of the exclusivity provided by Section 8.3(c)(ii).

   8.4 License to Certain Regulatory Data.

     (a) General. To the extent that any BMS Regulatory Data generated by BMS with respect
to a given Program contains pharmacokinetic data concerning Adnectins as a drug class generally,
and was conceived or created before the end of the Discovery Term with respect to such Program
(collectively, “Adnectin Class Specific Data”), BMS hereby grants to ATI and its Affiliates, a
worldwide, perpetual and irrevocable, royalty-free and fully paid-up, nontransferable (except in
connection with a permitted assignment of this Agreement in accordance with Section 18.1),
nonexclusive license to such Adnectin Class Specific Data, without the right to grant sublicenses
and solely for ATI’s internal research and development purposes. For clarity, any such Adnectin
Class Specific Data shall be treated as Confidential Information of BMS, and
the foregoing license grant shall not include any right to reference any Regulatory
Documentation filed with a Regulatory Authority.

     (b) Disclosure of Adnectin Class Specific Data. To the extent that any Adnectin Class
Specific Data is not already subject to disclosure by one Party to the other Party hereunder,
copies of any Adnectin Class Specific Data subject to a license grant in this Section 8.4 shall be
provided by BMS to ATI, when and as any such Adnectin Class Specific Data becomes available to BMS.

   8.5 PROfusion License Grant. Subject to the terms and conditions of this Agreement, on a
Program-by-Program basis, ATI hereby grants to BMS and its Affiliates, for Licensed Compound in the
Product Form for such Program and corresponding Licensed Products, a worldwide, nontransferable
(except as permitted by Section 8.7(a)) and royalty-bearing license, with the right to sublicense
only as provided in Section 8.7(b), under the PROfusion Patents, in the Field, and only for those
activities for which BMS has a then-effective license under Section 8.1. BMS and its Affiliates
and Sublicensees shall not practice the Technology claimed in any of the PROfusion Patents with
respect to the discovery or identification of Adnectins.

   8.6 License Agreement Between [ ** ]. ATI shall contemporaneously with entering into this
Agreement request that [**]. For clarity, no rights in or to the [**]. During the

30

 

Strategic Alliance and Collaboration Agreement

Term, ATI shall
pay amounts [**] under such License Agreement with BMS that are incurred by BMS in connection with
exercising its license under Section 8.1, either [**].

   8.7 Sublicensing Rights.

     (a) The licenses and covenant granted in Sections 8.1 and 8.6 are transferable only upon a
permitted assignment of this Agreement in accordance with Section 18.1.

     (b) In addition to the right to grant such limited sublicenses as may be necessary for
permitted subcontracting as set forth in Section 4.7, the licenses and covenant granted in Sections
8.1 and 8.6 may be sublicensed or extended (as applicable) by BMS (and/or its Affiliates) to Third
Parties (without the right to grant further sublicenses) to Develop and Commercialize a Licensed
Compound and the corresponding Licensed Product, but only on a Licensed Compound-by-Licensed
Compound basis, and provided, that as a condition precedent to any such sublicense:

          (i) BMS shall provide prior written notification to ATI of any such sublicense;

          (ii) BMS shall provide ATI with a copy of the sublicense agreement within thirty (30) calendar
days subsequent to execution thereof (with financial terms and other commercially sensitive
information redacted);

          (iii) BMS shall agree in writing to be responsible for any and all obligations of such
Sublicensee as if such Sublicensee were “BMS” hereunder;

          (iv) any such Sublicensee shall agree in writing to be bound by similar obligations as BMS
hereunder; and

          (v) ATI shall be made an express third-party beneficiary of any such Sublicensee’s obligations
under such sublicense that relate to compliance with the terms and conditions of this Agreement.

   8.8 Transfer and Use of Materials.

     (a) General. During Development, the Parties anticipate that each Party may transfer
certain biological or other materials to the other Party in furtherance of the Programs, including
Licensed Compounds and possibly nucleic acid sequences in clones or cells capable of expressing
same. Each Party agrees that it shall use such materials, and any expression product, progeny,
derivative or other improvement thereto (collectively, “Materials”), only for Development in
accordance with the Research Plan and/or Commercialization in accordance with this Agreement.
Except with the prior written consent of the other Party, the Party receiving Materials shall not
distribute or otherwise allow the release of Materials to any Third Party (except for (i) permitted
subcontracting hereunder, (ii) Clinical Studies conducted by BMS, (iii) Non-Clinical Studies
subsequent to the expiration of the R&D Period, or with respect to a Program or (iv) Manufacturing
purposes as contemplated by Article 6).

     (b) Specific Restrictions. Without limiting the generality of the foregoing, BMS
shall not attempt to change the amino acid sequence of, any nucleic acid sequence involved in the

31

 

Strategic Alliance and Collaboration Agreement

expression of (including coding and non-coding regions), or any other structural elements (e.g.,
changing amino acid side chains, appending other molecules, etc.) in, any Licensed Compound or
other Materials provided by ATI without ATI’s prior written consent, whether by site mutagenesis,
chemical or other means. If BMS learns or otherwise has reason to believe that any such change has
occurred, during Development or Commercialization or otherwise, whether or not intentionally, BMS
shall promptly notify ATI and provide a sample of such changed Licensed Compound or other Material,
and at ATI’s written request, shall cease its use of the same until such time as ATI is able to
confirm that such changed Licensed Compound or other Material remains Controlled by ATI and thus is
available for license to BMS hereunder use in the Programs.

     (c) MTA. Either Party may request that the Parties enter into a commercially
reasonable material transfer agreement, which agreement shall apply to all future transfers of
biological or other materials made in connection with this Agreement and which agreement shall be
consistent with and supersede the terms of this Section 8.8, and shall otherwise be subject in all
respects to the terms and conditions of this Agreement.

   8.9 No Other Licenses. No license or other right is or shall be created or granted hereunder by implication, estoppel
or otherwise. All such licenses and rights are or shall be granted only as expressly provided in
this Agreement.

ARTICLE — 9 BMS PAYMENTS AND ROYALTIES.

   9.1 Up-Front Payment. In partial consideration for the licenses granted to BMS hereunder, the
exclusivity for BMS set forth in Section 8.3, and prior research and development activities
undertaken by ATI with respect to the Programs, BMS shall pay to ATI, within ten (10) calendar days
subsequent to the Effective Date, a one-time payment of twenty million dollars (U.S.$20,000,000),
which shall be non-refundable and non-creditable and not subject to set-off.

   9.2 R&D Support and Expense Payments.

     (a) Funding in Accordance with the Research Plans. In furtherance of supporting ATI’s
efforts with respect to research, discovery, process development and clinical supply efforts with
respect to the Programs, BMS will fund FTEs at ATI to the extent that such FTEs are included in the
Research Plans which are attached as Exhibit F hereto, and which are subject to review and revision
by the JRC on a quarterly basis, provided that BMS with at least six (6) months prior written
notice to ATI may require that ATI increase the number of total committed FTEs working on all
Programs (collectively) up to an aggregate of [**] FTEs.

     (b) Minimum Committed FTE Funding. Notwithstanding the FTE funding described in
Section 9.2(a), BMS shall fund no less than the following minimum FTEs at Adnexus:

          (i) in the event that BMS does not exercise either of its options to add additional Programs
pursuant to Section 2.5(a) and Section 2.5(b): [**] FTEs during each of the [**] twelve-month
periods subsequent to the Effective Date and [**] FTEs during the [**] twelve-month period
subsequent to the Effective Date;

32

 

Strategic Alliance and Collaboration Agreement

          (ii) in the event that BMS exercises it option to add an additional Program pursuant to
Section 2.5(a) but does not exercise its option pursuant to Section 2.5(b): [**] FTEs during each
of the [**] twelve-month periods subsequent to the Effective Date and [**] FTEs during the [**]
twelve-month period subsequent to the Effective Date;

          (iii) in the event that BMS exercises it option to add one or more additional Programs
pursuant to Section 2.5(b) but does not exercise it option pursuant to Section 2.5(a): [**] FTEs
during each of the [**] twelve-month periods subsequent to the Effective Date and [**] FTEs during
the [**] twelve-month period subsequent to the Effective Date; or

          (iv) in the event that BMS exercises it option to add one or more additional Programs pursuant
to both Section 2.5(a) and Section 2.5(b): [**] FTEs during each of the [**] twelve-month periods
subsequent to the Effective Date.

     (c) Payments. BMS shall make payments with respect to the funding described in
paragraph (a) and (b) above at least fifteen (15) calendar days before the beginning of each
calendar quarter during the R&D Period with respect to any Program, and all such payments when owed
or paid shall be non-refundable and non-creditable and not subject to set-off. The first such
payment shall be payable to ATI within ten (10) calendar days subsequent to the Effective Date,
with the amount pro rated for the number of calendar days from the Effective Date until the end of
the applicable calendar quarter, and the last such payment payable for the last calendar quarter
starting in the R&D Period with respect to any Program shall be the difference between the first
such payment and a full payment.

     (d) FTE Rate. The initial FTE rate will be [**] Dollars (U.S.$[**]). The FTE Rate
for the second (and each subsequent) year of the R&D Period with respect to any Program shall
automatically increase by an amount equal to the Consumer Price Index (for the Boston,
Massachusetts area as reported as of April 1st in such year when compared to the
comparable statistic for April 1st of the preceding year), with the first such increase
effective as of April 1, 2008.

     (e) Payment for Certain External Expenses and Manufacturing Expenses. For each
calendar quarter during the R&D Period with respect to any Program, BMS shall pay ATI an amount for
certain external and Manufacturing expenses to be spent by ATI in support of such Program and the
corresponding Research Plan and as set forth in Article 6. Such expenses include payments for
Target protein production, toxicology studies, permitted subcontractor expenses, etc. Each such
payment shall be payable to ATI within thirty (30) days subsequent to the end of each calendar
quarter, and such payments when owed or paid shall be non-refundable and non-creditable and not
subject to set-off. ATI shall use such payments to pay Third Parties, but only at the direction of
the JRC.

   9.3
Milestone Payments. In partial consideration of the licenses and other rights granted to BMS
hereunder, BMS shall make milestone payments (each, a “Milestone Payment”) to ATI upon the
occurrence of each of the milestones events (each, a “Milestone Event”) as set forth below in this
Section 9.3. Each of the Milestone Payments shall be payable to ATI by BMS within ten (10)
calendar days subsequent to the achievement of the specified Milestone Event, and such payments
when owed or paid shall be non-refundable and non-creditable and not

33

 

Strategic Alliance and Collaboration Agreement

subject to set-off.
References to “Licensed Compound” in this Section 9.3 shall include Licensed Product containing
such Licensed Compound.

     (a) Development Milestones.

	 	 	 	 	 	 	 	 	 
	 	 	Milestone	 	 
	 	 	Payment for All	 	 
	 	 	Licensed	 	Milestone
	 	 	Products other	 	Payment for
	 	 	than the First	 	First Program 1
	 	 	Program 1 Target	 	Target Directed
	 	 	Directed Licensed	 	Licensed
	Milestone Event	 	Product (U.S.$)	 	Product (U.S.$)
	1. Upon designation by BMS of a
Licensed Compound as an ECN
	 	$	[**]	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 
	2. Upon the first IND submission
for a Licensed Compound in a given
Program
	 	$	[**]	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 
	3. Upon start of the first Phase 2
Study for a Licensed Compound in a
given Program
	 	$	[**]	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 
	4. Upon start of the first Phase 3
Study for a Licensed Compound in a
given Program
	 	$	[**]	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 
	5. Upon acceptance of the first
Drug Approval Application in the
U.S. for a Licensed Compound in a
given Program
	 	$	[**]	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 
	6. Upon first Regulatory Approval
with respect to the first Drug
Approval Application by the U.S.
FDA for a Licensed Compound in a
given Program
	 	$	[**]	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 
	7. Upon the first Regulatory
Approval in three Major Market
Countries for a Licensed Compound
in a given Program
	 	$	[**]	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 
	8. Upon first Regulatory Approval
with respect to the first Drug
Approval Application by the
Koseisho for a Licensed Compound in
a given Program
	 	$	[**]	 	 	$	[**]	 
	 
	9. Upon first Regulatory Approval
with respect to a Drug Approval
Application by the U.S. FDA for a
second indication for a Licensed
Compound in a given Program
	 	$	[**]	 	 	$	[**]	 

34

 

Strategic Alliance and Collaboration Agreement

     For this Section 9.3(a), for each Licensed Compound, if a Milestone Event is achieved that
triggers a Milestone Payment as set forth in the table of this Section 9.3(a), if any of the
preceding Milestone Events (based on the order in such table) have not yet occurred such that the
previous Milestone Payment(s) have not been previously paid, all such previous Milestone Payment(s)
shall become due and payable upon achievement of such Milestone Event. For example, if for a
Licensed Compound, a Phase 3 Study is started that triggers a Milestone Payment as set forth above
without a Phase 2 Study supporting such Phase 3 Study being previously started (and consequently
the applicable Phase 2 Study Milestone Payment under clause 2(b) has not been previously paid to
ATI), in addition to the Milestone Payment for the start of the Phase 3 Study, BMS shall also pay
to ATI the applicable Milestone Payment for the start of a Phase 2 Study. This paragraph shall not
apply to the Milestone Events and corresponding Milestone Payments in the foregoing clauses 7
through 9.

     With respect to clause 9 above, such second indication must be for a different tumor type or
other disease and must be therapeutically distinct and unrelated, from both the clinical
development and commercialization standpoints, to the indication(s) on which the milestone payment
was made pursuant to clause 6 above.

     All milestone payments shall be payable once per Program (i.e., on their first occurrence
regardless of the number of Licensed Products within the same Program that might achieve such
milestone). In the event that a Licensed Product (an “Initial Product”) achieves some, but not all
of the development milestones set forth above, and a backup program within the same Program (a
“Back-Up Product”) achieves a development milestone further in the development cycle than the last
milestone achieved by the Initial Product, then such later milestones shall be due and payable with
respect to such Back-Up Product as such later milestones are achieved as if such Back-Up Product
were the Initial Product.

35

 

Strategic Alliance and Collaboration Agreement

     (b) Sales Milestone.

	 	 	 	 	 
	 	 	Milestone
	Milestone Event	 	Payment
	Upon Net Sales from or on account of the worldwide sale or
distribution of all Licensed Products containing the same
Licensed Compound exceeding U.S.$[**]
	 	 	U.S.$[**]	 

     The sales-based milestone payment set forth above shall be payable only once per Licensed
Compound, and shall be paid by BMS in [**] installments, with the first installment due and payable
thirty (30) calendar days after the end of the year in which such milestone event is first met.
BMS shall pay the [**] installment(s) to ATI on the [**]; provided that
[**] of such Licensed Products containing the same Licensed Compound are [**].

     For clarity, the Milestone Event in this Section 9.3(b) shall be payable on a Licensed
Compound-by-Licensed Compound basis, and Net Sales from each Licensed Product containing the same
Licensed Compound shall be aggregated (even if in different dosages, by or administered by
different delivery mechanisms, or for different indications, etc.).

    9.4 Royalties.

     (a) Royalties and Rates. Subject to Section 9.4(b), BMS shall pay to ATI running
royalties based on the total aggregate annual Net Sales worldwide by BMS and its Affiliates and
Sublicensees of all Licensed Compounds and Licensed Products in a given calendar year at the
following royalty rates:

	 	 	 	 	 
	Aggregate Net Sales of all Licensed Compounds and	 	 
	Licensed Products in a calendar year	 	Royalty Rate
	For Net Sales up to U.S.$[**]
	 	 	[**]	%
	 
	 	 	 	 
	For Net Sales above U.S.$[**] up to U.S.$[**]
	 	 	[**]	%
	 
	 	 	 	 
	For Net Sales above U.S.$[**]
	 	 	[**]	%

     By way of example, in a given calendar year, if the aggregate annual worldwide Net Sales for
all Licensed Compounds and Licensed Products is $[**], the following royalty payment would be
payable for those Net Sales under this Section 9.4(a): [**].

36

 

Strategic Alliance and Collaboration Agreement

     (b) Royalty Term. Royalties under Section 9.4(a) shall be payable on the Net Sales of
a particular unit of Licensed Compound or Licensed Product if at least one of the following three
(3) conditions apply:

          (i) on a country-by-country and Licensed Compound or Product-by-Licensed Compound or Product
basis, if one or more Valid Claims within any of the ATI Patents (including the Joint Collaboration
Patents), the BMS Collaboration Patents or the RCT Patents would be infringed by the manufacture,
use, sale, offer for sale or importation of such unit of Licensed Compound or Licensed Product;

          (ii) if one or more Regulatory Exclusivity Periods would apply to the manufacture, use, sale,
offer for sale or importation of such unit of Licensed Compound or Licensed Product; or

          (iii) on a country-by-country and Licensed Compound-by-Licensed Compound basis, if Net Sales
of such Licensed Compound and Licensed Products containing such Licensed Compound, with respect to
each such unit sold or distributed for use in such country, were to accrue before the tenth
(10th) anniversary of the First Commercial Sale in such country of the first such
Licensed Product containing such Licensed Compound.

     (c) Additional Royalty Provisions. The royalties payable under Section 9.4(a) shall
be subject to the following:

          (i) Only one royalty shall be payable hereunder with respect to the same unit of Licensed
Compound or Licensed Product.

          (ii) Licensed royalties when owed or paid hereunder shall be non-refundable and non-creditable
and not subject to set-off (except as otherwise expressly provided in Section 9.5(c));

          (iii) ATI shall bear all Third Party milestones and royalties owed with respect to a Licensed
Product, on intellectual property that: (i) is licensed by ATI as of the Effective Date and also
licensed to BMS hereunder or pursuant to Section 8.6; or (ii) is a Patent that: (A) ATI received
written notice of potential infringement from a Third Party prior to the Effective Date and did not
disclose same to BMS in writing; and (B) covers the composition of matter, method of making or
method of using a Licensed Compound that ATI had Knowledge of prior to the Effective Date. Subject
to clauses (iv) and (v) below, BMS shall bear all other Third Party milestones and royalties owed
on intellectual property in connection with the Development, Manufacture and Commercialization of a
Licensed Product; provided that each Party shall bear all Third Party royalties arising from any
infringing activities by such Party prior to the Effective Date.

          (iv) BMS may deduct from the royalties it would otherwise owe to ATI pursuant to Section 9.4
for a particular Licensed Compound, an amount equal to [**] percent ([**]%) of all royalties
payable to a Third Party in consideration for rights necessary or commercially reasonably useful
for the manufacture, use or sale of such Licensed Compound, up to a maximum deduction of [**]
percent ([**]%) for a Program 1 Licensed Product or up to a maximum deduction of [**] percent
([**]%) for all other Licensed Products.

37

 

Strategic Alliance and Collaboration Agreement

          (v) Generic Competition. During the applicable Royalty Term for a particular Licensed
Product in a particular country while royalties are payable on the basis of Sections 9.4(b)(ii) or
9.4(b)(iii) (and not on the basis of Section 9.4(b)(i)), if any Third Parties are selling a Generic
Product in any such country in any year; and such sales of such Generic Product(s) in such country
for such year are, in the aggregate (on a unit equivalent basis):

               (1) greater than [**] percent ([**]%), but less than or equal to [**] percent ([**]%) of the
sum of the entire market for such Licensed Product in such country, then the royalties due to ATI
for such country in such year shall be reduced by [**] percent ([**]%) from what would otherwise
have been due under Section 9.4; or

               (2) greater than [**] percent ([**]%) of the sum of the entire market for such Licensed
Product in such country, then the royalties due to ATI for such country in such year shall be
reduced by [**] percent ([**]%) from what would otherwise have been due under Section 9.4.

          (vi) Limitation on Deductions. Notwithstanding anything to the contrary in this
Agreement, the operation of clauses (iv) or (v) above or elsewhere in this Agreement for a given
Licensed Product, whether singularly or in combination, shall not reduce in any payment period
hereunder the royalties due to ATI for such Licensed Product below [**] percent ([**]%) of what
would otherwise have been due based on the royalty rates specified in Section 9.4(a). For clarity,
in no event shall the reductions provided for in Section 9.4(c)(iv) be reduced below the caps
specified in such Section for any reason unless Section 9.4(c)(v) applies to a Licensed Product in
question, and then this Section 9.4(c)(vi) shall apply.

          (vii) By written notice to BMS, ATI shall have the right to waive, in its sole discretion,
retrospectively or prospectively, some or all of the royalties owed or that would otherwise be owed
in the future to ATI as a result of this Agreement, whether by country, product or reduction in the
applicable royalty rate(s), and ATI shall have no liability of any kind whatsoever as a result of
the presence or absence of any such waived obligation.

          (viii) If a particular unit of Licensed Compound or Licensed Product is sold or distributed in
one country with the intention of the selling or distributing entity for use in one or more other
countries, those other countries of intended use as well as such country of sale shall be treated
as the countries of sale or distribution for purposes of Section 9.4(b)(iii). The Parties agree
that the good faith estimate of such intended use by the selling entity shall be binding for such
purposes.

   9.5 Payment Terms.

     (a) Manner of Payment. All payments to be made by BMS hereunder shall be made in U.S.
dollars by wire transfer to such bank account as ATI may designate.

     (b) Reports and Royalty Payments. For as long as royalties or other payments are due
under this Article 9, BMS shall furnish to ATI a written report, within forty-five (45) calendar
days after the end of each calendar quarter, showing the amount of Net Sales of Licensed Product
and royalty due, and any other payments accrued during such calendar quarter. Royalty and other
payments for each calendar quarter shall be due at the same time as such written report

38

 

Strategic Alliance and Collaboration Agreement

for the
calendar quarter. The report shall include, at a minimum, the following information for the
applicable calendar quarter, each listed by Licensed Compound and Licensed Product, and by country
of sale or intended use: (i) the number of units of Licensed Compound and Licensed Product sold by
BMS and its Affiliates and Sublicensees; (ii) Net Sales; (iii) royalties, Milestone Payments,
Exclusivity Payments and other payments owed to ATI or already paid during such calendar quarter,
listed by category; (iv) the computations for any applicable currency conversions pursuant to
Section 9.5(d); (v) credits taken against royalties owed pursuant to Section 9.4(c), and the amount
of any outstanding credits be taken under such Section in future calendar quarters; and (vi) the
amount of aggregate Net Sales for any Licensed Compound, and all Licensed Products containing such
Licensed Compound, for purposes of determining whether the Milestone Event in Section 9.3(b) has
occurred.

     (c) Records and Audits. BMS shall keep, and shall cause each of its Affiliates and
Sublicensees, as applicable, to keep adequate books and records of accounting for the purpose of
calculating all royalties and other amounts payable to ATI hereunder and ensuring BMS’ compliance
hereunder, including the gross amounts of sales for Licensed Products and any deductions taken from
such gross amounts in order to calculate Net Sales. For the three (3) years next following the end
of the calendar year to which each shall pertain, such books and records of accounting (including
those of BMS’ Affiliates and Sublicensees, as applicable) shall be kept at each of their principal
place of business and shall be open for inspection and copying at reasonable times and upon
reasonable notice by an independent certified accountant selected by ATI, and which is reasonably
acceptable to BMS, for inspecting the royalties and other amounts
due to ATI under this Agreement. In no event shall such inspections be conducted hereunder
more frequently than once every twelve (12) months. Such accountant shall have executed and
delivered to BMS and its Affiliates and Sublicensees, as applicable, a customary confidentiality
agreement as reasonably requested by BMS. The results of such inspection, if any, may be shared by
the accountant with BMS and ATI at either Party’s request, and shall be binding on both Parties.
Any underpayments shall be paid by BMS within thirty (30) calendar days of notification of the
results of such inspection. Any overpayments shall be fully creditable against amounts payable in
subsequent payment periods but otherwise shall not be reimbursed by ATI. ATI shall pay for any
such inspections, except that in the event there is any upward adjustment in aggregate royalties or
other amounts payable for any calendar year shown by such inspection of more than five percent (5%)
of the amount paid, BMS shall reimburse ATI for any reasonable out-of-pocket costs of such
accountant or related to such inspection.

     (d) Currency Exchange. Conversion of sales recorded in local currencies to Dollars
shall be performed in a manner consistent with BMS’ normal practices used to prepare its audited
financial statements for internal and external reporting purposes, which uses a widely accepted
source of published exchange rates.

     (e) Taxes. BMS may withhold from payments due to ATI amounts for payment of any
withholding tax that is required by law to be paid to any taxing authority with respect to such
payments. BMS shall provide ATI all relevant documents and correspondence, and shall also provide
to ATI any other cooperation or assistance on a reasonable basis as may be necessary to enable ATI
to claim exemption from such withholding taxes and to receive a full refund of such withholding tax
or claim a foreign tax credit. BMS shall give proper evidence from time to time as to the payment
of such tax. The Parties shall cooperate with each other in seeking deductions

39

 

Strategic Alliance and Collaboration Agreement

under any double
taxation or other similar treaty or agreement from time to time in force. Such cooperation may
include BMS making payments from a single source in the U.S., where possible. Apart from any such
permitted withholding, the amounts payable BMS to ATI hereunder shall not be reduced on account of
any taxes, duties or other levies (except to the extent any such taxes, duties or levies are
permitted to be accounted for in the calculation of Net Sales in accordance with Section 1.48).

     (f) Blocked Payments. In the event that, by reason of applicable law in any country,
it becomes impossible or illegal for BMS (or any of its Affiliates, Sublicensees or Distributors)
to transfer, or have transferred on its behalf, payments owed ATI hereunder, BMS shall promptly
notify ATI of the conditions preventing such transfer and such payments shall be deposited in local
currency in the relevant country to the credit of ATI in a recognized banking institution
designated by ATI or, if none is designated by ATI within a period of thirty (30) calendar days, in
a recognized banking institution selected by BMS or its Affiliate, Sublicensee or Distributor, as
the case may be, and identified in a written notice given to ATI.

     (g) Interest Due. BMS shall pay ATI interest on any payments that are not paid on or
before the date such payments are due under this Agreement at a rate equivalent to (i) the prime
rate plus (ii) two percent (2.0%) per year or the maximum applicable legal rate, if less,
calculated on the total number of calendar days payment is delinquent.

   9.6 Mutual Convenience of the Parties. The royalty and other payment obligations set forth hereunder have been agreed to by the Parties
for the purpose of reflecting and advancing their mutual convenience, including the ease of
calculating and paying royalties and other amounts to ATI. BMS hereby stipulates to the fairness
and reasonableness of such royalty and other payments obligations and covenants not to allege or
assert, nor to allow any of its Sublicensees or Affiliates to allege or assert, nor further to
cause or support any other Third Parties to allege or assert, that any such royalty or other
payments obligations are unenforceable or illegal in any way (including by reason of patent misuse
or other anti-competition considerations).

ARTICLE — 10 INTELLECTUAL PROPERTY; PATENT PROSECUTION AND MAINTENANCE.

   10.1 Ownership.

     (a) The inventorship of all Sole Inventions and Joint Inventions shall be determined under the
patent laws of the United States.

     (b) Each Party shall own the entire right, title and interest in and to any and all of its
Sole Inventions, and Patents claiming such Sole Inventions (and no Joint Inventions) (“Sole
Invention Patents”). BMS and ATI shall be joint owners in and to any and all Joint Inventions and
Patents claiming such Joint Inventions (“Joint Invention Patents”). BMS and ATI as joint owners
each shall have the right to exploit and to grant licenses under such Joint Inventions, and where
exercise of such rights require, under the laws of a country, with the consent of and without
accounting to (by operation of this sentence) the other Party unless otherwise specified in this
Agreement.

40

 

Strategic Alliance and Collaboration Agreement

     (c) All employees, agents and contractors of each Party providing services in connection with
this Agreement (other than for Clinical Studies) shall be under written obligation to assign (or
license) any inventions and related intellectual property to the Party for whom they are employed
or are providing services to the extent required by such Party to assign and grant licenses to any
Collaboration Patents or Inventions as required hereunder (assuming Control thereof), unless
otherwise mutually agreed to by the Parties.

     (d) The Parties acknowledge and agree that this Agreement shall be deemed to be a Joint
Research Agreement under 35 U.S.C. 103(c), provided that neither Party shall be required by this
reference to have any Patent take advantage of or become subject to such § 103(c) without such
Party’s prior consent.

     (e) Notwithstanding the foregoing, all right, title and interest in and to Sole and Joint
Inventions of BMS first invented or discovered during the Discovery Term with respect to any
Program that are compounds, which compounds are Adnectins or Product Forms other than Adnectins or
Product Forms linked to (or used with) another agent or component Controlled by BMS (and Patents
claiming such Inventions only where and to the extent that any such Patent solely and specifically
claims such Invention(s)), shall be solely owned by ATI (and such Patents treated as “Sole
Invention Patents” of ATI hereunder), and BMS hereby assigns to ATI all
interest therein and thereto and agrees to take all necessary steps to perfect such assignment
and ATI’s sole ownership thereof.

   10.2 Disclosure. Each Party shall submit a written report to the JRC no less frequently than
within sixty (60) calendar days of the end of each quarter during the R&D Period with respect to
each Program describing any Sole Invention or Joint Invention arising during the prior quarter in
the course of the Program which it believes may be patentable or at such earlier time as may be
necessary to preserve patentability of such invention. Each Party shall provide to the other Party
such assistance and execute such documents as are reasonably necessary to permit the filing and
prosecution of such patent application to be filed on such Sole Invention or Joint Invention, or
the issuance, maintenance or extension of any resulting Patent. The foregoing reporting
obligations shall continue during the Discovery Term with respect to any Program for Inventions and
resulting Patents subject to the assignments and licenses contained hereunder.

   10.3 Patent Prosecution and Maintenance; Abandonment.

     (a) Filing, Prosecution and Maintenance of Certain Patents Controlled by ATI.

          (i) Prosecution. Subject to Sections 10.3(a)(ii) and (f) below, ATI shall be
responsible for the preparation, filing, prosecution (including any interferences, oppositions,
reissue proceedings and reexaminations) and maintenance of all ATI Target Patents (including Joint
Invention Patents that are “ATI Target Patents” hereunder) that in each case are exclusively
licensed to BMS under Section 8.1 (the “ATI Prosecuted Patents”), provided that such
responsibilities shall be carried out by external patent counsel selected by ATI, or by ATI’s
internal patent counsel in conjunction with external patent counsel selected by it, and provided
further that, in each case, such external patent counsel shall be subject to BMS’ approval (such
approval not to be unreasonably withheld, delayed or conditioned). ATI, or its outside counsel,
shall provide BMS with an update of the filing, prosecution and maintenance status for each of

41

 

Strategic Alliance and Collaboration Agreement

the
ATI Prosecuted Patents on a periodic basis, and shall use commercially reasonable efforts to
consult with and cooperate with BMS with respect to the filing, prosecution and maintenance of the
ATI Prosecuted Patents, including providing BMS with drafts of proposed filings to allow BMS a
reasonable opportunity for review and comment before such filings are due. ATI, or its outside
counsel, shall provide to BMS copies of any papers relating to the filing, prosecution and
maintenance of the ATI Prosecuted Patents promptly upon their being filed and received.

          (ii) Abandonment. In no event shall ATI knowingly permit any of the ATI Prosecuted
Patents to be abandoned in any country, or elect not to file a new patent application claiming
priority to a patent application within the ATI Prosecuted Patents either before such patent
application’s issuance or within the time period required for the filing of an international (i.e.,
Patent Cooperation Treaty), regional (including European Patent Office) or national application,
without BMS’ written consent (such consent to not be unreasonably withheld, delayed or conditioned)
or BMS otherwise first being given an opportunity to assume full responsibility (at BMS’ expense)
for the continued prosecution and maintenance of such ATI Prosecuted Patents or the filing of such
new patent application. Accordingly, ATI, or its outside counsel, shall provide BMS with notice of
the allowance and expected issuance date of any
patent within the ATI Prosecuted Patents, or any of the aforementioned filing deadlines, and
BMS shall provide ATI with prompt notice as to whether BMS desires ATI to file such new patent
application. In the event that ATI decides either: (A) not to continue the prosecution or
maintenance of a patent application or patent within the ATI Prosecuted Patents in any country; or
(B) not to file such new patent application requested to be filed by BMS, ATI shall provide BMS
with notice of this decision at least thirty (30) calendar days prior to any pending lapse or
abandonment thereof. In the event that BMS assumes such responsibility for such filing,
prosecution and maintenance, BMS shall have the right to transfer the responsibility for such
filing, prosecution and maintenance of such patent applications and patents to patent counsel
(outside or internal) selected by BMS, and ATI shall cooperate as reasonably requested by BMS to
facilitate control of such filing, prosecution and maintenance by BMS. In the case where BMS takes
over the filing, prosecution or maintenance of any patent or patent application as set forth above,
BMS shall keep ATI reasonably informed as to the status of such activities but shall not be liable
to ATI in any way with respect to its handling of, or the results obtained from, the filing,
prosecution, issuance, extension or maintenance of any such application or any resulting patent or
any failure by it to so file, prosecute, extend or maintain. In addition, ATI shall, at the
expense of BMS, provide such assistance and execute such documents as are reasonably necessary to
continue or permit the filing, prosecution or maintenance of such patent or patent application or
the issuance, maintenance or extension of any resulting patent, with any such Patents remaining
subject to all the terms of this Agreement (including license grants) and ATI’s subsequent right to
opt in if BMS later elects not to proceed therewith (which shall be on the same terms as BMS’
rights and obligations pursuant to this Section 10.3(a).

     (b) Filing, Prosecution and Maintenance of Remaining Joint Invention Patents. In
accordance with this Section 10.3(b), the Parties shall in good faith by mutual agreement designate
one of them to be responsible for (but not obligated with respect to) the preparation, filing,
prosecution (including any interferences, oppositions, reissue proceedings and reexaminations) and
maintenance of all Joint Invention Patents not subject to Section 10.3(a), on the terms set forth
in Section 10.3(a) with such designated Party acting as “ATI” under such Section and the other
Party as “BMS” thereunder, provided that ATI may elect to control

42

 

Strategic Alliance and Collaboration Agreement

prosecution (for clarity, on the
terms set forth in Section 10.3(a)) if any such Joint Invention Patents are subject to the licenses
to ATI contained in Section 8.2 or 17.5.

     (c) Filing, Prosecution and Maintenance of Sole Invention Patents Controlled by BMS.
In accordance with this Section 10.3(c), BMS shall be responsible for (but not obligated with
respect to) the preparation, filing, prosecution (including any interferences, oppositions, reissue
proceedings and reexaminations) and maintenance of all Sole Invention Patents Controlled by BMS,
provided that ATI shall have the rights contained in Section 10.3(a) with respect to those Patents
that are subject to the exclusive licenses to ATI contained in Section 8.2 or 17.5, with the roles
of the Parties reversed under Section 10.3(a).

     (d) Filing, Prosecution and Maintenance of Other ATI Patents. In accordance with this
Section 10.3(d), ATI shall be responsible for (but not obligated with respect to) the preparation,
filing, prosecution (including any interferences, oppositions, reissue proceedings and
reexaminations) and maintenance of all ATI Patents not subject to Section 10.3(a) or 10.3(b)
(including certain ATI Foundation Patents).

     (e) Patent Term Extension. ATI and BMS shall each cooperate with each another and
shall use commercially reasonable efforts in obtaining patent term extension (including any
pediatric exclusivity extensions as may be available) or supplemental protection certificates or
their equivalents in any country with respect to ATI Prosecuted Patents. If elections with respect
to obtaining such patent term extensions are to be made, or as to which Patents for which such
extensions shall be sought, BMS shall have the right to make such election(s); provided that such
election(s) shall be made so as to maximize the period of marketing exclusivity for the Licensed
Product.

     (f) Shared Expenses for ATI Prosecuted Patents and Joint Invention Patents. BMS shall
bear [**] and ATI [**] of the expenses (including reasonable fees for any outside counsel, but not
inside counsel fees) associated with the preparation, filing, prosecution (including any
interferences, oppositions, reissue proceedings and reexaminations) and maintenance of ATI
Prosecuted Patents and those Joint Invention Patents subject to Section 10.3(b).

     (g) BMS Sole Expenses. BMS shall bear the expenses (including reasonable fees for any
outside counsel, but not ATI inside counsel fees) associated with the preparation, filing,
prosecution (including any interferences, oppositions, reissue proceedings and reexaminations) and
maintenance of Patents pursuant to Section 10.3(c) (other than those exclusively licensed to ATI
under Section 8.2 or Section 17.5 (once such license becomes effective) or for which ATI elects its
opt-in rights under Section 10.3(c) by reference to Section 10.3(a), in each case for which ATI
shall bear the expenses).

     (h) ATI Sole Expenses. ATI shall bear the expenses (including reasonable fees for any
outside counsel, but not BMS inside counsel fees) associated with the preparation, filing,
prosecution (including any interferences, oppositions, reissue proceedings and reexaminations) and
maintenance of Patents subject to Section 10.3(d).

     (i) Non-payment of Expenses. If a Party elects not to pay its share of expenses
pursuant to Sections 10.3(f), 10.3(g) or 10.3(h) for any Patent, such non-paying Party shall inform
the

43

 

Strategic Alliance and Collaboration Agreement

other Party in writing not less than two (2) months before any relevant deadline (or, in the
event of a shorter period in which to respond to a patent office, as soon as reasonably
practicable) (such Patent(s) in such countries, as identified in such notice, being a
“Cost-Terminated Patent Right”). If such non-paying Party is a licensee hereunder to such
Cost-Terminated Patent Right, such non-Paying Party shall no longer have any rights under Section
8.1 if BMS or Sections 8.2 and 17.5 if ATI, as applicable, with respect to the relevant Patent in
such country, provided that all remaining rights and licenses under all other Patent(s) within such
licensed Patents would remain in effect. If such non-Paying Party is the licensor hereunder of
such Cost-Terminated Patent Right, and such Patent is subject to a back-up right of prosecution
under Section 10.3(a)(ii) for the other Party, then such other Party may deduct, from royalties
payable on such Patent (and not on account of any other Patent or Regulatory Exclusivity Period
hereunder), the amount that the non-paying Party would have paid for prosecution of such Patent
(but capped at no more than Fifty Thousand Dollars (U.S.$50,000) for each payment period hereunder)
if the other Party continues with such Patent, and otherwise the rights and licenses to such Patent
hereunder shall remain unchanged. It is also understood that in all such cases the non-Paying
Party shall be offered the opportunity to assume its share of the responsibility for the costs of
preparation, filing, prosecution and maintenance of any Patent(s) claiming priority
directly or indirectly from any such Cost-Terminated Patent Right, and that where such
expenses are assumed by such non-Paying Party, it shall be afforded all the rights and licenses as
provided under this Agreement for the licensed Patents (other than the Cost-Terminated Patent
Right) with respect to such Patent(s) claiming priority directly or indirectly from any such
Cost-Terminated Patent Right.

     (j) Reports. Each Party shall provide to the other Party, on a semi-annual basis, a
patent report that includes the serial number, docket number and status of each Patent for which,
pursuant to Sections 10.3(a) to 10.3(d), such Party has the right to direct the filing, prosecution
and maintenance and which covers a Sole Invention or Joint Invention. The Parties through their
patent counsel shall discuss as appropriate (but not more than semi-annually) ways in which to
allocate such out-of-pocket expenses in an appropriate, cost-effective manner consistent with the
purposes of this Agreement and ATI’s obligations to Third Parties. The Parties shall update
Exhibits C, D and E on at least an annual basis or at such time as either
Party may reasonably request.

     (k) Cooperation. Each Party shall cooperate fully with the other in the activities
covered by this Section 10.3. To the extent that a Third Party licensor of ATI has retained any
right to prepare, file, prosecute (including any interference, opposition, reissue proceeding or
reexamination) or maintain or extend any Patent subject to this Section 10.3 or otherwise be
involved in such activities, ATI shall use commercially reasonable efforts to cause such Third
Party licensor to take the actions specified by this Section 10.3 in a manner consistent with the
agreement(s) by which such Third Party retains such rights, but ATI shall not be deemed to be in
breach of its obligations under this Section 10.3 if, after using such commercially reasonable
efforts, it is unable to comply with such obligations because of actions taken or not taken by such
Third Party licensor.

44

 

Strategic Alliance and Collaboration Agreement

ARTICLE — 11 ENFORCEMENT OF IP RIGHTS; DEFENSE OF THIRD PARTY INFRINGEMENT CLAIMS.

   11.1 Enforcement of Patent Rights.

     (a) Enforcement of BMS Enforcement Patents.

          (i) Enforcement by ATI. In the event that management or in-house counsel for either
Party becomes aware of a suspected infringement of any Patent claiming a Sole Invention of BMS or
any Joint Invention Patent that claims (1) the composition of matter (including formulation),
manufacture or use of one or more Reverted Compounds that is being developed or commercialized
using Commercially Reasonable Efforts or (2) Adnectin Core Manufacturing and Formulation
Technology, and in each case which is exclusively licensed to ATI (for purposes of this Section
11.1(a) only, a “BMS Enforcement Patent”), such Party shall notify the other Party promptly, and
following such notification, the Parties shall confer. Each Party shall provide the same level of
disclosure to its in-house counsel concerning suspected infringement of a BMS Enforcement Patent as
such Party would provide with respect to suspected infringement of its own issued Patent or an
exclusively licensed issued Patent claiming a product it is
developing or commercializing independent of this Agreement. Subject to the rights of any
Third Party licensees of such Patent, and provided such infringement falls within the exclusive
scope of such license to ATI, ATI shall have the first right, but shall not be obligated, to bring
an infringement action at its own expense, in its own name and entirely under its own direction and
control, subject to Section 11.1(d). BMS shall reasonably assist ATI (at ATI’s expense) in such
actions or proceedings if so requested, and shall lend its name to such actions or proceedings if
requested by ATI or required by law, and ATI shall hold BMS harmless from any liability incurred by
BMS arising out of any such proceedings or actions. BMS shall have the right to participate and be
represented in any such suit by its own counsel at its own expense. No settlement of any such
action or defense which restricts the scope, or adversely affects the enforceability, of a BMS
Enforcement Patent may be entered into by ATI without the prior consent of BMS (such consent to not
be unreasonably withheld, delayed or conditioned).

          (ii) Enforcement by BMS. If ATI elects not to bring any action for infringement or to
defend any proceeding described in clause (1) of Section 11.1(a)(i) within a commercially
reasonable time period, then BMS may bring such action or defend such proceeding at its own
expense, in its own name and entirely under its own direction and control. ATI shall reasonably
assist BMS (at BMS’ expense) in any action or proceeding being prosecuted or defended by BMS, if so
requested by BMS or required by law, and BMS shall hold ATI harmless from any liability incurred by
ATI arising out of any such proceedings or actions. ATI shall have the right to participate and be
represented in any such suit by its own counsel at its own expense. No settlement of any such
action or defense which restricts the scope, or adversely affects the enforceability, of any such
BMS Enforcement Patent may be entered into by BMS without the prior of consent of ATI (such consent
to not be unreasonably withheld, delayed or conditioned). BMS shall have no back-up enforcement
right regarding any Section 11.1(a)(i) clause (2) infringement.

45

 

Strategic Alliance and Collaboration Agreement

     (b) Enforcement of ATI Enforcement Patents.

          (i) Enforcement by BMS. In the event that management or in-house counsel for either
Party becomes aware of a suspected infringement, by a Third Party of an ATI Prosecuted Patent that
claims the composition of matter (including formulation), manufacture or use of one or more
Licensed Products that is being developed or commercialized using Commercially Reasonable Efforts
and which is exclusively licensed to BMS under Section 8.1 (for purposes of this Section 11.1(b)
only, an “ATI Enforcement Patent”), such Party shall notify the other Party promptly, and following
such notification, the Parties shall confer. Each Party shall provide the same level of disclosure
to its in-house counsel concerning suspected infringement of an ATI Enforcement Patent as such
Party would provide with respect to suspected infringement of its own issued Patent or an
exclusively licensed issued Patent claiming a product it is developing or commercializing
independent of this Agreement. Provided such infringement falls within the exclusive scope of such
license to BMS, BMS shall have the first right, but shall not be obligated, to bring an
infringement action against any such Third Party at its own expense, in its own name and entirely
under its own direction and control. ATI shall reasonably assist BMS (at BMS’ expense) in such
actions or proceedings if so requested, and shall lend its name to such actions or proceedings if
requested by BMS or required by law, and BMS shall hold ATI harmless from any liability incurred by
ATI arising out of any such proceedings or actions at BMS request. ATI shall have the right to
participate and be represented in any such suit by its
own counsel at its own expense. No settlement of any such action or defense which restricts
the scope, or adversely affects the enforceability, of any such ATI Enforcement Patent may be
entered into by BMS without the prior consent of ATI (such consent to not be unreasonably withheld,
delayed or conditioned).

          (ii) Enforcement by ATI. If BMS elects not to bring any action for infringement or to
defend any proceeding described in Section 11.1(b)(i) within a commercially reasonable time period,
or where ATI (or any other party other than BMS who is licensed under such ATI Enforcement Patent)
otherwise desires to bring an action or to defend any proceeding directly involving an ATI
Enforcement Patent, then ATI may bring such action or defend such proceeding at its own expense, in
its own name and entirely under its own direction and control, subject to Section 11.1(d). BMS
shall reasonably assist ATI (at ATI’s expense) in any action or proceeding being prosecuted or
defended by ATI, if so requested by ATI or required by law, and ATI shall hold BMS harmless from
any liability incurred by BMS arising out of any such proceedings or actions. BMS shall have the
right to participate and be represented in any such suit by its own counsel at its own expense. No
settlement of any such action or defense which restricts the scope, or adversely affects the
enforceability, of an ATI Enforcement Patent may be entered into by ATI without the prior consent
of BMS (such consent to not be unreasonably withheld, delayed or conditioned).

     (c) Enforcement of Joint Patents. In the event that management or in-house counsel
for either Party becomes aware of a suspected infringement of a Patent that claims a Joint
Invention but is not subject to the enforcement rights specified in Sections 11.1(a) or 11.1(b)
(for purposes of this Section 11.1(c) only, an “Other Joint Patent”), such Party shall notify the
other Party promptly, and following such notification, the Parties shall confer. Each Party shall
provide the same level of disclosure to its in-house counsel concerning suspected infringement of
an Other Joint Patent as such Party would provide with respect to suspected infringement of its own
issued

46

 

Strategic Alliance and Collaboration Agreement

Patent or an exclusively licensed issued Patent claiming a product it is developing or
commercializing independent of this Agreement. The Parties shall jointly prosecute any such
infringement, and shall share equally the expenses thereto, unless one Party elects not to enforce,
and then the other Party shall have the right, but shall not be obligated, to prosecute an
infringement action at its own expense, in its own name and entirely under its own direction and
control, subject to Section 11.1(d). The non-enforcing Party shall reasonably assist the enforcing
Party (at the enforcing Party’s expense) in such actions or proceedings if so requested, and shall
lend its name to such actions or proceedings if requested by the enforcing Party or required by
law, and the enforcing Party shall hold the non-enforcing Party harmless from any liability
incurred by the non-enforcing Party arising out of any such proceedings or actions. The
non-enforcing Party shall have the right to participate and be represented in any such suit by its
own counsel at its own expense. No settlement of any such action or defense which restricts the
scope or affects the enforceability of an Other Joint Patent may be entered into by the enforcing
Party without the prior consent of the non-enforcing Party (such consent to not be unreasonably
withheld, delayed or conditioned).

     (d) Listable Patents. ATI’s enforcement rights specified above are subject to the
following limited restriction. For each Licensed Product for which a Phase 3 Study is initiated,
prior to the filing of a Drug Approval Application with respect to such Licensed Product, BMS may
provide written notice to ATI electing one Patent per country that (i) covers the composition
of matter of such Licensed Product, and (ii) is a Collaboration Patent or ATI Target Patent
(such Patent, a “Listable Patent”). ATI and its Affiliates and Third Party licensees shall not
enforce any Listable Patent without ATI first conferring with BMS with respect to any such
enforcement action or proceeding and obtaining the prior written consent of BMS to commence such
action or proceeding, such consent not to be unreasonably withheld, delayed or conditioned,
provided, that if BMS fails to consent to any such action or proceeding, the royalty term specified
in Section 9.4(b)(i) for any Licensed Product that is claimed in such Listable Patent shall in no
event be diminished by any failure to enforce such Listable Patent. A Listable Patent will only
remain a “Listable Patent” hereunder and subject to this Section 11.1(d), on a country-by-country
basis, for as long as the Licensed Product for which such Patent was designated under this Section
11.1(d) remains in active Development or Commercialization in such country.

     (e) General Provisions Relating to Enforcement of Patents.

          (i) Withdrawal. Subject to Section 11.1(d), if either Party brings such an action or
defends such a proceeding under this Section 11.1 and subsequently ceases to pursue or withdraws
from such action or proceeding, it shall promptly notify the other Party and the other Party may
substitute itself for the withdrawing Party under the terms of this Section 11.1 at its own
expense.

          (ii) Recoveries. In the event either Party exercises the rights conferred in this
Section 11.1 and recovers any damages or other sums in such action, suit or proceeding or in
settlement thereof, such damages or other sums recovered shall first be applied to all
out-of-pocket costs and expenses incurred by the Parties in connection therewith, including
attorneys fees. If such
recovery is insufficient to cover all such costs and expenses of both
Parties, it shall be shared in proportion to the total such costs and expenses incurred by each
Party. If after such

47

 

Strategic Alliance and Collaboration Agreement

reimbursement any funds shall remain from such damages or other sums
recovered, such funds that arise:

               (1) from enforcement under Section 11.1(c) shall be shared by the Parties equally if jointly
enforced, or retained by the enforcing Party if solely enforced; and

               (2) from enforcement under any other provision of this Section 11.1 (i) that represent
compensation for lost profits of Licensed Products/Reverted Compounds shall be retained by or paid
to the licensee Party, subject to the licensor Party retaining or being paid royalties as
calculated under this Agreement on the amount of hypothetical “Net Sales” that would have produced
such lost profits had the licensee Party sold the applicable Licensed Product(s)/Reverted
Compounds, (ii) that represents compensation for reasonable royalties (to the extent otherwise
payable hereunder), if concerning Licensed Product(s), shared equally, and if concerning Reverted
Compounds, twenty percent (20%) shall be retained by or paid to BMS and eighty percent (80%) shall
be retained by or paid to ATI, and (iii) that represents damages arising from enforcement of the
license grant of Section 8.2 shall be retained by or paid to ATI, and (iv) that represents damages
not addressed above or additional damages (for example, enhanced or punitive damages) shall be
shared by the Parties equally.

          (iii) Third Party Licensors. To the extent that a Third Party licensor has retained
any right to enforce or otherwise be involved in the activities specified in this Section 11.1 for
any
Patent, ATI shall use commercially reasonable efforts to cause such Third Party licensor to
take the actions specified by this Section 11.1 in a manner consistent with the agreement(s) by
which such Third Party retains such rights, but ATI shall not be deemed to be in breach of its
obligations under this Section 11.1 if, after using such commercially reasonable efforts, it is
unable to comply with such obligations because of actions taken or not taken by such Third Party
licensor.

     (f) Data Exclusivity and Orange Book Listings. With respect to data exclusivity
periods (such as those periods listed in the FDA’s Orange Book (including any available pediatric
extensions) or periods under national implementations of Article 10.1(a)(iii) of Directive
2001/EC/83, and all international equivalents), BMS shall use commercially reasonable efforts
consistent with its obligations under applicable law (including any applicable consent order) to
seek maintain and enforce all such data exclusivity periods available for the Licensed Products.
With respect to filings in the FDA Orange Book (and foreign equivalents) for issued patents
licensed exclusively to BMS for a Licensed Product, upon request by BMS (and at BMS’ expense), ATI
shall provide reasonable cooperation to BMS in filing and maintaining such Orange Book (and foreign
equivalent) listings.

     (g) No Action in Violation of Law. Neither Party shall be required to take any action
pursuant to this Section 11.1 that such Party reasonably determines in its sole judgment and
discretion conflicts with or violates any court or government order or decree applicable to such
Party. If BMS invokes this Section 11.1(g) with respect to Patents that are exclusively licensed
to Adnexus under Section 17.5, ATI shall have the right to require that BMS grant in a timely
manner to Adnexus such rights (including assignment of the applicable Patents) as may be necessary
for Adnexus to exercise its rights under this Article 11 with respect to such Patents (including
seeking, maintaining and enforcing all Regulatory Exclusivity Periods) without BMS’

48

 

Strategic Alliance and Collaboration Agreement

involvement
(unless any such granting of rights or assignment is prohibited by such court or government order
or decree). In the event of such grant of rights (including assignment) with respect to any such
Patents, such Patents shall continue to be treated as BMS Enforcement Patents and shall otherwise
continue to be subject to all of the terms and conditions of the Agreement in the same way as the
other BMS Enforcement Patents.

     (h) Notification of Patent Certification. ATI shall notify and provide BMS with
copies of any allegations of alleged patent invalidity, unenforceability or non-infringement of an
ATI Patent licensed hereunder pursuant to a Paragraph IV Patent Certification by a Third Party
filing an Abbreviated New Drug Application, an application under §505(b)(2) or other similar patent
certification by a Third Party, and any foreign equivalent thereof, with respect to a Licensed
Product. Such notification and copies shall be provided to BMS by ATI as soon as practicable and
at least within five (5) calendar days after ATI receives such certification, and shall be sent by
facsimile and overnight courier to the address set forth below:

Bristol-Myers Squibb Company

P.O. Box 4000

Route 206 & Province Line Road

Princeton, New Jersey 08543-4000

Attention: Vice President and Chief Intellectual Property Counsel

Telephone: 609-252-4825

Facsimile: 609-252-7884

BMS hereby agrees to a like provision with respect to Reverted Compounds and Patents subject to the
exclusive grant in Section 8.2 (with notice to ATI as provided in Section 18.6).

   11.2 Defense of Third Party Claims. If a claim is brought by a Third Party that any activity
related to work performed by a Party in connection with a Program infringes the intellectual
property rights of such Third Party, each Party shall give prompt written notice to the other Party
of such claim, and following such notification, the Parties shall confer on how to respond.

   11.3 Copyright Registrations. Copyrights and copyright registrations on copyrightable subject
matter shall be filed, prosecuted, defended, and maintained, and the Parties shall have the right
to pursue infringers of any copyrights owned or Controlled by it, in substantially the same manner
as the Parties have allocated such responsibilities, and the expenses therefor, for patent rights
under this Article 11.

   11.4 Patent Marking. BMS shall mark, and shall cause all of its Affiliates, Sublicensees and
Distributors to mark, all Licensed Products, or their containers, in accordance with all applicable
patent-marking laws in all countries with respect to any Patents within the ATI Patents, and with
such Patent marking shall indicate that the ATI Patents are licensed from ATI.

ARTICLE
— 12 COMPLAINTS AND ADVERSE EVENT REPORTING

   12.1 Adverse Event Reporting.

Each Party shall agree to provide the other Party with all information available to such Party that
such other Party may reasonably require to comply with its pharmacovigilance responsibilities

49

 

Strategic Alliance and Collaboration Agreement

under
Applicable Law, including notice of any Adverse Drug Experiences from pre-clinical or clinical
laboratory, animal toxicology and pharmacology studies, clinical trials and commercial experiences
with Licensed Compound or Licensed Product, whether by such Party, its Affiliates, and for BMS, its
Distributors and Sublicensees, and for ATI, its Third Party licensees. “Adverse Drug Experience”
shall mean (a) any finding from tests in laboratory animals or in vitro studies that suggests a
significant risk for human subjects including reports of mutagenicity, teratogenicity or
carcinogenicity and (b) any undesirable, untoward or noxious event or experience associated with
the clinical, commercial or other use, or occurring following administration, of Licensed Compound
or Licensed Product in humans, occurring at any dose, whether expected or unexpected and whether
considered related or unrelated to Licensed Compound or Licensed Product, including such an event
or experience as occurs in the course of the use of Licensed Compound or Licensed Product in
professional practice, in a clinical trial, from overdose, whether accidental or intentional, from
abuse, from withdrawal or from a failure of expected pharmacological or biological therapeutic
action of Licensed Compound or Licensed Product, and including those events or experiences that are
required to be reported to the FDA under 21 C.F.R. Sections 312.32 or 314.80, or to foreign
Regulatory Authorities under corresponding Applicable Law outside the United States.

   12.2 Pharmacovigilance Agreement. Subject to the terms of this Agreement, and within three (3)
months of the date when BMS has approved transition of a Licensed Compound into exploratory
development with respect to a Program, BMS and ATI (under the guidance of their respective
Pharmacovigilance Departments, or equivalent thereof) shall define and finalize the
responsibilities the Parties shall employ to protect patients and promote their well-being in a
written Agreement (hereafter referred to as the “Pharmacovigilance Agreement”). These
responsibilities shall include mutually acceptable guidelines and procedures for the receipt,
investigation, recordation, communication, and exchange (as between the Parties) of adverse event
reports, pregnancy reports, and any other information concerning the safety of any Licensed
Compound or Licensed Product. Such guidelines and procedures shall be in accordance with, and
enable the Parties and their Affiliates to fulfill, local and national regulatory reporting
obligations to government authorities. Furthermore, such agreed procedures shall be consistent
with relevant International Council for Harmonization (ICH) guidelines, except where said
guidelines may conflict with existing local regulatory safety reporting requirements, in which case
local reporting requirements shall prevail. Each Party hereby agrees to comply with its respective
obligations under such Pharmacovigilance Agreement (as the Parties may agree to modify it from time
to time) and to cause its Affiliates and Sublicensees to comply with such obligations.

ARTICLE — 13 PRODUCT RECALLS

     In the event that any Regulatory Authority issues or requests a recall or takes similar action
in connection with a Licensed Product, or in the event either Party determines that an event,
incident or circumstance has occurred that may result in the need for a recall or market
withdrawal, the Party notified of or desiring such recall or similar action shall, within
twenty-four (24) hours, advise the other Party thereof by telephone (and confirmed by email or
facsimile), email or facsimile. BMS shall have the sole right to decide, in its discretion,
whether to conduct a recall, at its sole expense, of a Licensed Product, and the manner in which
any such recall shall be conducted.

50

 

Strategic Alliance and Collaboration Agreement

ARTICLE
— 14 CONFIDENTIAL INFORMATION AND PUBLICITY

   14.1 Confidentiality.

     (a) Definition. For purposes of this Agreement, “Confidential Information” shall mean
(i) all tangible materials (including all Adnectin-containing molecules and other biologicals and
Materials), and (ii) all ideas and information of any kind, whether in written, oral, graphical,
machine-readable or other form, whether or not marked or identified as confidential or proprietary,
which are transferred, disclosed or made available by or at the request of either Party to the
other, including: Know-How, Patents, Clinical Data, Non-Clinical Data and Regulatory Documentation
and the identity of Collaboration Targets, Licensed Compounds, Licensed Products and Product Forms
hereunder. For clarity, Clinical Data and Non-Clinical Data generated in connection with this
Agreement, and Regulatory Documentation and the identity of Collaboration Targets and Product Forms
hereunder, shall be considered Confidential Information of BMS, except to the extent that ATI may
use such Non-Clinical Data for Patents purposes pursuant to Section 14.1(d)(ii).

     (b) Restrictions. Except as expressly provided herein, each of the Parties agrees
that, for itself and its Affiliates, and for as long as this Agreement is in effect and for a
period of ten (10) years thereafter, a Party and its Affiliates (the “Receiving Party”) receiving
or possessing Confidential Information of the other Party or its Affiliates (the “Disclosing
Party”) shall (i) not disclose such Confidential Information to any Third Party without the prior
written consent of the Disclosing Party, except for disclosures expressly permitted below, and (ii)
not use such Confidential Information for any purpose except those licensed or otherwise authorized
or permitted by this Agreement.

     (c) Exceptions. The obligations in Section 14.1(b) shall not apply with respect to
any portion of the Confidential Information that the Receiving Party can show by competent proof:

               (i) is publicly disclosed by the Disclosing Party, either before or after it is
disclosed to the Receiving Party hereunder;

               (ii) was known to the Receiving Party or any of its Affiliates, without any obligation
to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing
Party;

               (iii) is subsequently disclosed to the Receiving Party or any of its Affiliates by a
Third Party lawfully in possession thereof and without any obligation to keep it
confidential or any restriction on its use;

               (iv) is published by a Third Party or otherwise becomes publicly available or enters
the public domain, either before or after it is disclosed to the Receiving Party, in each
case without breach of an obligation of confidentiality under this Agreement by the
Receiving Party; or

               (v) has been independently developed by employees or contractors of the Receiving Party
or any of its Affiliates without the aid, application or use of Confidential Information of
the Disclosing Party, as evidenced by contemporaneous written records.

51

 

Strategic Alliance and Collaboration Agreement

     (d) Authorized Disclosures. The Receiving Party may disclose Confidential Information
belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is
reasonably necessary in the following instances:

               (i) by either Party in order to comply with Applicable Law (including any securities
law or regulation or the rules of a securities exchange) and with judicial process, if in
the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for
such compliance;

               (ii) by either Party, in connection with prosecuting or defending litigation,
Regulatory Documentation, and filing, prosecuting and enforcing Patents in connection with a
Party’s rights and obligations pursuant to this Agreement;

               (iii) by ATI in connection with exercising its rights hereunder, to its Affiliates,
potential and future collaborators (including Third Party licensees) subject to redaction of
financial terms, the identity of Targets or Product Forms and the Research Plan, permitted
acquirers or assignees under Section 18.1, investment bankers, investors, lenders, and their
and each of ATI and its Affiliates’ respective directors, employees, contractors and agents;
and

               (iv) by BMS in connection with exercising its rights hereunder, to its Affiliates,
potential and future collaborators (including Third Party licensees), permitted acquirers or
assignees under Section 18.1, permitted subcontractors, and their and BMS and its
Affiliates’ respective directors, employees, contractors and agents,

provided that (1) with respect to Section 14.1(d)(i) or 14.1(d)(ii), where reasonably possible, the
Receiving Party shall notify the Disclosing Party of the Receiving Party’s intent to make any
disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow the
Disclosing Party adequate time to take whatever action it may deem appropriate to protect the
confidentiality of the information to be disclosed, and (2) with respect to Sections 14.1(d)(iii)
or 14.1(d)(iv), each of those named people and entities must be bound prior to disclosure by
confidentiality and non-use restrictions at least as restrictive as those contained in this Article
14 (other than investment bankers, investors and lenders, which must be bound prior to disclosure
by commercially reasonable obligations of confidentiality), but in no case shall Confidential
Information created after the Effective Date be disclosed to a competitor with reference to the
Target or to the fact that the data was created under this Agreement.

   14.2 Terms of this Agreement; Publicity.

     (a) Restrictions. The Parties agree that the terms of this Agreement shall be treated
as Confidential Information of both Parties, and thus may be disclosed only as permitted by
Sections 14.1(c) and 14.1(d) (including clause (iii) and (iv) thereof). Each Party agrees not to
issue any press release or public statement disclosing information relating to this Agreement or
the transactions contemplated hereby or the terms hereof without the prior written consent of the
other Party not to be unreasonably withheld (or as such consent may be obtained in accordance with
Section 14.2(b)), or as permitted by Section 14.1(c) or 14.1(d) (including clause (iii) and (iv)
thereof).

52

 

Strategic Alliance and Collaboration Agreement

     (b) Review. In the event either Party (the “Issuing Party”) desires to issue a press
release or other public statement disclosing information relating to this Agreement or the
transactions contemplated hereby or the terms hereof, the Issuing Party shall provide the other
Party (the “Reviewing Party”) with a copy of the proposed press release or public statement (the
“Release”). The Reviewing Party shall have seven (7) calendar days to provide any comments on such
Release, and if the Receiving Party fails to provide any comments during such three-day period, the
Reviewing Party shall be deemed to have consented to the issuance of such Release. If the
Receiving Party provides any comments, the Parties shall consult on the such Release and work in
good faith to prepare a mutually acceptable Release. Either Party may subsequently publicly
disclose any information previously contained in any Release so consented to; provided that
subsequent descriptions and characterizations (including oral statements where applicable) are
consistent with those that were previously agreed by the Parties (i.e. extrapolations or
conclusions that were not contained in a Release may not be subsequently disclosed by a Party).

     (c) Joint Press Release. The Parties agree to issue the joint press release on
Exhibit G promptly following the Effective Date.

   14.3 Publications.

     (a) Except as required by Applicable Law (in which case the terms and conditions of Section
14.1(d) shall apply), each Party agrees that it shall not publish or present the results of studies
or clinical trials carried out by such Party as part of a Program without the opportunity for prior
review by the other Party; provided, however, that BMS may publish or present the results of
Clinical Studies with respect to Licensed Compound(s) and/or Licensed Product(s) without prior
review by ATI and as long as ATI is acknowledged in its contributions, including, as appropriate,
generation of the Licensed Compound(s) and/or Licensed Product(s), and authorship (to be determined
by customary means). In addition, BMS when reasonably practicable will acknowledge in the
appropriate format that a Licensed Compound in Clinical Studies contains an Adnectin that was
generated by ATI.

     (b) Subject to the limitation set forth in the proviso to paragraph (a) above, each Party
shall provide to the other Party the opportunity to review any of the submitting Party’s proposed
abstracts, manuscripts or presentations (including information to be presented verbally) which
directly relate to the Program and describe activities performed in connection with the Program at
least thirty (30) calendar days prior to their intended submission for publication, and such
submitting Party agrees, upon written request from the other Party, not to submit such abstract or
manuscript for publication or to make such presentation until the other Party is given a reasonable
period of time beyond such thirty (30) calendar day period to seek appropriate patent protection
(in accordance with, and subject to, Article 10) for any material in such publication or
presentation which it reasonably believes is patentable. Once such abstracts, manuscripts or
presentations have been reviewed by each Party and have been approved for publication, the same
abstracts, manuscripts or presentations do not have to be provided again to the other Party for
review for a later submission for publication. Expedited reviews for abstracts or poster
presentations may be arranged if mutually agreeable to the Parties. Each Party also shall have the
right to require in its sole discretion that Confidential Information that would be disclosed in
any such proposed publication be deleted prior to such publication.

53

 

Strategic Alliance and Collaboration Agreement

   14.4 Relationship to the Confidentiality Agreement. This Agreement supersedes the Confidentiality
Agreements, provided that all “Confidential Information” disclosed or received by the Parties under
either of the Confidentiality Agreements shall be deemed “Confidential Information” hereunder and
shall be subject to the terms and conditions of this Agreement.

ARTICLE — 15 WARRANTIES; LIMITATIONS OF LIABILITY: INDEMNIFICATION

   15.1 Representations and Warranties.

     (a) Each Party represents and warrants to the other as of the Effective Date that (i) it has
the legal right and power to enter into this Agreement, to extend the rights and licenses granted
or to be granted to the other in this Agreement, and to fully perform its obligations hereunder;
(ii) this Agreement is a legal and valid obligation binding upon it and is enforceable in
accordance with its terms, subject to applicable limitations on such enforcement based on
bankruptcy laws and other debtors’ rights; and (iii) its execution, delivery and performance of
this Agreement shall not conflict in any material fashion with the terms of any other agreement or
instrument to which it is a party or by which it is bound, nor violate any law or regulation of any
court, governmental body or administrative or other agency having authority over it.

     (b) During the Term, each Party shall use commercially reasonable efforts to maintain (but
without an obligation to renew) and not to breach any agreements with Third Parties that provide a
grant of rights from such Third Party to a Party that are Controlled by such Party and are licensed
or become subject to a license from such Party to the other Party under Article 8 or Section 17.5
(as applicable). Each Party agrees to provide promptly the other Party with notice
of any such alleged breach or obligation to renew. As of the Effective Date, ATI is in
compliance in all material respects with any aforementioned agreements with Third Parties.

     (c) ATI represents and warrants to BMS as of the Effective Date that it: (i) has full legal or
beneficial title to the ATI Patents and PROfusion Patents that are not in-licensed to ATI that are
licensed to BMS under this Agreement; (ii) has no Knowledge as of the Effective Date of claims to
inventorship by persons not already listed as inventors with respect to such Patents; (iii) has the
ability to grant the licenses contained in or required by this Agreement on the terms set forth
herein (e.g., exclusive or non-exclusive and/or with the right to sublicense where applicable); and
(iv) is not currently subject to any agreement with any Third Party or to any outstanding order,
judgment or decree of any court or administrative agency that restricts it in any way from granting
to the other Party such licenses or the right to exercise its rights hereunder.

     (d) ATI represents and warrants to BMS that, to its Knowledge as of the Effective Date, all
fees required to maintain the issued ATI Patents set forth in the Schedules to this Agreement have
been paid to date.

     (e) ATI represents and warrants to BMS that: (i) it has not granted as of the Effective Date,
and covenants that it shall not grant after the Effective Date and during the Term, any right,
license or interest in or to, or an option to acquire any of the foregoing with respect to, the
intellectual property rights licensed to BMS hereunder that is in conflict with the rights or
licenses granted or to be granted to BMS under this Agreement; and (ii) as of the Effective Date,

54

 

Strategic Alliance and Collaboration Agreement

it has not granted any lien, security interest or other encumbrance (excluding any licenses) with
respect to any of the intellectual property rights licensed to BMS hereunder that would that would
impair BMS’ rights under this Agreement, or permitted such a lien, security interest or other
encumbrance (excluding any permitted licenses) to attach to the intellectual property rights
licensed to the other Party hereunder.

     (f) To ATI’s Knowledge as of the Effective Date, ATI represents and warrants to BMS that no
for-profit Third Party has infringed any of the Patents that ATI is licensing to BMS within the
scope of the license in Section 8.1.

     (g) ATI represents and warrants that the balance sheet of ATI, in the form disclosed to BMS on
February 12, 2007, is the last regularly prepared balance sheet of ATI for purposes of determining
ATI’s net assets under the HSR Act, and that to ATI’s Knowledge as of the Effective Date, such
balance sheet is true and accurate.

   15.2 Disclaimers. EXCEPT AS EXPRESSLY SET FORTH HEREIN, NEITHER BMS NOR ATI MAKES ANY
REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, TITLE,
NONINFRINGEMENT, PERFORMANCE, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE.

   15.3 No Consequential Damages. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY SHALL BE LIABLE TO THE
OTHER OR ANY THIRD PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT FOR ANY INDIRECT,
PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES; PROVIDED, HOWEVER, THAT THIS SECTION 15.3 SHALL NOT
APPLY TO THE PARTIES’ INDEMNIFICATION RIGHTS AND OBLIGATIONS UNDER SECTION 15.5.

   15.4 Performance by Affiliates. The Parties recognize that each Party may perform some or all of
its obligations under this Agreement through Affiliates and Third Party contractors provided,
however, that each Party shall remain responsible and liable for the performance by its Affiliates
and Third Party contractors and shall cause its Affiliates and Third Party contractors to comply
with the provisions of this Agreement in connection therewith.

   15.5 Indemnification.

     (a) Indemnification of ATI. BMS shall indemnify ATI, its Affiliates and their
respective directors, officers, employees, Third Party licensors and agents, and their respective
successors, heirs and assigns, and defend and save each of them harmless, from and against any and
all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and
expenses) (collectively, “Losses”) in connection with any and all suits, investigations, claims or
demands of non-Affiliated Third Parties (collectively, “Third Party Claims”) arising from or
occurring as a result of: (i) the material breach by BMS of any term of this Agreement; (ii) any
gross negligence or willful misconduct on the part of BMS in performing its obligations under this
Agreement; or (iii) the Development or Commercialization by BMS or any of its Affiliates,
Sublicensees or Distributors of the Licensed Compound(s) or the Licensed Product(s), including

55

 

Strategic Alliance and Collaboration Agreement

any
such Third Party Claims relating to any alleged infringement or misappropriation of Patents or
other intellectual property rights, except in each case for those Losses as to which ATI has an
obligation to indemnify BMS pursuant to Section 15.5(b), as to which Losses each Party shall
indemnify the other to the extent of their respective liability; provided, however, that BMS shall
not be obligated to indemnify ATI for any Losses to the extent that such Losses arise as a result
of gross negligence or willful misconduct on the part of ATI or any of its Affiliates or Third
Party licensees.

     (b) Indemnification of BMS. ATI shall indemnify BMS, its Affiliates and their
respective directors, officers, employees and agents, and their respective successors, heirs and
assigns, and defend and save each of them harmless, from and against any and all Losses in
connection with any and all Third Party Claims arising from or occurring as a result of: (i) the
material breach by ATI of any term of this Agreement; (ii) any [**] with respect to activities
conducted by BMS in furtherance of the Programs pursuant to the Research Plan occurring after the
Effective Date but before BMS and [**], provided that BMS [**]; or (iii) any gross negligence or
willful misconduct on the part of ATI in performing its obligations under this Agreement, except in
each case for those Losses for which BMS has an obligation to indemnify ATI pursuant to Section
15.5(a), as to which Losses each Party shall indemnify the other to the extent of their
respective liability for the Losses; provided, however, that ATI shall not be obligated to
indemnify BMS for any Losses to the extent that such Losses arise as a result of gross negligence
or willful misconduct on the part of BMS or any of its Affiliates, Sublicensees or Distributors.

     (c) Notice of Claim. All indemnification claims provided for in Sections 15.5(a) and
15.5(b) shall be made solely by such Party to this Agreement (the “Indemnified Party”). The
Indemnified Party shall give the indemnifying Party prompt written notice (an “Indemnification
Claim Notice”) of any Losses or the discovery of any fact upon which the Indemnified Party intends
to base a request for indemnification under Section 15.5(a) or 15.5(b), but in no event shall the
indemnifying Party be liable for any Losses that result from any delay in providing such notice.
Each Indemnification Claim Notice must contain a description of the claim and the nature and amount
of such Loss (to the extent that the nature and amount of such Loss is known at such time). The
Indemnified Party shall furnish promptly to the indemnifying Party copies of all papers and
official documents received in respect of any Losses and Third Party Claims.

     (d) Defense, Settlement, Cooperation and Expenses.

          (i) Control of Defense. At its option, the indemnifying Party may assume the defense
of any Third Party Claim by giving written notice to the Indemnified Party within thirty (30)
calendar days after the indemnifying Party’s receipt of an Indemnification Claim Notice. The
assumption of the defense of a Third Party Claim by the indemnifying Party shall not be construed
as an acknowledgment that the indemnifying Party is liable to indemnify the Indemnified Party in
respect of the Third Party Claim, nor shall it constitute a waiver by the indemnifying Party of any
defenses it may assert against the Indemnified Party’s claim for indemnification. Upon assuming
the defense of a Third Party Claim, the indemnifying Party may appoint as lead counsel in the
defense of the Third Party Claim any legal counsel selected by the indemnifying Party. In the
event the indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party
shall immediately deliver to the indemnifying Party all original notices and documents (including
court papers) received by the Indemnified Party in

56

 

Strategic Alliance and Collaboration Agreement

connection with the Third Party Claim. Should
the indemnifying Party assume the defense of a Third Party Claim, except as provided in Section
15.5(d)(ii), the indemnifying Party shall be liable to the Indemnified Party for eighty percent
(80%) of legal costs or expenses subsequently incurred by such Indemnified Party in connection with
the analysis, defense or settlement of the Third Party Claim. In the event that it is ultimately
determined that the indemnifying Party is not obligated to indemnify, defend or hold harmless the
Indemnified Party from and against the Third Party Claim, the Indemnified Party shall reimburse the
indemnifying Party for any and all costs and expenses (including attorneys’ fees and costs of suit)
and any Third Party Claims incurred by the indemnifying Party in its defense of the Third Party
Claim.

          (ii) Right to Participate in Defense. Without limiting Section 15.5(d)(i), any
Indemnified Party shall be entitled to participate in, but not control, the defense of such Third
Party Claim and to employ counsel of its choice for such purpose; provided, however, that such
employment shall be at twenty percent (20%) of the Indemnified Party’s own cost and expense unless
(i) the employment thereof has been specifically authorized by the indemnifying Party in writing,
(ii) the indemnifying Party has failed to assume the defense and employ counsel in accordance with
Section 15.5(d)(i) (in which case the Indemnified Party shall control the defense) or (iii) the
interests of the Indemnified Party and the indemnifying Party with respect to
such Third Party Claim are sufficiently adverse to prohibit the representation by the same
counsel of both Parties under Applicable Law, ethical rules or equitable principles in which case
the indemnifying Party shall assume one hundred percent (100%) of any such costs and expenses of
counsel for the Indemnified Party.

          (iii) Settlement. With respect to any Third Party Claims relating solely to the
payment of money damages in connection with a Third Party Claim and that shall not result in the
Indemnified Party’s becoming subject to injunctive or other relief or otherwise adversely affecting
the business of the Indemnified Party in any manner, and as to which the indemnifying Party shall
have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the
indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into
any settlement or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its
sole discretion, shall deem appropriate. With respect to all other Losses in connection with Third
Party Claims, where the indemnifying Party has assumed the defense of the Third Party Claim in
accordance with Section 15.5(d)(i), the indemnifying Party shall have authority to consent to the
entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it
obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably
withheld). The indemnifying Party shall not be liable for any settlement or other disposition of a
Loss by an Indemnified Party that is reached without the written consent of the indemnifying Party.
Regardless of whether the indemnifying Party chooses to defend or prosecute any Third Party Claim,
no Indemnified Party shall admit any liability with respect to or settle, compromise or discharge,
any Third Party Claim without the prior written consent of the indemnifying Party, such consent not
to be unreasonably withheld.

          (iv) Cooperation. Regardless of whether the indemnifying Party chooses to defend or
prosecute any Third Party Claim, the Indemnified Party shall, and shall cause each other
Indemnified Party to, cooperate in the defense or prosecution thereof and shall furnish such
records, information and testimony, provide such witnesses and attend such conferences,

57

 

Strategic Alliance and Collaboration Agreement

discovery
proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith.
Such cooperation shall include access during normal business hours afforded to indemnifying Party
to, and reasonable retention by the Indemnified Party of, records and information that are
reasonably relevant to such Third Party Claim, and making Indemnified Parties and other employees
and agents available on a mutually convenient basis to provide additional information and
explanation of any material provided hereunder, and the indemnifying Party shall reimburse the
Indemnified Party for all its reasonable out-of-pocket costs and expenses in connection therewith.

          (v) Costs and Expenses. Except as provided above in this Section 15.5(d), the costs
and expenses, including attorneys’ fees and expenses, incurred by the Indemnified Party in
connection with any claim shall be reimbursed on a calendar quarter basis by the indemnifying
Party, without prejudice to the indemnifying Party’s right to contest the Indemnified Party’s right
to indemnification and subject to refund in the event the indemnifying Party is ultimately held not
to be obligated to indemnify the Indemnified Party.

   15.6 Insurance. Each Party shall maintain at its sole cost and expense, an adequate liability insurance or
self-insurance program (including product liability insurance) to protect against potential
liabilities and risk arising out of activities to be performed under this Agreement and any
agreement related hereto and upon such terms (including coverages, deductible limits and
self-insured retentions) as are customary in the U.S. pharmaceutical industry for the activities to
be conducted by such Party under this Agreement (the “Coverage”), provided that, if ATI exercises
its Co-Promote Option with respect to one or more Licensed Products, upon Launch of the first
Co-Promotion Product in the United States, ATI shall maintain commercial general liability
insurance or a self-insurance program with minimum limits of twenty-five million dollars
($25,000,000) per occurrence and in the aggregate. Subject to the preceding sentence, such
liability insurance or self-insurance program shall insure against all types of liability,
including personal injury, physical injury or property damage arising out of the manufacture, sale,
use, distribution or marketing of a Licensed Product. ATI shall furnish to BMS evidence of such
insurance or self insurance, upon request. Such insurance information shall be kept in confidence
in the same manner as any other Confidential Information disclosed by one Party to the other
hereunder. The coverage limits set forth herein shall not create any limitation on a Party’s
liability to the other under this Agreement.

ARTICLE — 16 REVERSION RIGHTS FOR DILIGENCE FAILURES

   16.1 General. ATI shall have reversion rights with respect to Programs and Licensed Compounds and
Licensed Products as provided in this Article 16.

   16.2 Reversion.

     (a) Development. ATI shall have reversion rights, on a Program-by-Program basis,
prior to the First Commercial Sale of Licensed Product from such Program, at ATI’s sole discretion,
in the event that BMS fails to use Commercially Reasonable Efforts to Develop at least one Licensed
Compound for such Program in violation of Section 4.3(a) or 4.3(c), provided that BMS has not
exercised such Commercially Reasonable Efforts within three (3) months following

58

 

Strategic Alliance and Collaboration Agreement

written notice by
ATI to BMS specifying the nature of such failure. Reversion under this Section 16.2(a) shall apply
to all Licensed Compounds in Development under such Program.

     (b) Commercialization. ATI shall have reversion rights, on a Licensed
Product-by-Licensed Product basis and country-by-country basis, at ATI’s sole discretion, in the
event that BMS fails to use Commercially Reasonable Efforts to Commercialize such Licensed Product
after its First Commercial Sale in violation of Section 7.1(b), provided that BMS has not exercised
such Commercially Reasonable Efforts for the applicable Licensed Product in the applicable country
or countries within three (3) months following written notice by ATI to BMS specifying the nature
of such failure. Reversion under this Section 16.2(b) shall apply to all Licensed Products
containing the same Licensed Compound, but only for the affected country or
countries, provided however, that if the failure relates to three or more Major Market
Countries, then reversion shall apply to all countries in Europe.

     (c) Consequences of Reversion. Upon ATI’s exercise of its reversion rights under
Section 16.2(a) or 16.2(b), then the consequences set forth in Sections 17.5(a) and for the
affected Program, Licensed Compounds and Licensed Products shall apply as provided therein as if
ATI had terminated such Program.

ARTICLE — 17 TERM, TERMINATION AND SURVIVAL

   17.1 Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated in
accordance with the terms hereof or by mutual written consent, shall continue on a Licensed
Compound-by-Licensed Compound and corresponding Licensed Products-by-Licensed Products, and
country-by-country basis, until there are no more payments owed ATI on such Licensed Compound and
corresponding Licensed Products in such country (the longest such period of time for any such
Licensed Compound and corresponding Licensed Products hereunder, the “Term”). Upon there being no
more such payments hereunder for any such Licensed Compound and corresponding Licensed Products in
such country, the license grants contained in Section 8.1 for Commercialization thereof, shall
become fully paid up with respect to such Licensed Compound, and Licensed Products containing such
Licensed Compound, in such country.

   17.2 Termination by ATI.

     (a) Breach. In the event of any material breach by BMS of any terms and conditions of
this Agreement (other than failure to use Commercially Reasonable Efforts to Develop or
Commercialize Licensed Compounds or Licensed Products as provided in Sections 4.3(a), 4.3(c) and
7.1(b), which is addressed by Article 16, ATI shall have the right, at ATI’s sole discretion:

          (i) if prior to the First Commercial Sale of a Licensed Product from a Program, to terminate
on a Program-by-Program basis, the Program to which such material breach primarily relates; and

          (ii) if after the First Commercial Sale of a Licensed Product hereunder, to terminate on a
Licensed Product-by-Licensed Product and on a country-by-country basis, the Licensed Product to
which such material breach primarily relates;

59

 

Strategic Alliance and Collaboration Agreement

provided that such breach has not been cured within ninety (90) calendar days after such notice
thereof is given by ATI to BMS specifying the nature of the alleged breach, provided, however, that
to the extent such material breach involves the failure to make a payment when due, such breach
must be cured within thirty (30) calendar days after written notice thereof is given by ATI to BMS.

   17.3 Termination by BMS.

     (a) Breach. BMS shall have the right to terminate this Agreement in full, at BMS’
sole discretion, upon delivery of written notice to ATI in the event of any material breach by ATI
of any terms and conditions of this Agreement, provided that such breach has not been cured within
ninety (90) calendar days after written notice thereof is given by ATI to BMS specifying the nature
of the alleged breach.

     (b) Termination by BMS for Strategic Reasons. If BMS reasonably determines that it is
not feasible for BMS to pursue the Development or Commercialization of one or more Licensed
Products in any given country(ies) due to a scientific, technical, regulatory or commercial reason,
including (i) safety or efficacy reasons, or (ii) reasons relating to the present or future
marketability or profitability of such Licensed Product(s) in such country(ies), which renders the
Commercialization of such Licensed Product(s) in such country(ies) no longer commercially
practicable for BMS, then BMS may terminate this Agreement, on a Program-by-Program, Licensed
Product-by-Licensed Product and/or country-by-country basis, upon one hundred and twenty (120)
calendar days’ prior written notice to ATI; provided that, if such termination relates to three or
more Major Market Countries, then termination shall apply to all countries in Europe; and provided
further that notwithstanding the termination by BMS of one or more Programs prior to the third
anniversary of the Effective Date, BMS shall, in any case, pay ATI the amounts that would otherwise
have been owed by BMS to ATI under Section 9.2(b) corresponding to BMS’ minimum FTE commitment.

17.4 Termination by Either Party.

     (a) Termination Upon Bankruptcy.

          (i) Either Party may terminate this Agreement if, at any time, the other Party shall file in
any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a
petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the
appointment of a receiver or trustee of that Party or of its assets, or if the other Party proposes
a written agreement of composition or extension of its debts, or if the other Party shall be served
with an involuntary petition against it, filed in any insolvency proceeding, and such petition
shall not be dismissed within sixty (60) calendar days after the filing thereof, or if the other
Party shall propose or be a Party to any dissolution or liquidation, or if the other Party shall
make an assignment for the benefit of its creditors.

          (ii) All rights and licenses granted under or pursuant to this Agreement by BMS or ATI or
their Affiliates are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the
U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined under Section 101 of
the U.S. Bankruptcy Code. The Parties agree that the Parties and their respective

60

 

Strategic Alliance and Collaboration Agreement

Affiliates,
Sublicensees and Third Party licensees, as (sub)licensees of such rights under this Agreement,
shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy
Code and any foreign counterparts thereto.

   17.5 Effects of Termination.

     (a) Generally. Upon termination by either Party under Sections 17.2, 17.3 or 17.4 of
this Agreement either in full or with respect to one or more applicable Programs, Licensed
Compounds, Licensed Products or countries pursuant to the applicable Section (all such terminated
Programs, Licensed Compounds, Licensed Products, Adnectins related thereto, and countries, the
“Terminated Rights”, with the rights and obligations of the Parties as to the remaining Programs,
Licensed Compounds, Licensed Products, countries and Adnectins related thereto, in which
termination under the applicable Section has not yet occurred, being unaffected by such
termination):

          (i) All rights and licenses granted by ATI to BMS in Section 8.1 shall terminate with respect
to the Terminated Rights, all rights of BMS under the ATI Patents, ATI Know-How and ATI Regulatory
Data with respect to the Terminated Rights shall revert to ATI, BMS and its Affiliates shall cease
all use of same, and all of the exclusivity and covenants by ATI contained in Section 8.3 with
respect to the Terminated Rights shall terminate. BMS and its Affiliates and Sublicensees shall
cease all Development and Commercialization of any Licensed Compound, Licensed Product or any
Adnectin used as part of a Program, and all other Program-related activities, in each case within
the Terminated Rights, from the effective date of such termination and for at least five (5) years
thereafter.

          (ii) BMS hereby consents and grants to ATI the right to access and reference (without any
further action required on the part of BMS, whose authorization to file this consent with any
Regulatory Authority is hereby granted), for any regulatory or other use or purpose, all BMS
Regulatory Data, Clinical Data and Non-Clinical Data, Regulatory Documentation (including all INDs
and Regulatory Approvals) and other documents relating to or necessary to further Develop,
Manufacture and Commercialize all Licensed Compounds and Licensed Products within the Terminated
Rights, and to advance all Programs within the Terminated Rights, as such data and documents exist
as of the effective date of such termination (including all related completed and ongoing Clinical
Studies), and BMS shall provide copies of same to ATI upon its request.

61

 

Strategic Alliance and Collaboration Agreement

          (iii) BMS shall grant to ATI and its Affiliates, and ATI and its Affiliates shall
automatically have, a worldwide, perpetual and irrevocable, nontransferable (except in connection
with a permitted assignment of this Agreement in accordance with Section 18.1), license, with the
right to grant sublicenses through multiple tiers, under Know-How and Patents that cover Inventions
and that are owned or otherwise Controlled by BMS and its Affiliates and Sublicensees relating to
any of the Terminated Rights, effective only as of and after the effective date of such
termination, (A) exclusively, solely where and to the extent reasonably necessary for clinically
Developing and Commercializing any such Licensed Compound and Licensed Product within the
Terminated Rights, and Adnectins contained therein, (B) nonexclusively, solely where and to the
extent reasonably necessary for Manufacturing any such Licensed Compound and Licensed Product and
Adnectins, and (C) nonexclusively, solely where and to the extent otherwise reasonably necessary to
pre-clinically Develop the Programs within the Terminated Rights. The following shall apply to
such license:

               (1) The Patents so licensed shall be subject to the rights and obligations set forth in
Article 10 and Article 11.

               (2) If BMS has in-licensed from a Third Party Patents and such Third Party Patents are
sublicensed to ATI pursuant to such license and used by ATI or any of its Affiliates or
Sublicensees in a manner that generates a royalty obligation for BMS on the terms under which BMS
took a license to such Third Party Patents, ATI shall reimburse BMS for any payments that BMS is
obligated in writing to pay such Third Party that results from ATI’s use of such sublicensed Third
Party Patent.

               (3) The license to Manufacture shall be worldwide and shall not be limited to the countries
terminated hereunder.

               (4) BMS and ATI shall promptly meet, over a sixty (60) day period, to negotiate in good faith
the commercially reasonable terms of a license agreement to such Reverted Compounds, including: (1)
the licenses described in this Section 17.5(a)(iii); (2) a royalty to BMS of [**] percent ([**]%)
of the net sales of a Reverted Compound if such transfer is made after the commencement of a Phase
1 Study and prior to the commencement of a Phase 2 Study with respect to such Reverted Compound,
and [**] percent ([**]%) of the net sales of a Reverted Compound if such transfer is made
subsequent to the commencement of a Phase 2 Study with respect to such Reverted Compound, provided
that there shall be no royalty due to BMS in the event that such license is the result of a
termination by ATI due to a material breach by BMS; and (3) other customary terms and provisions,
including terms and provisions relating to the royalty term, diligence, audit rights, and
intellectual property maintenance and enforcement, in each case substantially similar to the terms
of this Agreement (including Sections 9.4(b) and 9.4(c)).

          (iv) BMS shall assign (or, if applicable, cause its Affiliates or Sublicensees or Distributors
to assign) to ATI all of BMS’ (and such Affiliates’, Sublicensees’ and Distributors’) right, title
and interest in and to any registered or unregistered Trademarks or internet domain names that are
specific to Licensed Compounds and Licensed Products within the Terminated Rights in the countries
within the Terminated Rights (it being understood that the foregoing shall

62

 

Strategic Alliance and Collaboration Agreement

 not include any Trademarks or internet domain names that contain the corporate or business
name(s) of BMS).

          (v) Should BMS or any of its Affiliates or Sublicensees have any inventory of Licensed
Compounds or Licensed Products within the Terminated Rights, or any Adnectins or other components
contained therein, suitable for use in Clinical Studies, BMS shall offer to sell such Licensed
Compounds or Licensed Products or Adnectins to ATI at BMS’ fully-burdened cost (but ATI shall be
under no obligation to purchase same unless it agrees to do so in writing at such time).

          (vi) For clarity, to the extent that the Terminated Rights only apply to certain countries,
the foregoing Sections 17.5(a)(i) through 17.5(a)(v) shall apply only to those countries, as
applicable.

          (vii) Exception for Termination for Safety Reasons. The licenses granted to ATI under
this Section 17.5 shall be of no force or effect with respect to any given Licensed Compound(s) or
Licensed Product(s) where BMS’ termination of pre-clinical development, clinical development and/or
commercialization of such Licensed Compound(s) or Licensed Product(s) was due to Safety Reasons.
For purposes of this Section 17.5(a)(vii), “Safety Reasons” means it is BMS’ or any of its
Affiliates’ or Sublicensee’s reasonable belief that there is an unacceptable risk for harm in
humans based upon: (a) pre-clinical safety data, including data from animal toxicology studies; or
(b) the observation of serious adverse effects in humans after a Licensed Compound or Licensed
Product has been administered to or taken by humans, such as during a clinical trial or after the
launch of a Licensed Product, but without reference to any other development or marketed product
opportunities. BMS shall provide ATI with all relevant data for such terminated Licensed Compound
or Licensed Product but shall not be obligated to provide ATI with any rights of reference to any
regulatory documents/filings relating to such terminated such Licensed Compound or Licensed
Product.

     (b) Scope of Termination. Except as otherwise expressly provided herein, termination
of this Agreement shall be as to all countries worldwide, all Programs and all Licensed Compounds
and Licensed Products.

   17.6 Survival. The following provisions shall survive termination or expiration of this Agreement,
as well as any other provision which by its terms or by the context thereof, is intended to survive
such termination: Sections 4.6, 8.2, 8.4, 8.8, 8.9, 9.3, 9.4, 9.5 (to the extent any payments are
owed post-Term, plus the audit and record rights in Section 9.5(c) for the time period specified
therein), 9.6, 10.1, 11.1(a), 11.1(c), 11.1(e), 11.1(g), the last sentence of Section 11.1(h),
11.2, 11.3 (to the extent the foregoing provisions of Article 11 survive), 17.1, 17.4(a)(ii), 17.5
and 17.6, and Articles 1, 14 (other than Section 14.3), 15 (other than Section 15.1) and 18. In
addition, after the Term, (i) Section 10.3(b) and 10.3(f) shall continue to apply to all Joint
Invention Patents, (ii) Sections 10.3(c) and 10.3(g) shall continue to apply with respect to those
Patents that are subject to the licenses to ATI contained in Section 8.2 or 17.5, and (iii)
Sections 10.3(i), 10.3(j) and 10.3(k) shall continue to apply to activities conducted pursuant to
those surviving Sections. Termination or expiration of this Agreement shall not relieve the
Parties of any liability or obligation which accrued hereunder prior to the effective date of such
termination or expiration nor preclude either Party from pursuing all rights

63

 

Strategic Alliance and Collaboration Agreement

and remedies it may
have hereunder or at law or in equity with respect to any breach of this Agreement nor prejudice
either Party’s right to obtain performance of any obligation. All other rights and obligations
shall terminate upon expiration of this Agreement.

ARTICLE — 18 GENERAL PROVISIONS

   18.1 Assignment. Neither Party may assign this Agreement, delegate its obligations or otherwise
transfer licenses or other rights created by this Agreement, except as otherwise expressly
permitted hereunder or without the prior written consent of the other Party, which consent shall
not be unreasonably withheld; provided that each Party may assign this Agreement as a whole without
such consent to an Affiliate or in connection with the acquisition (whether by merger,
consolidation, sale or otherwise) of such Party or of that part of such Party’s business to which
this Agreement relates, provided that such Party provides written notice to the other Party of such
assignment and the assignee thereof agrees in writing within a reasonable period of time to be
bound as such Party hereunder. Any assignment, delegation or transfer in violation of this Section
18.1 shall be void. This Agreement shall inure to the benefit of, and be binding upon, the legal
representatives, successors and permitted assigns of the Parties.

   18.2 Change of Control of ATI.

     (a) Consequences for IP. Notwithstanding anything to the contrary herein, no
Know-How, Materials, Clinical Data, Non-Clinical Data, Patents or other intellectual property
rights not Controlled by ATI or any of its Affiliates prior to a Change of Control of ATI shall be
Controlled for purposes of this Agreement after such Change of Control, other than (i)
Collaboration Patents and Know-How no matter when Controlled, (ii) any Patent that is filed
subsequent to a Change of Control within twelve (12) months that covers an invention made prior to
such Change of Control, and (iii) any Patent that claims priority, directly or indirectly, to any
other Patent first Controlled before the Change of Control shall be Controlled thereafter no matter
when such Patent is filed or issued. For clarity, BMS’ licenses to Know-How, Materials, Clinical
Data, Non-Clinical Data, Patents or other intellectual property rights that were Controlled by ATI
or any of its Affiliates prior to a Change of Control of ATI shall remain in full force and effect
subsequent to any such Change of Control of ATI.

     (b) Technology Transfer in the Event of Material Breach. In the event that,
subsequent to a Change of Control of ATI, ATI materially breaches its obligations to BMS with
respect to ATI’s prescribed activities under one or more Research Plans, then BMS shall have the
right to receive a technology transfer with respect to any ATI Know-How and/or Materials Controlled
by ATI that are necessary or reasonably useful for BMS to perform the activities otherwise assigned
to ATI with respect to such Research Plan(s). BMS’ rights under this Section 18.2(b) shall be
limited to the performance of such activities that are necessary or reasonably useful for, and
solely for the purposes originally licensed hereunder to, BMS to enjoy the benefit of the
licenses granted hereunder with respect to the Programs and Licensed Compounds and Licensed
Products arising therefrom, and any Materials or ATI Know-How transferred pursuant to this Section
18.2(b) shall be used solely for such purpose. BMS shall be entitled to seek specific performance
with respect to the remedy described in this Section 18.2(b) as set forth in Section 18.11, and ATI
hereby stipulates to the fairness and reasonableness of such a remedy and covenants not to allege
or assert, nor to allow any of its Affiliates to assert, nor further to cause

64

 

Strategic Alliance and Collaboration Agreement

or support any other
Third Parties to assert, that such remedy is inappropriate or unenforceable or illegal in any way.
BMS hereby agrees that the term “Discovery Term” for purposes of Sections 8.2 and 10.1(e) shall
include any period of time during which BMS uses any such transferred Materials or ATI Know-How.

     (c) Specific Definitions. For the purposes of this Agreement, (1) “Change of Control”
of ATI means that during the Term (i) ATI shall have become an Affiliate of an entity that is a
Drug Company, (ii) any sale, lease, exchange or other transfer (in one transaction or a series of
related transactions) of all or substantially all of the assets of ATI shall have occurred to a
Drug Company, or (iii) any Drug Company (whether individually or as part of a group) shall have
become the owner, directly or indirectly, of voting securities entitled to cast more than fifty
percent (50%) of the votes in the election of directors of ATI, and (2) “Drug Company” means any
entity that conducts any research and/or development, activities, or that manufactures, promotes,
markets, distributes and/or sells any products, in the biotechnology or pharmaceutical industry.

   18.3 Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be
deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or
performing any term of this Agreement (other than any obligation to pay monies hereunder) if, but
only to the extent that, such failure or delay results from causes beyond the reasonable control of
the affected Party, potentially including fire, floods (including El Niño), embargoes, terrorism,
war, acts of war (whether war be declared or not), insurrections, mass pandemics, riots, civil
commotions, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays
in acting by any governmental authority or any other Party; provided that the Party affected shall
promptly notify the other of the force majeure condition and shall exert reasonable efforts to
eliminate, cure or overcome any such causes and to resume performance of its obligations as soon as
possible.

   18.4 Severability. If any one or more of the provisions contained in this Agreement is held
invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the
remaining provisions contained herein shall not in any way be affected or impaired thereby, unless
the absence of the invalidated provision(s) adversely affects the substantive rights of the
Parties. The Parties shall in such an instance use their reasonable best efforts to replace the
invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s)
which, insofar as practical, implement the purposes of this Agreement.

   18.5 Amendment; Waiver. This Agreement may not be modified, amended or rescinded, in whole or
part, except by a written instrument signed by the Parties; provided that any unilateral
undertaking or waiver made by one Party in favor of the other shall be enforceable if undertaken in
a writing signed by the Party to be charged with the undertaking or waiver. No delay or omission
by either Party hereto in exercising any right or power occurring upon any noncompliance or default
by the other Party with respect to any of the terms of this Agreement shall impair any such right
or power or be construed to be a waiver thereof. A waiver by either of the Parties of any of the
covenants, conditions or agreements to be performed by the other shall not be construed to be a
waiver of any succeeding breach thereof or of any other covenant, condition or agreement herein
contained.

65

 

Strategic Alliance and Collaboration Agreement

   18.6 Notices. Except as otherwise provided herein, all notices under this Agreement shall be sent
by certified mail or by overnight courier service, postage prepaid, to the following addresses of
the respective Parties:

	 	 	 
	If to ATI, to:

	 	Adnexus Therapeutics, Inc.
	 

	 	100 Beaver Street
	 

	 	Waltham, Massachusetts 02453
	 

	 	Attention: Chief Executive Officer
	 

	 	Facsimile: (781) 891-3796
	 
	 	 
	With a required copy to:

	 	Goodwin Procter LLP
	 

	 	53 State Street
	 

	 	Boston, MA 02109
	 

	 	Attention: Kingsley L. Taft, Esq.
	 

	 	Facsimile: (617) 523-1231
	 
	 	 
	If to BMS, to:

	 	Bristol-Myers Squibb Company
	 

	 	P.O. Box 4000
	 

	 	Route 206 and Province Line Road
	 

	 	Princeton, NJ 08543-4000
	 

	 	Attention: Senior Vice President,
Corporate and Business Development
	 

	 	Phone: 609-252-3413
	 

	 	Fax: 609-252-6880
	 
	 	 
	With a required copy to:

	 	Bristol-Myers Squibb Company
	 

	 	P.O. Box 4000
	 

	 	Route 206 and Province Line Road
	 

	 	Princeton, NJ 08543-4000
	 

	 	Attention: Vice President and
Senior Counsel, Corporate and Business Development
	 

	 	Phone: 609-252-5328
	 

	 	Fax: 609-252-4232

or to such address as each Party may hereafter designate by notice to the other Party. A notice
shall be deemed to have been given on the date it is received by all required recipients for the
noticed Party.

   18.7 Dispute Resolution.

     (a) Process. Except with respect to any matters under (i) the purview of the JRC and
thus subject to Section 3.1, or (ii) matters arising under Section 2.3 or Articles 10, 11 or 14 of
this Agreement, in the event of any dispute or other claim or controversy arising out of or
relating to the rights, obligations and remedies of the Parties arising out of this Agreement,
either Party may refer such dispute to the Senior VP of Drug Discovery of BMS and the Chief
Executive Officer of ATI, or their respective designee(s) (who shall be a senior executive(s)), who
shall, as soon as practicable, attempt in good faith to resolve such dispute, claim or controversy.
If such dispute,

66

 

Strategic Alliance and Collaboration Agreement

claim or controversy is not resolved within sixty (60) calendar days of the date
of initial referral of the matter to such senior executives, either Party may submit the dispute to
a court of competent jurisdiction.

     (b) Scientific Disputes. With respect to any dispute arising out of Section 2.3 or
2.4 (i.e. as to whether a [**] or as to whether a Target is a Substitution
Target, Oncology Related or an ATI Target), that is not resolved internally by the JRC or the
Parties must be finally resolved through binding arbitration by JAMS (formerly, the Judicial
Arbitration and Mediation Service) (“JAMS”) in accordance with its Streamlined Arbitration Rules
and Procedures in effect at the time the dispute arises, except as modified in this Agreement and
applying the substantive law specified in Section 18.8. Either Party may initiate arbitration
under this Section 18.7(b) by written notice to the other Party of its intention to arbitrate, and
such notice shall specify in reasonable detail the nature of the dispute. For each arbitration:
(A) each Party shall submit to the arbitrator its proposal for resolving such dispute, such
proposal based on the applicable scientific factors, and shall provide a copy of such proposal to
the other Party; (B) each Party may, within fifteen (15) calendar days of receipt of the other
Party’s proposal, provide a rebuttal to such other Party’s proposal to the arbitrator (which
rebuttal shall be limited to responding to arguments or scientific evidence presented in such other
Party’s proposal), and shall provide a copy of such rebuttal to the other Party; (C) the arbitrator
shall select the proposal that is the most scientifically reasonable; and (D) such proposal shall
become effective. Notwithstanding anything to the contrary, the arbitrators will not have the
ability to change the terms of either Party’s proposal. The determination of the arbitrator shall
be final. The arbitration proceedings shall be conducted in such location as determined by the
arbitrator.
The Parties agree that they shall share equally the cost of the arbitration filing and hearing
fees, and the cost of the arbitrator. Each Party shall bear its own attorneys’ fees and associated
costs and expenses.

     (c) Equitable Relief. Notwithstanding the dispute resolution process set forth in
Section 18.7(a), in the event of an actual or threatened breach hereunder, the aggrieved Party may
seek equitable relief (including restraining orders, specific performance or other injunctive
relief) in a court of competent jurisdiction, without submitting to such dispute resolution process
if there is a reasonable likelihood of the occurrence of irreparable harm during the period of the
dispute resolution process.

     (d) Tolling. The Parties agree that all applicable statutes of limitation and
time-based defenses (such as estoppel and laches) shall be tolled while the dispute resolution
process set forth in Section 18.7(a) is pending, and the Parties shall cooperate in taking any and
all actions necessary to achieve such a result.

   18.8 Governing Law. This Agreement shall be governed and construed in accordance with the internal
laws of the State of New York, without regard to its conflicts of law provisions, provided that any
dispute relating to the scope, validity, enforceability or infringement of any Patents or Know-How
shall be governed by, and construed and enforced in accordance with, the substantive laws of the
jurisdiction in which such Patents or Know-How apply.

   18.9 Jurisdiction. To the extent any dispute cannot be resolved in accordance with Section 18.7,
and for all matters other than those arising under Articles 10 or 11, the Parties

67

 

Strategic Alliance and Collaboration Agreement

hereby
irrevocably consent to the non-exclusive jurisdiction and venue of any state or federal court
sitting in the metropolitan area of New York, New York, over any action or proceeding arising out
of or relating to this Agreement or any agreement or document delivered in connection herewith or
therewith, and agree that all claims in respect of such action or proceeding may be heard and
determined in such state or federal court, and each of the Parties consents to the jurisdiction and
venue of such court or courts and agrees that the service upon it of a summons and complaint by
ordinary mail shall be sufficient for such court or courts to exercise personal jurisdiction over
the Parties.

     18.10 Further Assurances. Each Party agrees to do and perform all such further acts and things and
shall execute and deliver such other agreements, certificates, instruments and documents necessary
or that the other Party may deem advisable in order to carry out the intent and accomplish the
purposes of this Agreement and to evidence, perfect or otherwise confirm its rights hereunder.

     18.11 Cumulative Remedies; Irreparable Harm. All rights and remedies of the Parties hereunder
shall be cumulative and in addition to all other rights and remedies provided hereunder or
available by agreement, at law or otherwise. Each Party acknowledges that money damages alone
shall not adequately compensate the other Party for breach of any of covenants and agreements of
the Party herein and, therefore, agrees that in the event of the breach or threatened breach of any
such covenant or agreement, in addition to all other remedies available to the other Party, at law,
in equity or otherwise, the other Party shall be entitled to injunctive relief compelling specific
performance of, or other compliance with, the terms hereof.

     18.12 Relationship of the Parties. Each Party is an independent contractor under this Agreement.
Nothing contained herein is intended or is to be construed so as to constitute BMS and ATI as
partners, agents or joint venturers. Neither Party shall have any express or implied right or
authority to assume or create any obligations on behalf of or in the name of the other Party or to
bind the other Party to any contract, agreement or undertaking with any Third Party. There are no
express or implied third party beneficiaries hereunder (except for ATI Indemnitees and BMS
Indemnitees for purposes of Section 15.5).

     18.13 Entire Agreement. This Agreement (along with the Exhibits) contains the entire understanding
of the Parties with respect to the subject matter hereof and supersedes and replaces any and all
previous arrangements and understandings, including the Confidentiality Agreements, whether oral or
written, between the Parties with respect to the subject matter hereof.

     18.14 Headings. The captions to the several Sections hereof are not a part of this Agreement, but
are merely guides or labels to assist in locating and reading the several Sections hereof.

     18.15 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel
in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule
of construction that any ambiguity in this Agreement shall be construed against the drafting party
shall not apply.

68

 

Strategic Alliance and Collaboration Agreement

     18.16 Interpretation. Whenever any provision of this Agreement uses the term “including” (or
“includes”), such term shall be deemed to mean “including without limitation” (or “includes without
limitations”). “Herein,” “hereby,” “hereunder,” “hereof” and other equivalent words refer to this
Agreement as an entirety and not solely to the particular portion of this Agreement in which any
such word is used. All definitions set forth herein shall be deemed applicable whether the words
defined are used herein in the singular or the plural. Unless otherwise provided, all references
to Articles, Sections, Schedules and Exhibits in this Agreement are to Articles, Sections,
Schedules and
Exhibits of this Agreement. References to any Sections include Sections and subsections that are
part of the related Section (e.g., a section numbered “Section 2.1 would be part of “Article 2”,
and references to “Section 2.4” would also refer to material contained in the subsection described
as “Section 2.4(a)”)

     18.17 Counterparts; Facsimiles. This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original and all of which together shall constitute one and the same
instrument. Facsimile execution and delivery of this Agreement by either Party shall constitute a
legal, valid and binding execution and delivery of this Agreement by such Party.

[Remainder of this Page Intentionally Left Blank]

69

 

Strategic Alliance and Collaboration Agreement

     IN WITNESS WHEREOF, the Parties have caused this Strategic Alliance & Collaboration Agreement
to be executed by their respective duly authorized officers as of the Effective Date.

	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 	 	Adnexus Therapeutics, Inc.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ John Mendlein	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	(Signature)	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:
	 	John Mendlein	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:
	 	CEO	 	 
	 
	 	 	 	 	 	 
	 

	 	Date:
	 	February 14, 2007	 	 
	 
	 	 	 	 	 	 
	 	 	Bristol-Myers Squibb Company	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Elliott Sigal	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	(Signature)	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:
	 	Elliott Sigal	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:
	 	Executive Vice President, ESO	 	 
	 

	 	 	 	President, PRI	 	 
	 
	 	 	 	 	 	 
	 

	 	Date:
	 	February 14, 2007	 	 

 

 

Strategic Alliance and Collaboration Agreement

Exhibit A-1

Program One

The Product Form for Program One is a monospecific molecule comprising one or more Adnectins that
each bind to [**].

The Product Form for Program One includes one or more Adnectins that each bind to [**]:

     (a) [**]

     (b) [**];

     provided however, in no case does a Product Form include or cover [**].

For illustration purposes, a Licensed Compound for Program One comprises:

     A. [**]

     B. [**]

     C. [**]

     D. [**]

     E. [**];

     provided however, in no case does a Licensed Compound include or cover [**].

The Target of Program One has the amino acid sequence of [**] set forth below [**]:

[**]

 

 

Strategic Alliance and Collaboration Agreement

Exhibit A-2

Program Two

The Product Form for Program Two is a bispecific molecule comprising (i) one or more Adnectins that
each bind to [**] and (ii) one or more Adnectins that each bind to [**].

The Product Form for Program Two includes one or more Adnectins that each bind to [**] and one or
more Adnectins that each bind to [**]:

     (a) [**]

     (b) [**];

     provided however, in no case does a Product Form include or cover [**].

For illustration purposes, a Licensed Compound for Program Two comprises:

     A. [**]

     B. [**]

     C. [**]

     D. [**]

     E. [**]

     F. [**].

     provided however, in no case does a Licensed Compound include or cover [**].

The first Target of Program Two has the amino acid sequence of [**] set forth in Exhibit A-1 [**].

The second Target of Program Two has the amino acid sequence of [**] set forth below [**]:

[**]

 

 

Strategic Alliance and Collaboration Agreement

Exhibit A-3

Program Three

The Product Form for Program Three is a monospecific molecule comprising one or more Adnectins that
each bind to [**].

The Product Form for Program Three includes one or more Adnectins that each bind to [**]:

     (a) [**]

     (b) [**];

     provided however, in no case does a Licensed Compound include or cover [**].

For illustration purposes, a Licensed Compound for Program Three comprises:

     A. [**]

     B. [**]

     C. [**]

     D. [**]

     E. [**].

     provided however, in no case does a Licensed Compound include or cover [**].

The Target of Program Three has the amino acid sequence of [**] set forth below [**]:

[**]

 

 

Strategic Alliance and Collaboration Agreement

Exhibit B

Product Form Definition

The following describes in more detail the definition provided for “Product Form” in Section 1.57.

Product Form shall mean for each Program [**].

The Product Form in the case of [**] shall include [**] as provided in a Program. The Product Form
in the case of [**] provided in the Program.

The Product Form in the case of [**] shall include [**] and [**] as provided in a Program. The
Product Form in the case of [**] provided in the Program.

The Product Form in the case of [**] shall include [**] as provided in a Program. The Product Form
in the case of [**] provided in the Program.

Product Form includes [**]. By way of example, the Product Form [**].

 

 

Strategic Alliance and Collaboration Agreement

Exhibit C

PROfusion Patents

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	Family I:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-501 (U.S.
Prov.)

	 	 	60/090970	 	 	 	n/a	 	 	CNV
	 	Methods for Generating

Highly Diverse Libraries
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PWO-501 (PCT)

	 	1999US0014776
	 	WO 00/00632
	 	NTL
	 	Methods for Generating

Highly Diverse Libraries
	 	1/6/00
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-501

(United States)

	 	 	09/342980	 	 	 	n/a	 	 	ABD
	 	Methods for Generating

Highly Diverse Libraries
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-501

(United States)

	 	 	09/434834	 	 	U.S. 6,846,655 
	 	PAT
	 	Methods for Generating

Highly Diverse Libraries
	 	01/25/05
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-501

(Australia)

	 	 	48470/99	 	 	AU0761570B2
	 	PAT
	 	Methods for Generating

Highly Diverse Libraries
	 	04/29/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCA-501

(Canada)

	 	 	2331926	 	 	CA2331926AA
	 	PEN
	 	Methods for Generating

Highly Diverse Libraries
	 	01/06/00

i

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PCN-501 (China)

	 	 	998079774	 	 	 	n/a	 	 	ABD
	 	Methods for Generating

Highly Diverse Libraries
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCZ-501 (Czech 

Republic)

	 	 	2000-4564	 	 	 	 	 	 	ABD
	 	Methods for Generating

Highly Diverse Libraries
	 	06/13/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-501

(Europe)

	 	 	99932081.5	 	 	EP1092039A1
	 	PEN
	 	Methods for Generating

Highly Diverse Libraries
	 	04/18/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PHK-501 (Hong 

Kong)

	 	 	01107096.7	 	 	 	1037681	 	 	ABD
	 	Methods for Generating

Highly Diverse Libraries
	 	02/15/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIL-501

(Israel)

	 	 	140100	 	 	 	n/a	 	 	ABD
	 	Methods for Generating

Highly Diverse Libraries
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIN-501 (India)

	 	00684/MUM
	 	 	n/a	 	 	ABD
	 	Methods for Generating

Highly Diverse Libraries
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PJP-501 (Japan)

	 	 	2000-557385	 	 	JP2002519038T2
	 	PEN
	 	Methods for Generating

Highly Diverse Libraries
	 	07/02/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PKR-501 (Korea)

	 	 	2000-7014838	 	 	 	n/a	 	 	ABD
	 	Methods for Generating

Highly Diverse Libraries
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PNO-501

(Norway)

	 	 	20006675	 	 	 	n/a	 	 	ABD
	 	Methods for Generating

Highly Diverse Libraries
	 	n/a

ii

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PNZ-501 (New 

Zealand)

	 	 	508287	 	 	NZ508287
	 	PAT
	 	Methods for Generating

Highly Diverse Libraries
	 	12/08/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PRU-501

(Russia)

	 	 	2001102509	 	 	 	n/a	 	 	ABD
	 	Methods for Generating

Highly Diverse Libraries
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PZA-501 (South 

Africa)

	 	 	2000/7261	 	 	ZA2000/7261
	 	PAT
	 	Methods for Generating

Highly Diverse Libraries
	 	07/31/02
	 
	Family II:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-502 (U.S.
Prov.)

	 	 	60/080686	 	 	 	n/a	 	 	CNV
	 	Addressable Protein Arrays
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-502

(United States)

	 	 	09/282734	 	 	US 6,537,749
	 	PAT
	 	Addressable Protein Arrays
	 	03/25/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-502

(United States)

	 	 	10/348627	 	 	US20030143616
	 	ABD
	 	Addressable Protein Arrays
	 	07/31/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PWO-502 (PCT)

	 	1999US0007203
	 	WO 99/51773
	 	NTL
	 	Addressable Protein Arrays
	 	10/14/99
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-502

(Australia)

	 	 	34636/99	 	 	 	n/a	 	 	ABD
	 	Addressable Protein Arrays
	 	n/a

iii

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PA1-502

(Australia)

	 	 	2004200234	 	 	 	n/a	 	 	ABD
	 	Addressable Protein Arrays
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCA-502

(Canada)

	 	 	2323638	 	 	CA2323638AA
	 	ABD
	 	Addressable Protein Arrays
	 	10/14/99
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-502

(Europe)

	 	 	99916283.7	 	 	 	1068356	 	 	PAT
	 	Addressable Protein Arrays
	 	09/27/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIL-502

(Israel)

	 	 	138668	 	 	 	n/a	 	 	ABD
	 	Addressable Protein Arrays
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PJP-502 (Japan)

	 	 	2000-542484	 	 	JP2002510505T2
	 	ABD
	 	Addressable Protein Arrays
	 	04/0902
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PTH-502

(Thailand)

	 	 	049605	 	 	 	n/a	 	 	ABD
	 	Addressable Protein Arrays
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PTW-502

(Taiwan)

	 	 	88105298	 	 	 	n/a	 	 	ABD
	 	Addressable Protein Arrays
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family III:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	COTH-P60-503 (U.S.
Prov.)

	 	 	60/137032	 	 	 	n/a	 	 	CNV
	 	Methods for Producing 5’-

Nucleic Acid-Protein

Conjugates
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-503

(United States)

	 	 	09/585207	 	 	US 6,623,926
	 	PAT
	 	Methods for Producing 5’-

Nucleic Acid-Protein

Conjugates
	 	9/23/03

iv

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PWO-503 (PCT)

	 	2000US0015077
	 	WO 00/72869
	 	NTL
	 	Methods for Producing 5’-

Nucleic Acid-Protein

Conjugates
	 	12/7/00
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-503

(Australia)

	 	 	54555/00	 	 	 	779491	 	 	PAT
	 	Methods for Producing 5’-

Nucleic Acid-Protein

Conjugates
	 	01/27/05
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCA-503

(Canada)

	 	2000US0015077
	 	WO 00/72869
	 	ABD
	 	Methods for Producing 5’-

Nucleic Acid-Protein

Conjugates
	 	12/7/00
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PHK-503 (Hong 

Kong)

	 	 	02105898.0	 	 	 	n/a	 	 	ABD
	 	Methods for Producing

5’-Nucleic Acid-Protein

Conjugates
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIL-503

(Israel)

	 	 	146015	 	 	 	n/a	 	 	ABD
	 	Methods for Producing

5’-Nucleic Acid-Protein

Conjugates
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-503

(Europe)

	 	 	00939474.3	 	 	EP1187626A1
	 	ABD
	 	Methods for Producing 5’-

Nucleic Acid-Protein

Conjugates
	 	03/20/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PJP-503 (Japan)

	 	 	2000-620978	 	 	JP2003500081T2
	 	ABD
	 	Methods for Producing 5’-

Nucleic Acid-Protein

Conjugates
	 	01/7/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PN1-503 (New 

Zealand)

	 	 	530162	 	 	 	n/a	 	 	ABD
	 	Methods for Producing

5’-Nucleic Acid-Protein

Conjugates
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PNO-503

(Norway)

	 	 	20015828	 	 	 	n/a	 	 	ABD
	 	Methods for Producing

5’-Nucleic Acid-Protein

Conjugates
	 	n/a

v

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PNZ-503 (New 

Zealand)

	 	 	514772	 	 	 	n/a	 	 	ABD
	 	Methods for Producing

5’-Nucleic Acid-Protein

Conjugates
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family IV:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-504 (U.S.
Prov.)

	 	 	60/096818	 	 	 	n/a	 	 	CNV
	 	Methods for Producing
Nucleic Acids Lacing
3’-Untranslated Regions
and Optimizing Cellular
RNA-Protein Fusion
Formation
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-504

(United States)

	 	 	09/374962	 	 	US 6,312,927
	 	PAT
	 	Methods for Producing
Nucleic Acids Lacing
3’-Untranslated Regions
and Optimizing Cellular
RNA-Protein Fusion
Formation
	 	11/6/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-504

(United States)

	 	 	09/910518	 	 	US20020160377A1
	 	ABD
	 	Methods for Producing
Nucleic Acids Lacing
3’-Untranslated Regions
and Optimizing Cellular
RNA-Protein Fusion
Formation
	 	10/31/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P03-504

(United States)

	 	 	10/646985	 	 	US20040086980
	 	ABD
	 	Methods for Producing
Nucleic Acids lacking
3’-Untranslated Regions
and Optimizing Cellular
RNA-Protein Fusion
Formation
	 	05/06/04

vi

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PWO-504 (PCT)

	 	1999US0018603
	 	WO 00/09737
	 	NTL
	 	Methods for Producing
Nucleic Acids Lacking
3’-Untranslated Regions
and Optimizing Cellular
RNA-Protein Fusion
Formation
	 	02/24/00
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-504

(Australia)

	 	 	54883/99	 	 	AU5488399A1
	 	ABD
	 	Methods for Producing
Nucleic Acids Lacking
3’-Untranslated Regions
and Optimizing Cellular
RNA-Protein Fusion
Formation
	 	03/06/00
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PA1-504

(Australia)

	 	 	2004200998	 	 	 	n/a	 	 	ABD
	 	Methods for Producing
Nucleic Acids Lacking
3’-Untranslated Regions
and Optimizing Cellular
RNA-Protein Fusion
Formation
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCA-504

(Canada)

	 	 	2334946	 	 	CA2334946AA
	 	ABD
	 	Methods for Producing
Nucleic Acids Lacking
3’-Untranslated Regions
and Optimizing Cellular
RNA-Protein Fusion
Formation
	 	02/24/00
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-504

(Europe)

	 	 	99941179.6	 	 	EP1105516A1
	 	ABD
	 	Methods for Producing
Nucleic Acids Lacking
3’-Untranslated Regions
and Optimizing Cellular
RNA-Protein Fusion
Formation
	 	06/13/01

vii

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PJP-504 (Japan)

	 	 	2000-565171	 	 	JP2002522091T2
	 	ABD
	 	Methods for Producing
Nucleic Acids Lacking
3’-Untranslated Regions
and Optimizing Cellular
RNA-Protein Fusion
Formation
	 	07/23/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family V:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	COTH-P60-505

(Provisional)

	 	 	60/096820	 	 	 	n/a	 	 	CNV
	 	Identification of
Compound Protein
Interactions Using
Libraries of
Protein-Nucleic Acid
Fusion Molecules
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-505

(United States)

	 	 	09/374964	 	 	US 6,602,685
	 	PAT
	 	Identification of
Compound Protein
Interactions Using
Libraries of
Protein-Nucleic Acid
Fusion Molecules
	 	08/05/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PWO-505 (PCT)

	 	1999US0018600
	 	WO 00/09464
	 	NTL
	 	Identification of
Compound Protein
Interactions Using
Libraries of
Protein-Nucleic Acid
Fusion Molecules
	 	02/24/00
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-505

(Australia)

	 	 	00/09464	 	 	AU0757955B2
	 	PAT
	 	Identification of
Compound Protein
Interactions Using
Libraries of
Protein-Nucleic Acid
Fusion Molecules
	 	07/03/03

viii

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PCA-505

(Canada)

	 	 	2337490	 	 	CA2337490AA
	 	PEN
	 	Identification of
Compound Protein
Interactions Using
Libraries of
Protein-Nucleic Acid
Fusion Molecules
	 	02/24/00
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-505

(Europe)

	 	 	99948042.9	 	 	EP1105360A1
	 	PEN
	 	Identification of
Compound Protein
Interactions Using
Libraries of
Protein-Nucleic Acid
Fusion Molecules
	 	06/13/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PJP-505 (Japan)

	 	 	2000-564919	 	 	JP2002522057T2
	 	PEN
	 	Identification of
Compound Protein
Interactions Using
Libraries of
Protein-Nucleic Acid
Fusion Molecules
	 	07/23/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family VI:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-506 (U.S.
Prov.)

	 	 	60/110549	 	 	 	n/a	 	 	CNV
	 	DNA Protein Fusion and
Uses Thereof
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-506

(United States)

	 	 	09/453190	 	 	US 6,416,950
	 	PAT
	 	DNA Protein Fusion and
Uses Thereof
	 	07/09/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-506

(United States)

	 	 	10/180819	 	 	US20020177158
	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	11/28/02

ix

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PWO-506 (PCT)

	 	1999US0028472
	 	WO 00/32823
	 	NTL
	 	DNA Protein Fusion and
Uses Thereof
	 	06/08/00
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAT-506

(Austria)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-506

(Australia)

	 	 	23509/00	 	 	AU0775997B2
	 	PAT
	 	DNA Protein Fusion and
Uses Thereof
	 	08/19/04
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PBE-506

(Belgium)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCA-506

(Canada)

	 	 	2350417	 	 	CA2350417AA
	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	06/08/000
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCH-506 (Czech 

Republic)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PDE-506

(Germany)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PDK-506

(Denmark)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-506

(Europe)

	 	 	99967171.2	 	 	EP1137812
	 	PAT
	 	DNA Protein Fusion and
Uses Thereof
	 	02/21/07

x

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PES-506 (Spain)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PFI-506

(Finland)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PFR-506

(France)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PGB-506

(United Kingdom)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PHK-506 (Hong 

Kong)

	 	 	02100680.3	 	 	 	n/a	 	 	ABD
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIE-506

(Ireland)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIL-506

(Israel)

	 	 	143238	 	 	 	n/a	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIN-506 (India)

	 	00549MUM
	 	 	n/a	 	 	ABD
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIT-506 (Italy)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01

xi

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PJP-506 (Japan)

	 	 	2000-585454	 	 	JP2002531105T2
	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	09/24/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PKR-506 (Korea)

	 	 	2001-7006742	 	 	 	n/a	 	 	ABD
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PLU-506

(Luxembourg)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PMC-506

(Monaco)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PNL-506 (The 

Netherlands)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PNO-506

(Norway)

	 	 	20012735	 	 	 	n/a	 	 	ABD
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PNZ-506 (New 

Zealand)

	 	 	511699	 	 	NZ0511699A
	 	PAT
	 	DNA Protein Fusion and
Uses Thereof
	 	06/09/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PPT-506

(Portugal)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 

xii

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PSE-506

(Sweden)

	 	 	99967171.2	 	 	 	1137812	 	 	PEN
	 	DNA Protein Fusion and
Uses Thereof
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family VII:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-509 (U.S.
Prov.)

	 	 	09/614264	 	 	 	n/a	 	 	CNV
	 	C-Terminal Protein Tagging
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-509

(United States)

	 	 	09/614264	 	 	US 6,660,473
	 	PAT
	 	C-Terminal Protein Tagging
	 	12/9/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-509

(United States)

	 	 	10/730367	 	 	US20040198963
	 	ABD
	 	C-Terminal Protein Tagging
	 	10/7/04
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PWO-509 (PCT)

	 	2000US0040347
	 	WO 01/04265
	 	NTL
	 	C-Terminal Protein Tagging
	 	01/18/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-509

(Australia)

	 	 	71338/00	 	 	AU0071338B2
	 	PAT
	 	C-Terminal Protein Tagging
	 	11/18/04
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCA-509

(Canada)

	 	 	2372795	 	 	CA2372795AA
	 	ABD
	 	C-Terminal Protein Tagging
	 	01/18/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-509

(Europe)

	 	 	00960132.9	 	 	EP1194594A2
	 	ABD
	 	C-Terminal Protein Tagging
	 	04/10/02

xiii

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PHK-509 (Hong 

Kong)

	 	 	02106434.9	 	 	 	1044966A	 	 	ABD
	 	C-Terminal Protein Tagging
	 	11/08/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIL-509

(Israel)

	 	 	146451	 	 	 	1490	 	 	ABD
	 	C-Terminal Protein Tagging
	 	08/29/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PNZ-509 (New 

Zealand)

	 	 	515292	 	 	NZ0515292A
	 	PAT
	 	C-Terminal Protein Tagging
	 	12/08/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family VIII:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-510 (U.S.
Prov.)

	 	 	60/145834	 	 	 	n/a	 	 	CNV
	 	Peptide Acceptor Ligation

Methods
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-510

(United States)

	 	 	09/619103	 	 	US 6,429,300
	 	PAT
	 	Peptide Acceptor Ligation

Methods
	 	08/06/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-510

(United States)

	 	 	10/208357	 	 	US 7,078,197
	 	PAT
	 	Peptide Acceptor Ligation

Methods
	 	7/18/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P03-510

(United States)

	 	 	11/483,495	 	 	US-2006-0246549-A1
	 	PEN
	 	Peptide Acceptor Ligation

Methods
	 	11/02/06

xiv

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PWO-510 (PCT)

	 	2000US0019653
	 	WO 01/07657
	 	NTL
	 	Peptide Acceptor Ligation

Methods
	 	02/01/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-510

(Australia)

	 	 	61112/00	 	 	 	781783	 	 	PAT
	 	Peptide Acceptor Ligation

Methods
	 	10/06/05
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PA1-510

(Australia)

	 	 	2005211548	 	 	 	n/a	 	 	PEN
	 	Peptide Acceptor Ligation

Methods
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCA-510

(Canada)

	 	 	2377468	 	 	CA2377468AA
	 	PEN
	 	Peptide Acceptor Ligation

Methods
	 	02/01/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-510

(Europe)

	 	 	00947524.5	 	 	EP1196637A1
	 	PEN
	 	Peptide Acceptor Ligation

Methods
	 	04/17/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PHK-510 (Hong 

Kong)

	 	 	02106728.4	 	 	 	1045351	 	 	ABD
	 	Peptide Acceptor Ligation

Methods
	 	11/22/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIL-510

(Israel)

	 	 	147037	 	 	 	n/a	 	 	ABD
	 	Peptide Acceptor Ligation

Methods
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PJP-510 (Japan)

	 	 	2001-512922	 	 	JP2003505094T2
	 	PEN
	 	Peptide Acceptor Ligation

Methods
	 	02/12/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PKR-510 (Korea)

	 	 	2002-7001058	 	 	 	2002-00337	 	 	ABD
	 	Peptide Acceptor Ligation

Methods
	 	07/05/02

xv

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PN1-510 (New 

Zealand)

	 	 	530163	 	 	 	n/a	 	 	ABD
	 	Peptide Acceptor Ligation

Methods
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PNO-510

(Norway)

	 	 	20020348	 	 	 	n/a	 	 	ABD
	 	Peptide Acceptor Ligation

Methods
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PNZ-510 (New 

Zealand)

	 	 	516055	 	 	 	n/a	 	 	ABD
	 	Peptide Acceptor Ligation

Methods
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PRU-510

(Russia)

	 	 	2002104938	 	 	 	n/a	 	 	ABD
	 	Peptide Acceptor Ligation

Methods
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family IX:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-511 (U.S.
Prov.)

	 	 	60/151261	 	 	 	n/a	 	 	CNV
	 	Methods for Encoding and
Sorting In Vitro
Translated Proteins
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-511

(United States)

	 	 	09/648040	 	 	US 6,436,665
	 	PAT
	 	Methods for Encoding and
Sorting In Vitro
Translated Proteins
	 	08/20/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-511

(United States)

	 	 	10/217914	 	 	US20030013160
	 	PEN
	 	Methods for Encoding and
Sorting In Vitro
Translated Proteins
	 	01/16/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PWO-511 (PCT)

	 	2000US0023414
	 	WO 01/16352
	 	NTL
	 	Methods for Encoding and
Sorting In Vitro
Translated Proteins
	 	03/08/01

xvi

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PAU-511

(Australia)

	 	 	69387/00	 	 	 	779653	 	 	PAT
	 	Methods for Encoding and
Sorting In Vitro
Translated Proteins
	 	06/02/05
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCA-511

(Canada)

	 	 	2382545	 	 	CA2382545AA
	 	PEN
	 	Methods for Encoding and
Sorting In Vitro
Translated Proteins
	 	03/08/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-511

(Europe)

	 	 	00957818.8	 	 	EP1212452A1
	 	PEN
	 	Methods for Encoding and
Sorting In Vitro
Translated Proteins
	 	06/12/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PJP-511 (Japan)

	 	 	2001-512922	 	 	JP2003508761T2
	 	PEN
	 	Methods for Encoding and
Sorting In Vitro
Translated Proteins
	 	03/04/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family X:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-512 (U.S.
Prov.)

	 	 	60/309231	 	 	 	n/a	 	 	CNV
	 	Modular Assembly of
Nucleic Acid-Protein
Fusion Multimers
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-512

(United States)

	 	 	10/208967	 	 	US20030027194
	 	ABD
	 	Modular Assembly of
Nucleic Acid-Protein
Fusion Multimers
	 	2/6/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PWO-512 (PCT)

	 	2002US0024180
	 	WO 03/012146
	 	NTL
	 	Modular Assembly of
Nucleic Acid-Protein
Fusion Multimers
	 	2/13/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-512

(Australia)

	 	 	2002324571	 	 	 	n/a	 	 	ABD
	 	Modular Assembly of
Nucleic Acid-Protein
Fusion Multimers
	 	n/a

xvii

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PCA-512

(Canada)

	 	 	2456105	 	 	CA2456105AA
	 	ABD
	 	Modular Assembly of
Nucleic Acid-Protein
Fusion Multimers
	 	2/13/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-512

(Europe)

	 	 	02759221.1	 	 	EP1419274A1
	 	ABD
	 	Modular Assembly of
Nucleic Acid-Protein
Fusion Multimers
	 	5/19/04
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PJP-512 (Japan)

	 	 	2003-517319	 	 	 	n/a	 	 	ABD
	 	Modular Assembly of
Nucleic Acid-Protein
Fusion Multimers
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family XI:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-513 (U.S.
Prov.)

	 	 	60/177873	 	 	 	n/a	 	 	CNV
	 	Sensitive, Multiplexed

Diagnostic Assays for

Protein Analysis
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-513

(United States)

	 	 	09/755663	 	 	US 6,489,116
	 	PAT
	 	Sensitive, Multiplexed

Diagnostic Assays for

Protein Analysis
	 	12/03/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-513

(United States)

	 	 	10/212620	 	 	US 7,022,479
	 	PAT
	 	Sensitive, Multiplexed

Diagnostic Assays for

Protein Analysis
	 	4/4/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-513

(United States)

	 	 	11/398,494	 	 	 	n/a	 	 	ABD
	 	Sensitive, Multiplexed

Diagnostic Assays for

Protein Analysis
	 	n/a

xviii

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PWO-513 (PCT)

	 	2001US0000291
	 	WO 01/53539
	 	NTL
	 	Sensitive, Multiplexed

Diagnostic Assays for

Protein Analysis
	 	07/26/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-513

(Australia)

	 	 	29279/01	 	 	 	783689	 	 	PAT
	 	Sensitive, Multiplexed

Diagnostic Assays for

Protein Analysis
	 	03/09/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCA-513

(Canada)

	 	 	2396810	 	 	CA2396810AA
	 	PEN
	 	Sensitive, Multiplexed

Diagnostic Assays for

Protein Analysis
	 	07/26/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-513

(Europe)

	 	 	01942678.2	 	 	EP1250463B1
	 	PAT
	 	Sensitive, Multiplexed

Diagnostic Assays for

Protein Analysis
	 	04/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PJP-513 (Japan)

	 	 	2001-553398	 	 	JP2003520050T2
	 	PEN
	 	Sensitive, Multiplexed

Diagnostic Assays for

Protein Analysis
	 	07/02/03

xix

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	Family XII:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-514 (U.S.
Prov.)

	 	 	60/184515	 	 	 	n/a	 	 	CNV
	 	Methods for Generating

Catalytic Proteins
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-514

(United States)

	 	 	09/795037	 	 	US20010024789A1
	 	ABD
	 	Methods for Generating

Catalytic Proteins
	 	09/27/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-514

(United States)

	 	 	10/725945	 	 	US20040166516
	 	ABD
	 	Methods for Generating

Catalytic Proteins
	 	08/26/04
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PWO-514 (PCT)

	 	2001US0006147
	 	WO 01/62983
	 	NTL
	 	Improved Methods for

Generating Catalytic

Proteins
	 	08/30/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-514

(Australia)

	 	 	43290/01	 	 	AU0143290A5
	 	ABD
	 	Improved Methods for

Generating Catalytic

Proteins
	 	09/03/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCA-514

(Canada)

	 	 	2399241	 	 	CA2399241AA
	 	ABD
	 	Improved Methods for

Generating Catalytic

Proteins
	 	08/30/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-514

(Europe)

	 	 	01916243.7	 	 	EP1266035A1
	 	ABD
	 	Improved Methods for

Generating Catalytic

Proteins
	 	12/18/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PJP-514 (Japan)

	 	 	2001-561791	 	 	JP2003523756T2
	 	ABD
	 	Improved Methods for

Generating Catalytic

Proteins
	 	08/12/03

xx

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	Family XIII:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-515 (U.S.
Prov.)

	 	 	60/300267	 	 	 	n/a	 	 	CNV
	 	In Vitro Protein

Interaction Detection

Systems
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-515

(United States)

	 	 	10/176826	 	 	 	U.S. 6,951,725	 	 	PAT
	 	In Vitro Protein

Interaction Detection

Systems
	 	10/04/05
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-515

(United States)

	 	 	11/243449	 	 	 	n/a	 	 	PEN
	 	In Vitro Protein

Interaction Detection

Systems
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PWO-515 (PCT)

	 	2002US0019937
	 	WO 03/000856
	 	ABD
	 	In Vitro Protein

Interaction Detection

Systems
	 	01/03/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family XVI:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-519 (U.S.
Prov.)

	 	 	60/333470	 	 	 	n/a	 	 	CNV
	 	Solid-Phase
Immobilization of
Proteins and Peptides
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-519

(United States)

	 	 	10/302456	 	 	US 7,125,669
	 	PAT
	 	Solid-Phase
Immobilization of
Proteins and Peptides
	 	10/24/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PWO-519 (PCT)

	 	2002US37743
	 	WO 03/045975
	 	ABD
	 	Solid-Phase
Immobilization of
Proteins and Peptides
	 	06/05/03

xxi

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 	 	 
	Docket	 	 	 	 	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Application Number	 	Number	 	Status	 	Title	 	l. Date
	Family I:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	PROfusionTM
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-701 (U.S.
Prov.)

	 	 	09/007005	 	 	 	n/a	 	 	CNV
	 	Methods for
Selection of
Proteins using
RNA-Protein Fusions
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P61-701 (U.S.
Prov.)

	 	 	60/064491	 	 	 	n/a	 	 	CNV
	 	Methods for
Selection of
Proteins using
RNA-Protein Fusions
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-701

(United States)

	 	 	09/007005	 	 	US 6,258,558
	 	PAT
	 	Methods for
Selection of
Proteins using
RNA-Protein Fusions
	 	07/10/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-701

(United States)

	 	 	09/238710	 	 	US 6,518,018
	 	PAT
	 	RNA-Antibody
Fusions and Their
Selection
	 	02/11/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P03-701

(United States)

	 	 	09/244796	 	 	US 6,281,344
	 	PAT
	 	Nucleic
Acid-Protein Fusion
Molecules and
Libraries
	 	08/28/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P04-701

(United States)

	 	 	09/247190	 	 	US 6,261,804
	 	PAT
	 	Selections of
Proteins using
RNA-Protein Fusions
	 	07/17/01

xxii

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 	 	 
	Docket	 	 	 	 	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Application Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-P05-701

(United States)

	 	 	09/244794	 	 	US 6,214,553
	 	PAT
	 	Libraries of
Protein Encoding
RNA-Protein Fusions
	 	04/10/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P06-701

(United States)

	 	 	09/430049	 	 	US 6,207,446
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	03/27/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P07-701

(United States)

	 	 	09/876235	 	 	US20030022236
	 	PEN
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	01/30/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P08-701

(United States)

	 	 	10/764799	 	 	US20040253612
	 	ABD
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	12/16/04
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PWO-701 (PCT)

	 	1998US0000807
	 	WO 98/31700
	 	NTL
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/23/98
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PW1-701 (PCT)

	 	2000US0002589
	 	WO 00/47775
	 	NTL
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	11/01/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAT-701

(Austria)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-701

(Australia)

	 	 	62419/98	 	 	AU 738328B2
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	09/13/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PA1-701

(Australia)

	 	 	34793/00	 	 	AU 773236B2
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	05/20/04

xxiii

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 	 	 
	Docket	 	 	 	 	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Application Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PA2-701

(Australia)

	 	 	97069/01	 	 	AU 776478B2
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	09/09/04
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PBE-701

(Belgium)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCA-701

(Canada)

	 	 	2278786	 	 	CA2278786AA
	 	PEN
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/23/98
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PC1-701

(Canada)

	 	 	2361725	 	 	CA2361725AA
	 	PEN
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	08/17/00
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCH-701 (Czech 

Republic)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCN-701 (China)

	 	 	98803511.1	 	 	CN 98803511.1
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	01/25/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PDE-701

(Germany)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PDK-701

(Denmark)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-701

(Europe)

	 	 	98904574.5	 	 	EP 0971946B1
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	7/5/06

xxiv

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 	 	 
	Docket	 	 	 	 	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Application Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PE1-701

(Europe)

	 	 	00913326.5	 	 	EP 1150714A1
	 	PEN
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	11/07/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PE2-701

(Europe)

	 	 	06013825.2	 	 	EP 1712623
	 	PEN
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	10/18/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PES-701

(Spain)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PFI-701

(Finland)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PFR-701

(France)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PGB-701

(United Kingdom)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PHK-701 (Hong 

Kong)

	 	 	00106756.1	 	 	1027577/HK1027577
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	01/19/01/09/01/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PH1-701 (Hong 

Kong)

	 	 	02103482.7	 	 	 	1042524	 	 	PEN
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	08/16/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIL-701

(Israel)

	 	 	131016	 	 	IL 131016
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	03/16/05

xxv

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 	 	 
	Docket	 	 	 	 	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Application Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PI1-701

(Israel)

	 	 	144518	 	 	IL0144518A0
	 	PEN
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	05/23/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIE-701

(Ireland)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIN-701

(India)

	 	00964/MUM
	 	 	n/a	 	 	PEN
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PI2-701

(India)

	 	158/DEL/98
	 	 	n/a	 	 	PEN
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PI3-701

(India)

	 	1024/DEL/2001
	 	 	n/a	 	 	ABD
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIT-701

(Italy)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PJP-701

(Japan)

	 	 	10-534534	 	 	JP 3692542
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/01/05
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PJ1-701

(Japan)

	 	 	2000-598669	 	 	JP2002536025T2
	 	PEN
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	10/29/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PKR-701
(S. Korea)

	 	 	99-7006594	 	 	 	0566859	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	03/27/06

xxvi

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 	 	 
	Docket	 	 	 	 	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Application Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PK1-701
(S. Korea)

	 	 	2001-7009987	 	 	 	2002-00081	 	 	PEN
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	01/29/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PLU-701

(Luxembourg)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PMC-701

(Monaco)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PNL-701 (The 

Netherlands)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PNO-701

(Norway)

	 	 	20013842	 	 	NO20013842A0
	 	PEN
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	08/07/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PNZ-701

(New Zealand)

	 	 	513153	 	 	NZ513153B
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/07/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PPT-701

(Portugal)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PRU-701

(Russia)

	 	 	99118585	 	 	RU2233878C2
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	08/10/04
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PR1-701

(Russia)

	 	 	2001124810	 	 	RU2238326C2
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	10/20/04

xxvii

 

Strategic
Alliance and Collaboration Agreement — Exhibit C

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 	 	 
	Docket	 	 	 	 	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Application Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PSE-701

(Sweden)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PTH-701

(Thailand)

	 	 	98904574.5	 	 	 	0971946	 	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	07/05/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PTW-701

(Taiwan)

	 	 	87100513	 	 	TW203315
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	10/04/04
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PZA-701
(S. Africa)

	 	 	98/0489	 	 	ZA9800489A
	 	PAT
	 	Selection of
Proteins Using
RNA-Protein Fusions
	 	11/25/98

xxviii

 

Strategic Alliance and Collaboration Agreement

Exhibit D

ATI Foundation Patents

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	Family I:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	COTH-P60-003 (U.S.
Prov.)

	 	 	60/527886	 	 	 	n/a	 	 	CNV
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P01-003

(United States)

	 	 	11/007651	 	 	Unpublished
	 	ABD
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-003

(United States)

	 	 	11/101954	 	 	Unpublished
	 	ABD
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PWO-003 (PCT)

	 	US04/040885
	 	WO 05/056764
	 	NTL
	 	Inhibitors of Type
2 Vascular Endothelial Growth
Factor Receptors
	 	6/23/05
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P03-003

(United States)

	 	 	11/448171	 	 	Unpublished
	 	PEN
	 	
Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors	 	 

i

 

Strategic
Alliance and Collaboration Agreement — Exhibit D

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-P04-003

(United States)

	 	 	11/482641	 	 	Unpublished
	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PTW-003

(Taiwan)

	 	 	093137723	 	 	 	200531979	 	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors
	 	10/1/05
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-003

(Australia)

	 	 	2004296376	 	 	Unpublished
	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PBR-003

(Brazil)

	 	PI04173023
	 	Unpublished
	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCA-003

(Canada)

	 	 	2552435	 	 	Unpublished
	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCN-003

(China)

	 	 	80041450.X	 	 	Unpublished
	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-003

(Europe)

	 	 	4813230.2	 	 	 	1711196	 	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors
	 	10/18/2006
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIN-003

(India)

	 	3287/DELNP/06
	 	Unpublished
	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 

ii

 

Strategic
Alliance and Collaboration Agreement — Exhibit D

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PIL-003

(Israel)

	 	 	176135	 	 	Unpublished
	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PJP-003

(Japan)

	 	 	 	 	 	Unpublished
	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PKR-003 (S.
Korea)

	 	 	2006-7013519	 	 	Unpublished
	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PMX-003

(Mexico)

	 	 	2006/006406	 	 	Unpublished
	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PRU-003

(Russia)

	 	 	2006123945	 	 	Unpublished
	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PSG-003

(Singapore)

	 	 	200603808-7	 	 	Unpublished
	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PTW-003

(Taiwan)

	 	 	093137723	 	 	 	200531979	 	 	PEN
	 	Inhibitors of Type
2 Vascular
Endothelial Growth
Factor Receptors
	 	10/01/05
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Family II:
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P60-507 (U.S.
Prov.)

	 	 	60/111737	 	 	 	n/a	 	 	CNV
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	n/a

iii

 

Strategic
Alliance and Collaboration Agreement — Exhibit D

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-P01-507

(United States)

	 	 	09/456693	 	 	Unpublished
	 	ABD
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P02-507

(United States)

	 	 	09/515260	 	 	US 6,818,418
	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/16/04
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P03-507

(United States)

	 	 	09/688566	 	 	Unpublished
	 	ABD
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	n/a
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P04-507

(United States)

	 	 	10/728078	 	 	US 7,115,396
	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	10/3/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P05-507

(United States)

	 	 	10/989723	 	 	 	20050255548	 	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/17/05
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P06-507

(United States)

	 	 	11/483808	 	 	 	2006-0270604-	 	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/30/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P07-507

(United States)

	 	 	11/483918	 	 	 	2006-0246059	 	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/02/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-P08-507

(United States)

	 	 	11/543316	 	 	Unpublished
	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins	 	 

iv

 

Strategic
Alliance and Collaboration Agreement — Exhibit D

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PWO-507 (PCT)

	 	1999US0029317
	 	WO 00/34784
	 	NTL
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	06/15/00
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PW1-507 (PCT)

	 	2001US0006414
	 	WO 01/64942
	 	NTL
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	09/07/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PW2-507 (PCT)

	 	2001US0032233
	 	WO 02/32925
	 	NTL
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	04/25/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAU-507

(Australia)

	 	 	23572/00	 	 	AU0775076B2
	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	10/28/04
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PA1-507

(Australia)

	 	 	2001241850	 	 	AU0141850A5
	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	09/12/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PA2-507

(Australia)

	 	 	2002213251	 	 	AU0213251A5
	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	4/29/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PA4-507

(Australia)

	 	 	2004218675	 	 	AU04218675A1
	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	10/08/04
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PAT-507

(Austria)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PBE-507

(Belgium)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06

v

 

Strategic
Alliance and Collaboration Agreement —Exhibit D

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PCA-507

(Canada)

	 	 	2351346	 	 	CA2351346AA
	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	06/15/00
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PC1-507

(Canada)

	 	 	2400058	 	 	CA2400058AA
	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	09/07/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PC2-507

(Canada)

	 	 	2418835	 	 	CA2418835AA
	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	04/25/02
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PCH-507 (Czech
Republic)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PDE-507

(Germany)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PDK-507

(Denmark)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PEP-507

(Europe)

	 	 	99967261.1	 	 	EP1137941A1
	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	10/04/01
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PE1-507

(Europe)

	 	 	01913159.8	 	 	EP1266025A1/1266025
	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	12/18/02/11/22/06

vi

 

Strategic
Alliance and Collaboration Agreement — Exhibit D

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH-PE2-507

(Europe)

	 	 	01981621.4	 	 	EP1356075A2
	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	10/29/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PES-507

(Spain)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PFI-507

(Finland)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PFR-507

(France)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PGB-507

(United Kingdom)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIE-507

(Ireland)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PIT-507

(Italy)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PJP-507 (Japan)

	 	 	2000-587187	 	 	JP2002532072T2
	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	10/02//02

vii

 

Strategic
Alliance and Collaboration Agreement — Exhibit D

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	Application	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Number	 	Number	 	Status	 	Title	 	l. Date
	COTH- PJ1-507

(Japan)

	 	 	2001-563629	 	 	JP2003525487T2
	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	08/26/03
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH- PJ2-507

(Japan)

	 	 	2002-536306	 	 	JP2004526419T2
	 	PEN
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	09/02/04
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PLU-507

(Luxembourg)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PMC-507

(Monaco)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PNL-507 (The 

Netherlands)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PPT-507

(Portugal)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COTH-PSE-507

(Sweden)

	 	 	01913159.8	 	 	 	1266025	 	 	PAT
	 	Protein Scaffolds
for Antibody Mimics
and Other Binding
Proteins
	 	11/22/06

viii

 

Strategic Alliance and Collaboration Agreement

Exhibit E

ATI Target Patents

	 	 	 	 	 	 	 	 	 	 	 
	Attorney	 	 	 	 	 	 	 	 	 	 
	Docket	 	 	 	Patent/Publ.	 	 	 	 	 	Issue/Pub
	Number	 	Application Number	 	Number	 	Status	 	Title	 	l. Date
	Family I:
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	COTH-013-001
	 	60/860,605	 	n/a	 	PEN	 	Targeted	 	n/a
	 
	 	 	 	 	 	 	 	Therapeutics Based	 	 
	 
	 	 	 	 	 	 	 	on Engineered	 	 
	 
	 	 	 	 	 	 	 	Proteins for	 	 
	 
	 	 	 	 	 	 	 	Tyrosine Kinases	 	 
	 
	 	 	 	 	 	 	 	Receptors,	 	 
	 
	 	 	 	 	 	 	 	Including IGF-IR	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	COTH-013-002
	 	60/879,666	 	n/a	 	PEN	 	Targeted	 	n/a
	 
	 	 	 	 	 	 	 	Therapeutics Based	 	 
	 
	 	 	 	 	 	 	 	on Engineered	 	 
	 
	 	 	 	 	 	 	 	Proteins for	 	 
	 
	 	 	 	 	 	 	 	Tyrosine Kinases	 	 
	 
	 	 	 	 	 	 	 	Receptors,	 	 
	 
	 	 	 	 	 	 	 	Including IFR-IR	 	 

 

 

Strategic Alliance and Collaboration Agreement

Exhibit F

Research Plan(s)

     Attached.

 

 

Strategic
Alliance and Collaboration Agreement

Confidential materials omitted and filed separately with the Securities and Exchange Commission.
Asterisks denote omissions.

[**]

 

 

Strategic Alliance and Collaboration Agreement

Exhibit G

Press Release

     Attached.

 

 

Strategic Alliance and Collaboration Agreement

			
	 	 	 
	
	 	
	 	 	 

BRISTOL-MYERS
SQUIBB COMPANY AND ADNEXUS THERAPEUTICS

ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE

INNOVATIVE ONCOLOGY COMPOUNDS

Companies To Leverage Adnexus’ Proprietary Adnectin-PROfusion Product Engine

For Advanced Biologics

Princeton, NJ and Waltham MA, February 21, 2007 — Bristol-Myers Squibb Company (NYSE: BMY) and
AdnexusTM Therapeutics today announced a worldwide strategic alliance to discover, develop and
commercialize Adnectin-based therapeutics for important oncology-related targets.

The goal of the collaboration is to discover and develop biologic compounds specifically tuned to
modulate oncology targets of high clinical impact. Adnexus will deploy its PROfusion technology on
up to six research programs to identify and deliver pre-clinical Adnectin candidates to
Bristol-Myers Squibb. Bristol-Myers Squibb will be responsible for global development and
commercialization activities, with Adnexus retaining a limited co-promotion right to the first
product to achieve regulatory approval in the United States.

Under the terms of the agreement, Bristol-Myers Squibb will provide committed funds of
approximately $30 million over the next three years to Adnexus, consisting of upfront and
guaranteed research payments. Adnexus also is eligible to receive regulatory milestone payments of
up to $210 million per product, as well as royalties on product sales and sales-based milestone
payments.

“Bristol-Myers Squibb is focused on discovering and commercializing medicines to treat serious
diseases with unmet medical need, including cancer, and we are committed to expanding our biologics
portfolio because we believe these medicines have the potential to improve patient treatment
options” said Francis Cuss, M.D, senior vice president of Discovery & Exploratory Clinical
Research for Bristol-Myers Squibb. “The company continues to invest in new approaches to drug
discovery, and this collaboration allows us to obtain key product rights to multi-functional
Adnectins. We are excited about combining Bristol-Myers Squibb’s broad experience in oncology
research with Adnexus’ new platform to explore novel biologic
oncology treatments.”

“Bristol-Myers Squibb has world class expertise in oncology, and we look forward to working together using our
PROfusion and Adnectin combination to discover potential therapies
for people with cancer,” said
John Mendlein, Ph.D., J.D., CEO of Adnexus. Our recently published
clinical data on Adnexus,
selective VEGFR-2 blocker, AngioceptTM, validates the broad utility of our proprietary Adnectin
class, especially in cancer.”

-more-

 

 

Strategic
Alliance and Collaboration Agreement

About the New Adnectin Product Class and the PROfusion System

Adnectins
are an emerging, proprietary protein therapeutic class that can be designed
to address a broad range of diseases. They are based on human fibronectin, an
extracellular protein that is naturally abundant in human serum. The intrinsic
properties of an Adnectin align with the properties needed to make a successful drug,
including high potency, specificity, stability, favorable half life, favorable IP
profile and high yield E. coli production.

Adnectins
are designed using the PROfusion
SystemTM. Adnexus’ patented protein design
engine, to achieve high potency and specificity for a therapeutic target while
simultaneously selecting for ideal pharmaceutical product characteristics. PROfusion
enables Adnexus to screen over 1 trillion unique Adnectins for each drug discovery
program to “redirect” naturally occurring human fibronectin to act as a protein
therapeutic. This greatly accelerates Adnectin drug discovery and development.

Adnexus is the exclusive developer of Adnectins. Adnexus solely owns the Adnectin
patent estate that controls issued and pending patent properties to fundamental
Adnectin forms. In addition, Adnexus exclusively controls its patented PROfusion
protein design engine. Adnexus has over 100 issued and pending patent properties
relating to Adnectins and PROfusion.

About Adnexus Therapeutics

Adnexus Therapeutics is focused on generating vital medicines through the discovery,
development, and commercialization of its broadly applicable new therapeutic class,
Adnectins. Adnexus’ lead product candidate, CT-322, is in Phase 1 clinical development
in oncology in the United States. The company also has a pipeline of other Adnectin
products in preclinical research across multiple therapeutic areas. Adnectins are
designed and optimized using PROfusion, the company’s patented protein design engine
that uniquely enables rapid optimization of protein therapeutics. The company is
funded by four leading venture capital firms: Atlas Venture, Flagship Ventures, Polaris
Venture Partners, and Venrock Associates. For more information, please visit
www.adnexustx.com

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical and related health care products company
whose mission is to extend and enhance human life.

Adnexus Forward-Looking Statement

This news release contains certain forward-looking statements that involve risks and
uncertainties. Such statements are only predictions and the company’s actual results
may differ materially from those anticipated in these forward-looking statements.
Factors that may cause such differences include the timing of clinical trials, the risk
that products that appeared promising in early research and clinical trials do not
demonstrate safety or efficacy in clinical trials and the risk that the company will
not obtain approval to market its products.

AdnectinTM, Adnexus TherapeuticsTM and PROfusionTM are trademarks of Adnexus
TherapeuticsTM, Inc. Adnexus Therapeutics
SM is a service mark of Adnexus
TherapeuticsTM.

-more-

 

 

Strategic Alliance and Collaboration Agreement

Bristol-Myers Squibb Forward-Looking Statement

This press release contains “forward-looking statements” as that term is defined in
the Private Securities Litigation Reform Act of 1995, a research collaboration
agreement to discovery and development of biologic compounds. Such
forward-looking statements are based on current expectations and involve inherent
risks and uncertainties, including factors that could delay, divert or change any of
them, and could cause actual outcomes and results to differ materially from current
expectations. No forward-looking statement can be guaranteed. Among other risks, there
can be no guarantee that the research collaboration agreement described in this
release will result in the discovery, development and commercialization of biologic
compounds. Forward-looking statements in the press release should be evaluated
together with the many uncertainties that affect Bristol-Myers Squibb’s business,
particularly those identified in the cautionary factors discussion in Bristol-Myers
Squibb’s Annual Report on Form 10-K for the year ended December
31, 2005, its Quarterly Reports on Form 10-Q, and Current Reports on
Form 8-K. Bristol-myers
Squibb undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or otherwise.

	 	 	 
	For information contact:
	 	 
	 
	Bristol-Myers Squibb Investor Relations

	 	Adnexus Corporate Contact:
	Contact:

	 	Katrine Bosley
	John Elicker

	 	Vice President Business Development
	Investor Relations

	 	Adnexus Therapeutics. Inc.
	212-546-3775

	 	781-891-3745
	john.elicker@bms.com

	 	pr@adnexustx.com
	 
	 	 
	Bristol-Myers Squibb Media Contact:

	 	Adnexus Media Contact:
	Jeff Macdonald

	 	Courtney.Harris
	Business and R&D Communications

	 	Feinstein Kean Healthcare
	212-546-4824

	 	617-761-6744
	jeffrey.macdonald@bms.com

	 	Courtney.Harris@fkhealth.com

###

 

Strategic Alliance and Collaboration Agreement

Schedule 2.3(b)

Certain ATI Targets

[**].exv10w2

 

      Confidential
Materials omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote omissions.

Exhibit 10.2

 TCG:TJR License Agreement between RCT and Phylos; RCT Project No. 060-1710; Koide.

LICENSE AGREEMENT

     Effective July 1, 1999 (the “Effective Date”), Research Corporation Technologies, Inc.
(“RCT”), a Delaware nonprofit corporation with offices at 101 North Wilmot, Ste. 600, Tucson,
Arizona, 85711-3365, and , Phylos, Inc. a Massachusetts corporation, with offices at 128 Spring
Street, Lexington, MA 02421-7802 (“Phylos”), agree as follows:

1. DEFINITIONS.

     1.1. “AFFILIATE” means any entity which directly or indirectly controls, is controlled by, or
is under common control with, a party to this Agreement. “Control” shall constitute the right to
cast, or the right to direct the casting of, at least 50% of the votes at a meeting of such owners,
or at a meeting of the entity’s directors or governing body, or the right to designate a majority
of the entity’s directors or members of the entity’s governing body, or the power to direct or
cause the direction of the management or policies of an entity, whether through the ownership of
voting securities, by contract, or otherwise.

     1.2. “CALENDAR QUARTER” means any period of three (3) consecutive months beginning with
January 1, April 1, July 1, or October 1 of each calendar year.

     1.3. “CATALYTIC PRODUCT” means a LICENSED MONOBODY that is neither a DIAGNOSTIC PRODUCT nor a
PHARMACEUTICAL PRODUCT.

     1.4. “DIAGNOSTIC PRODUCT” means a LICENSED MONOBODY suitable or intended for USE in the
diagnosis of a disease condition or of protein profiles of cells from biological sources.

     1.5. “INSTITUTION” means the University of Rochester.

     1.6 “INVENTION” means the certain invention entitled “Artificial Antibody Scaffolding,” which
is the subject of RCT Project
 No. 060-1710.

     1.7. “LICENSED MONOBODY” means a a purified peptide or protein configuration, the manufacture,
USE, or SALE of which infringes, or induces or contributes to the infringement of, a PATENT CLAIM.

     1.8. “LICENSED PATENTS” means:

     (a) the patents and patent applications identified in EXHIBIT A attached to this
Agreement;

     (b) all divisional or continuation, in whole or in part, applications based on any of
the foregoing;

     (c) any and all foreign applications corresponding to the patent applications described
in (a) and (b) above;

     (d) any and all issued and unexpired patents resulting from any of the applications
described in Paragraph (a), (b) or (c) above; and

     (e) any and all issued and unexpired reissues, reexaminations, renewals or extensions
that may be based on any of the patents described in Paragraphs (a) or (d) above.

     1.9. “MANUFACTURED PRODUCT” means a product made at any stage of its manufacture with the
USE or benefit of a LICENSED MONOBODY.

     1.10. “NET SALES” of any PRODUCT means the gross billings for the SALE or importation thereof
less the deductions identified below.

     1.10.1. Determining Gross Billings. The gross billings used for calculating NET SALES of any
PRODUCT SOLD or imported under this Agreement shall be determined as follows:

1

 

 TCG:TJR License Agreement between RCT and Phylos; RCT Project No. 060-1710; Koide.

     (a) If Phylos or its AFFILIATE SELLS a PRODUCT:

     1. To a third party that is not a RELATED PARTY, gross billings shall be Phylos’s or
its AFFILIATE’S actual gross billings, as the case may be;

     2. To a RELATED PARTY for subsequent SALE by such RELATED PARTY, gross
billings shall be such RELATED PARTY’S actual gross billings for such subsequent SALE;

     3. To a RELATED PARTY for USE by such RELATED PARTY gross billings shall
be the gross billings that would result from a hypothetical arm’s length SALE to a third party (that is not a RELATED PARTY) by Phylos or its AFFILIATE, as the case may be;

     (b) If Phylos or its AFFILIATE USES a LICENSED MONOBODY in a manner or for a purpose other
than in or for the manufacture of a MANUFACTURED PRODUCT, gross billings shall be the gross
billings that would result from a hypothetical arm’s length SALE of such LICENSED MONOBODY to a
third party (that is not a RELATED PARTY) by Phylos or its AFFILIATE, as the case may be.

     1.10.2. Allowable Deductions. When factually applicable, the following deductions may be
deducted from gross billings as determined above:

     (a) rebates, volume, quantity, trade or cash discounts, allowed and taken, in amounts
customary in the trade;

     (b) sales taxes and/or use taxes and/or duties imposed upon, and with specific reference to,
particular SALE to the extent included in the amount of gross billings;

     (c) amounts allowed or credited on returns, rejections or recalls, voluntary or otherwise (not
exceeding the original gross billings); and

     (d) charges for freight, freight allowances, and outbound transportation costs prepaid to the
extent included in such gross billings.

No other allowance or deduction shall be made including without limitation allowances or deductions
for any commissions or sales fees by whatever name known.

     1.11. “PATENT CLAIM” means a valid claim in an unexpired or pending LICENSED PATENT. A PATENT
CLAIM shall be presumed to be valid unless and until it has been held to be invalid by a final
judgment of a court of competent jurisdiction from which no appeal can be or is taken. For the
purposes of this Agreement, and especially for purposes of earned royalty determination and payment
under this Agreement, any claim being presented in a pending patent application shall be deemed to
be the equivalent of a valid claim of an issued, unexpired patent and in consideration of RCT’s
agreement to grant a license under any patent issuing thereon earned royalties shall be payable in
respect thereto as though it were a valid patent claim.

     1.12. “PHARMACEUTICAL PRODUCT” means a LICENSED MONOBODY that is intended for USE in the
treatment or prevention of a disease.

     1.13. “PRODUCT” means any one or more of a CATALYTIC PRODUCT, a DIAGNOSTIC PRODUCT,
MANUFACTURED PRODUCT, or a PHARMACEUTICAL PRODUCT as appropriate from the context.

     1.14. “RELATED PARTY” means any one of Phylos, its AFFILIATES, third parties to this Agreement
to which RCT has granted a license under the LICENSED PATENTS, or any person enjoying a special
course of dealing with Phylos or its AFFILIATES. By way of example but not limitation, a “special
course of dealing” includes co-marketing arrangements between Phylos and a third party wherein the
third party may SELL products, arrangements under which a third party will SELL products under a
private labelling arrangement with Phylos, distribution arrangements with third parties in which
Phylos or its AFFILIATE shares, directly or indirectly, in the

2

 

 TCG:TJR License Agreement between RCT and Phylos; RCT Project No. 060-1710; Koide.

proceeds from such distributor’s
SALES of an PRODUCT, or barter arrangements in which Phylos exchanges products for other products
in kind. A distributor (other than an AFFILIATE) of Phylos’s product under Phylos’s name or mark
shall not be considered a RELATED PARTY if Phylos (or its AFFILIATE) does not share, either
directly or indirectly, in the proceeds from such distributor’s sales of Phylos’s product.

     1.15. “SALE” (and any cognate noun form and cognate conjugated verb form thereof) shall mean
to sell, or otherwise part with or dispose of, for value.

     1.16. “USE” (and any cognate noun form and cognate conjugated verb form thereof) shall mean to
use for commercial purposes.

2. [THIS ARTICLE IS RESERVED]

3. GRANT OF LICENSES

     3.1. RCT hereby grants to Phylos a non-exclusive license under the LICENSED PATENTS to make
LICENSED MONOBODIES, to have LICENSED MONOBODIES made, to USE LICENSED MONOBODIES in the
manufacture of MANUFACTURED PRODUCTS, to SELL LICENSED MONOBODIES, to offer to SELL LICENSED
MONOBODIES, and to import LICENSED MONOBODIES, free from suit by RCT for infringement of the PATENT
CLAIMS in all countries of the world in which RCT has LICENSED PATENTS. No other or further
license or right is granted or implied under this Agreement. No license or rights are granted or
implied under any patent application or patent not in the LICENSED PATENTS. Except as expressly
provided in Paragraph 3.2, Phylos shall have no right or power to grant sublicenses under the
LICENSED PATENTS.

     3.2. At such times as Phylos is not in material default under any of its obligations to RCT
under this Agreement, Phylos shall have the right to extend the licenses granted under Paragraph
3.1 to AFFILIATES. Any such extension shall be in writing and shall be accepted in writing by any
such AFFILIATE. All terms and provisions of this Agreement, except this right to extend and the
obligation to make payments under Paragraph 4.3, shall apply to such AFFILIATE to the same extent
as they apply to Phylos. The operations and action of such AFFILIATE under such extension shall be
deemed to be the operations and actions of Phylos under this Agreement and Phylos shall be
primarily responsible for the performance by such AFFILIATE of all of its obligations hereunder.
Phylos shall notify RCT promptly in writing of any such extension. If an AFFILIATE ceases to be an
AFFILIATE, any license extended to such AFFILIATE under this Paragraph 3.2 shall terminate
concurrently with such AFFILIATE’S ceasing to be an AFFILIATE.

     3.3. Phylos may enter into arrangements with third parties, not an AFFILIATE, to promote,
market distribute and SELL PRODUCTS on Phylos’ behalf. Phylos or such third parties may find it
necessary or desirable that such third parties have a separate license to practice under the
LICENSED PATENTS. Upon written request from Phylos, RCT shall reasonably consider, to facilitate
Phylos’ business arrangements, the granting to such third parties such separate licenses [**]
provided in Article 4 but at the [**] terms in other respects.

4. PAYMENTS

     4.1. Phylos shall pay to RCT a non-refundable and non-creditable license issue fee of $[**]
payable as follows: (a) $[**] upon the execution and delivery of this Agreement; (b) $[**] on of
before the date one year after the Effective Date; and (c) $[**] on or before the date two years
after the Effective Date. If this Agreement is terminated any time on or before the date the
license issue fee is paid in full, Phylos shall pay to RCT the remaining balance of the license
issue fee on or before the effective date of the termination of this Agreement.

     4.2. Phylos shall pay to RCT earned royalties as follows:

     4.2.1. Phylos shall pay to RCT an earned royalty equal to [**]% of the NET SALES of
each DIAGNOSTIC PRODUCT made, SOLD, or imported, by or for Phylos or its AFFILIATES during
the term of this Agreement, including any DIAGNOSTIC PRODUCT made or imported during the
term of this Agreement but SOLD after the termination of this Agreement.

3

 

 TCG:TJR License Agreement between RCT and Phylos; RCT Project No. 060-1710; Koide.

     4.2.2. Phylos shall pay to RCT an earned royalty equal to [**]% of the NET SALES of
each PHARMACEUTICAL PRODUCT made, SOLD, or imported, by or for Phylos or its AFFILIATES
during the term of this Agreement, including any PHARMACEUTICAL PRODUCT made or imported
during the term of this Agreement but SOLD after the termination of this Agreement.

     4.2.3. Phylos shall pay to RCT an earned royalty equal to [**]% of the NET SALES of
each CATALYTIC PRODUCT made. SOLD, or imported, by or for Phylos or its AFFILIATES during
the term of this Agreement, including any such LICENSED MONOBODY made or imported during the
term of this Agreement but SOLD after the termination of this Agreement

     4.2.4. If a LICENSED MONOBODY may comprise two or more of a DIAGNOSTIC PRODUCT,
PHARMACEUTICAL PRODUCT, or CATALYTIC PRODUCT, the earned royalty payable thereon shall be
the [**] earned royalty determined under Paragraph 4.2.1, 4.2.2, and 4.2.3 above. Only one
earned royalty will accrue and be paid on a given LICENSED MONOBODY even if the manufacture
of such LICENSED MONOBODY in one country is covered by the LICENSED PATENTS and the USE,
SALE, or importation in another country is covered by the LICENSED PATENTS.

     4.2.5. Phylos shall pay to RCT an earned royalty equal to [**]% of the NET SALES of
each MANUFACTURED PRODUCT made, SOLD or imported by or for Phylos or its AFFILIATE during
the term of this Agreement, including any MANUFACTURED PRODUCT manufactured during the term
of this Agreement but SOLD or imported after the termination of this Agreement.

     4.2.6. If Phylos SELLS LICENSED MONOBODIES to a third party that has a license under
the LICENSED PATENTS to make, USE, SELL, offer to SELL, or import LICENCSED MONOBODIES, the
earned royalty on such SALE shall accrue and be paid under such third party’s license so
long as such third party licensee pays such earned royalty. If Phylos purchases LICENSED
MONOBODIES from a third party that has a license to make, SELL, offer to SELL, or import
LICENSED MONOBODIES, the earned royalty on such SALE shall accrue and be paid under this
license. Only one earned royalty will accrue and be paid on a given PRODUCT, even if such
PRODUCT is SOLD or transferred between RELATED PARTIES for subsequent USE or RESALE.

     4.2.7. Earned royalty payments for Phylos’ activities in a given CALENDAR QUARTER
during the term of this Agreement are due on or before the date forty-five days after the
end of such CALENDAR QUARTER. The earned royalty payable on a given PRODUCT shall not become
due until such PRODUCT is USED or SOLD.

     4.3. Phylos shall pay to RCT a non-refundable, non-creditable annual license maintenance fee
of $[**]. Phylos shall pay the first maintenance fee on or before July 1, 2000, and shall pay
subsequent maintenance fees on or before July 1 of each year thereafter during the term of this
Agreement.

     4.4. All payments due hereunder are expressed in and shall be paid in United States of America
currency, without deduction of exchange, collection or other charges by wire transfer to: RESEARCH
CORPORATION TECHNOLOGIES, INC., Wells Fargo Bank, N.A., Tucson Main Office, 150 N. Stone Ave., P.O.
Box 1871, Tucson, AZ 85702, ABA & Transit No. 121000248, Acct. 4159-527159—RCT CHECKING; or to the
account of RCT at such other bank as RCT may from time to time designate in writing. Phylos shall
pay the cost of any wire transfer fees. If the amount is $100,000 or less, Phylos may elect to pay
by company check, instead of wire transfer, at the address shown in Paragraph 14..

     4.5. Phylos agrees to take all reasonable and necessary steps to register this Agreement in
any country of the LICENSED PATENTS where such is required to permit the transfer of funds and/or
payment of royalties to RCT hereunder or is otherwise required by the government or law of such
country to effectuate or carry out this Agreement. In no event shall Phylos be relieved of any
obligations under this Agreement because it failed to register this Agreement in any such country.
If Phylos or an AFFILIATE SELLS any PRODUCT for currency other than United States currency, Phylos
shall determine the earned royalty payable for such PRODUCT in such currency and then convert the
earned royalty into its equivalent in United States currency at the New York foreign exchange
selling rate for such currency for the last business day of the calendar quarter for which
payment is made, as

4

 

 TCG:TJR License Agreement between RCT and Phylos; RCT Project No. 060-1710; Koide.

published by the Wall Street Journal. If such rate is not so published, the
conversion shall be at the selling rate for such currency for the last business day of the
calendar quarter for which payment is made, as published by a leading New York, New York bank
chosen by Phylos and reasonably acceptable to RCT. If Phylos is late in making any payment, the
applicable exchange rate obtained from the sources described above shall be the greater of the rate
on the date payment was actually made or the rate on the date on which payment was due.

     4.6. If Phylos fails to make any payment required under this Agreement on or before the date
ten days after Phylos’s receipt of RCT’s written notice of such failure, Phylos shall pay interest
on such amount at an annual rate equal to the prime rate, as quoted by Wells Fargo Bank, N.A., plus
3%, which interest shall accrue on the entire, unpaid amount from the date the payment not timely
manner became due until the date such payment is paid in full. The interest shall be compounded on
the last day of each CALENDAR QUARTER. If such rate exceeds the rate allowable by applicable law,
then the highest rate allowed by law shall apply. Any payments received shall be applied first to
any unpaid, accrued interest and then to the satisfaction of any unpaid principal.

     4.7. Phylos shall bear all taxes and charges assessed or imposed on it by a government
authority other than income tax imposed by the United States or a political or governmental
subdivision thereof, and all payments hereunder shall be made undiminished by any such tax or
charge. Such taxes and charges shall not include any U.S. maintenance fees for keeping in force any
issued U.S. patent included under the LICENSED PATENTS. Phylos shall cooperate with and assist RCT
in obtaining any exemption from taxes imposed by any government (or instrumentality) of any country
of the LICENSED PATENTS on royalty payments made by Phylos to RCT. To that end, Phylos shall ensure
that all payments made under this Agreement from Phylos to RCT shall originate in the United
States.

     4.8 RCT intends to grant non-exclusive licenses to others under the LICENSED PATENTS. In such
event, the following provisions shall govern the effect of such licenses on this Agreement:

     4.8.1. If, after the Effective Date, RCT, under substantially identical provisions and
conditions, grants a license (the “Lower-Rate License”) under the LICENSED PATENTS in a
given country to any third party (other than Phylos’ AFFILIATE) at an earned royalty rate
for a given PRODUCT that is lower than that provided in Paragraph 4.2, and if such PRODUCT
made and SOLD by such third party under the Lower-Rate License competes with Phylos’ SALES
of LICENSED PRODUCTS in such country under this Agreement, RCT shall promptly modify this
Agreement, upon Phylos’ election pursuant to Paragraph 4.8.2 below to modify this Agreement,
by reducing the earned royalty rate in Paragraph 4.2, as it applies to such PRODUCT and such
country only, to such lower earned royalty rate. Such modification shall become effective on
the first day of the calendar quarter immediately following the date on which such third
party first SELLS such PRODUCT in such country under the Lower-Rate License in competition
with Phylos’ SALES of LICENSED PRODUCTS in the same country. Such modification shall also
include any less favorable terms in the Lower-Rate License and shall continue in effect only
through the earlier to occur of (i) the calendar quarter in which the Lower-Rate License
ceases to be in effect in such county; or (ii) the calendar quarter in which such third
party ceases to sell products in such country made under the Lower-Rate License in
competition with Phylos’ SALES of such PRODUCTS in the same county. If the Lower-Rate
License expires or is otherwise terminated, the earned royalty rate payable under this
Agreement without regard to any adjustment under this Paragraph 4.8 shall apply unless and
until another Lower-Rate License calls into operation the provisions of this Paragraph 4.8.

     4.8.2. On or before the date thirty days after the date on which RCT grants a
Lower-Rate License, RCT shall provide Phylos written notice of the grant of such Lower-Rate
License. If Phylos elects to modify the provisions of this Agreement in the manner provided
by Paragraph 4.8.1 above, Phylos shall provide, on or before the date sixty days after
Phylos’ receipt of RCT’s written notice, RCT written notice, along with reasonable
supporting documentation demonstrating that such third party licensee’s sale of products
compete or will compete with Phylos’ SALES of PRODUCTS under this Agreement. On or before
the date thirty days after RCT’s receipt of such written notice, RCT shall notify Phylos if
it contests Phylos’ conclusion that the third-party’s sales are in competition with Phylos’
SALES or that Phylos is entitled to the lower earned royalty rate. If RCT does not timely
notify Phylos that RCT contests Phylos’ conclusion, RCT shall be deemed to concur with such
conclusion. If RCT does timely notify Phylos that it contests Phylos’ conclusion, and if, on
or before the date ninety date after RCT’s receipt of Phylos’ written notice,

5

 

 TCG:TJR License Agreement between RCT and Phylos; RCT Project No. 060-1710; Koide.

Phylos and RCT
are unable to agree on whether Phylos is entitled to a lower earned royalty rate for such
PRODUCT in such country, the parties shall submit the matter to a neutral third party
mutually acceptable to the parties whose determination shall be binding on the parties as to
such PRODUCT and such country. If the neutral third party determines that Phylos is entitled
to such lower earned royalty and that this Agreement should be modified accordingly, Phylos
shall not be entitled to any refund for amounts previously paid to RCT after the effective
date of such modification, but Phylos shall be entitled to credit the amount of any
overpayment made through the date of such determination against future earned royalties due
to RCT under this Agreement.

     4.8.3. Phylos shall not be entitled to such lower earned royalty rate if the
third-party has obtained such lower earned royalty rate in return for substantial and unique
consideration that Phylos is unable to provide to RCT. The provisions of this Paragraph 4.8
shall not be called into operation because of the existence or operation of any license
granted or to be granted to or on behalf of any government or any increase in the earned
royalty rate because of taxes imposed by any government.

     4.9. If Phylos provides RCT written notice that the earned royalty paid to RCT under this
Agreement for a particular PRODUCT diminishes Phylos’ capability to respond to competitive
pressures in the market for such PRODUCT along with justification for such view, RCT agrees to
consider, but shall not be obligated to grant Phylos, a reasonable reduction in the earned royalty
rate. provided above for such PRODUCT for the period during which such market conditions exist.
Factors determining the size of the reduction may include profit margin of PRODUCTS, prices of
competitive product, and additional earned royalty obligations of Phylos to third parties. Any such
reduction may he granted in RCT’s sole discretion.

5. RECONDS, REPORTS, AND INSPECTION.

     5.1. Phylos shall render to RCT, at the same time as each of the earned royalty payments
referred to in Paragraph 4.2 are made, a written statement providing the following details:

     (a) the unit quantities of DIAGNOSTIC PRODUCTS, PHARMACEUTICAL PRODUCTS, CATALYTIC
PRODUCTS, and MANUFACTURED PRODUCT SOLD by Phylos or its AFFILIATES, separately stated for
each such class of LICENSED MONOBODY, during the CALENDAR QUARTER covered by the report in
each country in which such billing occurred. The statement shall include the identity of
each type of DIAGNOSTIC PRODUCT, PHARMACEUTICAL PRODUCT, and CATALYTIC PRODUCT SOLD;

     (b) the United States dollar value of the billings on such quantities in (a) above;

     (c) the calculation of NET SALES of the DIAGNOSTIC PRODUCT, PHARMACEUTICAL PRODUCT,
CATALYTIC PRODUCT, and MANUFACTURED PRODUCTS SOLD, separately stated for each class of
LICENSED MONOBODY, based on the dollar value determined in (b) above including a detailed
accounting of any allowed deductions from the invoice amounts to arrive at the NET SALES;

     (d) the computation of earned royalties based on the NET SALES computed under (c)
above;

     (e) the quantities of such LICENSED PRODUCTS transferred between RELATED PARTIES or
USED by RELATED PARTIES, the computation of earned royalties thereon, and the total
royalties so computed.

If no earned royalties are due, Phylos shall so report. On or before the date ninety days after the
end of the CALENDAR QUARTER in which this Agreement is terminated Phylos shall provide to RCT a
written report that complies in all respects with this Paragraph along with a payment of any
amounts to be paid in respect thereof.

     5.2. Phylos shall keep and maintain records in accordance with generally accepted accounting
principles sufficient to enable RCT to determine the monies payable to RCT by Phylos under the
terms of this Agreement and Phylos’s compliance in other respects with this Agreement. Phylos shall
retain such records for five years after the end of the reporting period to which they pertain.
Phylos shall make such records available to inspection and

6

 

 TCG:TJR License Agreement between RCT and Phylos; RCT Project No. 060-1710; Koide.

copying by a certified public accountant
appointed by RCT at RCT’s expense and reasonably acceptable by Phylos, at any reasonable time
during normal business hours, but not more often than once per calendar year, to the extent
necessary for RCT to verify the records and payments due under this Agreement. If any such
inspection discloses an underpayment of earned royalties of 7.5% or more of the amount of earned
royalties actually due for any CALENDAR QUARTER, then Phylos shall promptly pay the reasonable cost
of such inspection after Phylos’s receipt of the bill / invoice for such inspection.

     5.3. RCT shall maintain the reports made pursuant to Paragraph 5.1 and their content, and any
information obtained or copied pursuant to Paragraph 5.2, in confidence, and shall not disclose,
divulge or otherwise communicate such Confidential Information to others, except to its officers,
employees, consultants and agents.
RCT may disclose information pertaining to this Agreement to the INSTITUTION and the inventors
of the LICENSED PATENTS pursuant to RCT’s and the INSTITUTION’S Agreement for Disclosure,
Evaluation, and Commercialization. RCT’s obligations of confidentiality under this Paragraph 5.3
shall not apply to any information that: (a) at the time of receipt by RCT, was independently known
to RCT from a source other than Phylos or its AFFILIATES; or (b) at the time RCT discloses it to a
third party, is generally known to the public through no fault of RCT; or (c) at the time RCT
discloses it to a third party, has been made available to RCT by a third party having the lawful
right to do so without breaching any obligation of confidentiality to Phylos.

6. LIMITATION OF LIABILITY; INDEMNITY; INSURANCE.

     6.1. Except for RCT’s breach of the Agreement, none of RCT, INSTITUTION or any inventor
identified on any LICENSED PATENT, shall be liable for any damages, whether direct or otherwise,
arising out of the use by Phylos, its AFFILIATE or any third party of information, samples or
materials supplied hereunder, or LICENSED MONOBODY made under this Agreement and sold by Phylos or
its AFFILIATE. None of RCT, INSTITUTION, or any such inventor shall be liable for lost or
prospective profits or special or consequential damages, whether or not any one of them has been
advised of the possibility of such damages. None of RCT, INSTITUTION, or any such inventor shall be
liable for any claim by a third party against Phylos except to the extent any such claim is
attributable to the gross negligence or willful misconduct on the part of RCT, INSTITUTION, or such
inventor, as the case may be, pertaining to the samples or materials provided by Phylos to RCT
although those of RCT, INSTITUTION or such inventor not guilty of such gross negligence or willful
misconduct shall not be subject to this exception and shall continue to benefit from such exclusion
of liability.

     6.2. None of RCT, INSTITUTION or any inventor identified on any LICENSED PATENT: (a) shall
have the right to control or will control the manner in which any product licensed under this
Agreement is made or practiced; (b) has provided any know-how or operating instructions or other
information with respect to any such product; and (c) makes any representation or warranty
whatsoever with respect to any such product. In recognition of the foregoing, Phylos agrees to
indemnify and hold harmless RCT, INSTITUTION, any inventor identified on any LICENSED PATENT, and
all directors, officers and employees of RCT or INSTITUTION, (collectively, the “Indemnitees”) from
and against any and all third party claims, demands, actions, liabilities, judgments, costs and
expenses of whatever kind, whether based on contract, negligence, strict liability, product
liability, or statutory liability, and without regard to any contributory negligence on the part of
Indemnitees, including, without limitation, attorney’s fees and cost of defense, arising out of or
related in any way to Phylos’s production, USE or SALE of LICENSED MONOBODIES. RCT shall ensure
that Phylos is promptly notified of any such claims in which it intends to invoke this Paragraph
6.2. RCT and its employees shall cooperate fully Phylos and its legal representatives in the
investigation and defense of any action, claim or liability covered by this indemnification. The
foregoing indemnity shall not be available to RCT, INSTITUTION, or any such inventor to the extent
any claim, damage, or liability arises from gross negligence or willful misconduct of RCT,
INSTITUTION or such inventor, as the case may be, in the manufacture, use, sale, or importation of
an LICENSED MONOBODY, although those of RCT, INSTITUTION , or such inventor not guilty of such acts
shall not be subject to this limitation and shall continue to benefit from such indemnity.

     6.3. On or before the earlier of the date Phylos begins clinical trials involving the use of
any PRODUCT, or marketing of any PRODUCT, Phylos shall obtain and, thereafter throughout the term
of this Agreement, and for a period of 15 years after termination of this Agreement, maintain in
force products liability insurance and other insurance coverages typically carried by entities
engaged in Phylos’s business in amounts not less than Two Million U.S. Dollars (US$2,000,000) per
accident or occurrence. Such insurance policies shall name the Indemnitees as

7

 

 TCG:TJR License Agreement between RCT and Phylos; RCT Project No. 060-1710; Koide.

additional insureds
as respects this Agreement. Such policies shall provide or be endorsed to provide that such
insurance is primary and any other insurance carried by any of the Indemnitees shall be excess and
not contributing with the insurance required hereunder. The policies shall contain Cross Liability
and/or Severability of Interests provisions so as to not impair the right of one insured against
another insured. The insurance policies shall provide or be endorsed to provide that written notice
by registered mail shall be given to the Indemnitees at least thirty days before termination,
cancellation, or reduction of coverage. The insurance policies required to be carried by Phylos
under this Agreement shall be with companies that are reasonably acceptable to, and approved by,
RCT. Phylos shall furnish RCT and the INSTITUTION with a certificates of insurance evidencing
coverage and, when requested, a copy of such policy. The requirements of this Paragraph 6.3 shall
survive termination of this Agreement.

7. REPRESENTATIONS AND WARRANTIES. Nothing contained in this Agreement shall be construed
as a representation by RCT that the LICENSED PATENTS can be or will be used to prevent the
importation, SALE or
USE by a third party of a product in any country of the LICENSED PATENTS where such product is
placed in commerce under circumstances which applicable laws or treaties preclude the use of the
LICENSED PATENTS to prevent such importation, SALE or USE. Nothing contained in this Agreement
shall be construed as a representation or warranty: (a) as to the scope or validity of any patent
or patent application in the LICENSED PATENTS; or (b) that any performance, or practice under any
patent or patent application in the LICENSED PATENTS is not an infringement of any patent of
others. RCT warrants that it is the owner of the LICENSED PATENTS and that it has the right to
grant the licenses granted under Paragraph 3.1 hereof. Each party represents and warrants to the
other that this Agreement constitutes a valid and binding agreement of the representing and
warranting party, that execution, delivery and performance of this Agreement by the representing
and warranting party are within such party’s corporate power, have been duly authorized by all
necessary corporate action, and that it shall exercise its good faith in performing under this
Agreement. Neither Phylos nor RCT makes any other warranties, express or implied. As of the
Effective Date, to RCT’s knowledge, RCT does not own or control any patent or patent application,
apart from the LICENSED PATENTS, directed to a construct of fibronectin or fragment thereof for use
as a protein scaffold.

8. FORCE MAJEURE. No failure or omission by any party in the performance of any obligation
of this Agreement (except payments hereunder) shall be deemed a breach of this Agreement nor create
any liability if the same shall arise from any cause or causes beyond the control of the party in
question, as the case may be, including, but not restricted to, the following, which, for the
purpose of this Agreement, shall be regarded as beyond the control of the party in question: acts
of God; acts or omissions of any government or any agency thereof; compliance with any governmental
authority or any officer, department, agency or instrumentality thereof; fire; storm; flood;
earthquake; accident; acts of the public enemy; war, declared or undeclared; rebellion;
insurrection; riot; sabotage; invasion; quarantine restrictions; strike; lockout; disputes or
differences with workmen; transportation embargoes or delays in transportation.

9. TERM AND TERMINATION

     9.1. Unless earlier terminated as hereinafter provided, this Agreement shall automatically
expire in each country on the date on which the last to expire of the LICENSED PATENTS that Phylos
is practicing under expires. Phylos may terminate this Agreement at any time by giving RCT three
months’ written notice of Phylos’s election to terminate.

     9.2. If a party defaults under any of the terms, covenants or provisions of this Agreement,
such party shall have thirty days after the giving of written notice of such default within which
to correct such default. If such default is not corrected within such thirty day period, the other
party shall have the right, at its option, and in addition to any other remedy available at law or
equity, to cancel and terminate this entire Agreement and the licenses granted hereunder, including
the licenses extended to AFFILIATES.

     9.3. Termination of this Agreement shall not constitute a termination or a waiver of any
rights of any party against any other party accruing at or prior to the time of such termination.
Without limiting the generality of the foregoing, Phylos’s obligations to pay any amount payable to
RCT under this Agreement, and to report and pay royalties to RCT as to any PRODUCT or LICENSED
MONOBODY made before termination of this Agreement or expiration of the pertinent LICENSED PATENTS
(even if such PRODUCT or LICENSED MONOBODY is SOLD or imported after the termination of this
Agreement or expiration of the pertinent LICENSED PATENTS), shall

8

 

 TCG:TJR License Agreement between RCT and Phylos; RCT Project No. 060-1710; Koide.

survive such termination or
expiration. In addition to any provision of this Agreement that expressly provides for acts or
obligations to continue beyond the termination of this Agreement, the provisions of ARTICLES 5
(“Reports, Records and Inspection”), 6 (“Limitation of Liability; Indemnity”), 7 (“Representations
and Warranties”), and 13 (“Validity”) and this Paragraph 9.3 shall survive the termination of this
Agreement.

10. INTEGRATION. WAIVERS. This Agreement, and any exhibits attached to this Agreement,
constitute the entire agreement between the parties as to the subject matter of such documents. All
prior and contemporaneous negotiations, representations, warranties, agreements, statements,
promises, and understandings are superseded and merged into, extinguished by, and completely
expressed by such documents. No party shall be bound by or charged with any written or oral
agreements, representations, warranties, statements, promises, or understandings not specifically
set forth in such documents. A party’s express or implied consent or waiver of the other party’s
breach of its obligations hereunder shall not be deemed to be, or construed as, a consent to, or
waiver of, any other breach of the other party. A party’s failure, no matter how long, to: (a)
complain of any act, or failure to act, by the other party; (b) declare the other party in default;
(c) insist upon the strict performance of any obligation or condition of this
Agreement; or (d) exercise any right or remedy consequent upon a breach thereof; shall not
constitute a waiver by such party of its rights, such breach, or any other obligation or condition.
A party’s consent in any one instance shall not limit or waive the necessity to obtain such party’s
consent in any future instance. No single or partial exercise of any right, power or privilege by a
party hereunder shall preclude any other or further exercise thereof or the exercise of any other
right, power or privilege by such party. In any event, no consent or waiver shall be effective for
any purpose hereunder unless such consent or waiver is in writing and signed by the party granting
such consent or waiver.

11. ASSIGNABILITY. This Agreement and any modification thereof shall be binding upon and
shall inure to the benefit of RCT, its assigns and successors in interest. This Agreement and any
modification thereof shall be binding upon and shall inure to the benefit of Phylos and the
successor to its entire business and good will, but shall not otherwise be assigned by Phylos
without prior approval by RCT being first obtained in writing, which approval will not be
unreasonably withheld.

12. LAW. This Agreement shall be governed by and construed according to the laws of the
United States of America, and the internal laws of the state of Arizona, United States of America.
The parties shall make all reasonable efforts to resolve any dispute concerning this Agreement, its
construction, or its actual or alleged breach, by face-to-face negotiations between senior
executives. Should such negotiation fail to resolve the matter, either party may bring judicial
proceedings to resolve the matter in any state or federal court of competent jurisdiction sitting
in the State of Arizona, Pima County. By executing and delivering this Agreement, each party, for
itself and in respect of its property, irrevocably consents and submits to the exclusive
jurisdiction and venue of such courts in any such proceeding and otherwise waives any objection or
defense, including any objection or defense based on forum non conveniens or improper venue, which
it may now or hereafter have to the bringing of any such proceedings in such courts. Each party
further agrees that service of process of notice in any such proceeding shall be effective if in
writing and sent in the manner provided in ARTICLE 14 of this Agreement, or in any other manner
permitted by Arizona law.

13. VALIDITY. Nothing in this Agreement shall be construed to require the commission of any
act contrary to law. If any of the provisions of this Agreement are held to be invalid or
unenforceable, the parties will attempt to replace them with new provisions which have the same
force and effect and the remaining provisions shall not be affected. The parties agree that each
party has reviewed this Agreement and that any rule of construction to the effect that ambiguities
are to be resolved against the drafting party shall not apply to the interpretation of this
Agreement.

14. ADDRESSES. All notices, requests, reports and other communications provided in this
Agreement shall be in writing and shall be deemed to have been made or given: (a) when delivered,
if delivered by hand or sent by facsimile or the like; (b) on the day following deposit with an
overnight courier; or (c) on the date three days following deposit with the United States Mail,
certified or registered:

If to RCT:

President

Research Corporation Technologies, Inc.

101 N. Wilmot Rd., Suite 600

Tucson, AZ 85711-3365

Fax: 520-748-0025

9

 

 TCG:TJR License Agreement between RCT and Phylos; RCT Project No. 060-1710; Koide.

If to Phylos:

President

Phylos Corporation

128 Spring Street

Lexington, Massachusetts 02421-7802

Fax: 781-402-8800

Such addresses may be altered by notice so given. If no time limit is specified for a notice
required or permitted to be given by this Agreement, the time limit therefor shall be three full
business days, not including the day of mailing. The foregoing address shall be used for purposes
of delivery of Biological Materials.

15. INFRINGEMENT AND PATENT PROSECUTION.

     15.1. RCT will protect the LICENSED PATENTS from infringement and prosecute alleged infringers
when, in its sole judgment, such action may be necessary, proper, and justified. Phylos shall fully
cooperate with RCT, as RCT may request, in connection with any such action, at no out-of-pocket
expense to Phylos.

     15.2. At its sole cost and expense, RCT shall maintain and prosecute the LICENSED PATENTS. RCT
does not represent or warrant to Phylos that any patent will issue or be granted based on any
LICENSED PATENT. RCT may, in its sole discretion, abandon any LICENSED PATENT. Phylos shall
cooperate with RCT in the prosecution of any LICENSED PATENT, and in RCT’s efforts in seeking any
available extension of the term of any LICENSED PATENT. To that end, Phylos shall provide RCT with
any data, experimental materials, research or test results in Phylos’s possession or control and
that RCT may reasonably request for its patent prosecution or patent term extension efforts in
connection with the LICENSED PATENTS. In addition, Phylos shall cooperate with RCT, and shall cause
its employees to cooperate with RCT, in the preparation of any declarations or affidavits that are
to be signed by Phylos or employees of Phylos. RCT agrees to take commercially
reasonable actions to ensure that such any agencies or regulatory bodies to which RCT discloses
such information, materials or samples shall treat the same as confidential.

16. INDEPENDENT CONTRACTOR. In its performance under this Agreement, each party shall be an
independent contractor and neither party (nor its employee or agent) shall be an agent or partner
of the other party.

17. HEADINGS. The headings of the various Paragraph of this Agreement are used solely for
the convenience of the parties, do not form a part of this Agreement, do not affect the
interpretation or meaning of this Agreement, and do not define, limit, extend, or describe its
scope or intent.

18. NO THIRD PARTY BENEFICIARIES. Except for Paragraphs 6.1, 6.2, and 6.3, which shall
also be for the benefit of, and enforceable by, the INSTITUTION and the inventor of the LICENSED
PATENTS, none of the provisions of this Agreement shall be for the benefit of, or enforceable by,
any third-party. The agreements herein contained are made for the sole benefit of the parties
hereto and no other person or entity is intended to or shall have any rights or benefits hereunder,
whether as a third party beneficiary or otherwise.

19. COMPUTATION OF TIME. In computing any period of time pursuant to this Agreement, the
day or date of the act, notice, event, or default from which the designated period of time begins
to run will not be included. The last day of the period so computed will be included, unless it is
a Saturday, Sunday, or federal holiday which event the period runs until the end of the next day
which is not a Saturday, Sunday, or federal holiday.

20. PATENT MARKING. Phylos and its AFFILIATES shall mark all PRODUCTS with a legible notice
indicating that the PRODUCTS are covered by claims in a pending patent application or an issued
LICENSED PATENT, as the case may be.

10

 

 TCG:TJR License Agreement between RCT and Phylos; RCT Project No. 060-1710; Koide.

21. NON-USE OF NAMES. Neither Phylos nor its AFFILIATES shall use the name of any inventor,
the INSTITUTION, RCT, or any adaptation of any of them, in any advertising, promotional or sales
literature, without prior written consent obtained from the inventor, the INSTITUTION, or RCT, as
applicable.

     IN WITNESS WHEREOF, the parties hereto have each caused a duly authorized officer to sign this
Agreement to be effective the Effective Date.

	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	Phylos Corporation	 	Research Corporation Technologies, Inc.	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	/s/ illegible
	 	By:
	/s/ Gary M. Munsingner	 	 
	 

	 
	 	 	 	 	 
	 

	President
	 	 	President	 	 
	 
	 	 	 	 	 	 	 	 
	Date: July 1, 1999	 	Date: June 25, 1999	 	 

11

 

 TCG:TJR License Agreement between RCT and Phylos; RCT Project No. 060-1710; Koide.

EXHIBIT A

LICENSED PATENTS

Inventors: Dr. Shohei Koide

Invention: “Artificial Antibody Scaffolding”

RCT Project No. 060-1710

PATENT APPLICATIONS

	 	 	 	 	 
	Countries	 	Serial No. 	 	Filing Date
	United States
	 	096,749	 	June 12, 1998 derived from
Provisional Application filed June 12, 1997
	 
	PCT designating:
	 	US98/12099	 	June 12, 1998
	Australia
	 	 	 	 
	Canada
	 	 	 	 
	Japan
	 	 	 	 
	Austria
	 	 	 	 
	Belgium
	 	 	 	 
	Cyprus
	 	 	 	 
	Denmark
	 	 	 	 
	France
	 	 	 	 
	Finland
	 	 	 	 
	Greece
	 	 	 	 
	Germany
	 	 	 	 
	Italy
	 	 	 	 
	Luxembourg
	 	 	 	 
	Monaco
	 	 	 	 
	Netherlands
	 	 	 	 
	Portugal
	 	 	 	 
	Spain
	 	 	 	 
	Sweden
	 	 	 	 
	Switzerland
	 	 	 	 

12

 

AMENDMENT NO. 1 TO LICENSE AGREEMENT

     Effective January 15, 2003 (the “Amendment Effective Date”), Research Corporation
Technologies, Inc., a Delaware nonprofit corporation with offices at 101 North Wilmot Rd., Suite
600, Tucson, Arizona 85711-3365 (“RCT”), and Phylos, Inc., a Massachusetts corporation, with
offices at 128 Spring Street, Lexington, Massachusetts 02421-7802 (“Licensee”), agree as follows:

ARTICLE I

BACKGROUND

     SECTION 1.1. RCT and Licensee are parties to that certain license agreement made effective
July 1, 1999 (the “Agreement”).

     SECTION 1.2. RCT and Licensee desire to amend the Agreement to reflect the likelihood that
Licensee will enter into arrangements with certain commercial partners to develop and/or
commercialize certain PHYLOS PRODUCTS (as defined below).

     SECTION 1.3. Unless otherwise provided for herein, initially- and fully-capitalized terms have
the same Meaning in the Agreement.

ARTICLE II

AMENDMENT

     SECTION 2.1. Article I of the Agreement is amended by adding at the end thereof new Paragraphs
1.17 and 1.18 which read in their entirety as follows:

     1.17. “ADNEXUS PRODUCT” means a DIAGNOSTIC PRODUCT or PHARMACEUTICAL PRODUCT wherein
the LICENSED MONOBODY comprising that PRODUCT has been identified, isolated or discovered
through the use of ADNEXUS TECHNOLOGY .”

     1.18. “ADNEXUS TECHNOLOGY” means the [**] molecules are generated with a [**] and
wherein peptides or proteins having a desired binding affinity are [**]. The ADNEXUS
TECHNOLOGY, including a description of [**], is described and [**].”

     SECTION 2.2. Paragraph 3.3 of the Agreement is amended by deleting it in its entirety and
replacing it with the following:

     3.3. Licensee may enter into arrangements with a commercial partner, not an
AFFILIATE, to develop and/or commercialize PHYLOS PRODUCTS (a “Qualified
Licensee Prospect”). In connection with that development and/or
commercialization effort, Licensee may desire that the Qualified Licensee
Prospect have the right to research, develop, make, market and SELL PHYLOS
PRODUCTS. From time to time, Licensee may provide to RCT a written request that
RCT grant a license under the LICENSED PATENTS to a Qualified Licensee Prospect. Promptly
after receiving such written request, RCT shall offer to the Qualified Licensee Prospect identified in
Licensee’s written notice a license under the LICENSED PATENTS to research, develop, make,
USE, SELL, offer to SELL and import PHYLOS PRODUCTS at the [**] and the other terms of which
will be substantially in the form of Exhibit B to this Agreement. [**]. For the avoidance of
doubt, [**]. For purposes of clarity, a Qualified Licensee Prospect is a RELATED PARTY of
Licensee under this Agreement.”

     SECTION 2.3. Article 10 of the Agreement is hereby amended by changing the first line thereof
to read as follows:

     This Agreement (and any exhibits attached to this Agreement), as amended by that
certain Amendment No. 1 made effective January 15,2003, constitute the entire agreement
between the parties as to the subject matter of such documents.

 

 

     SECTION 2.4. Exhibit B, in the form attached hereto, shall be attached to, and become a part
of, the Agreement as Exhibit B thereto.

     SECTION 2.5. Except as expressly set forth in this Amendment, all terms and conditions of the
Agreement remain unchanged and in full force and effect. The Agreement, as amended by this
Amendment, is hereby ratified and confirmed.

     SECTION 2.6. This Amendment shall be governed and construed according to the laws of the
United States of America, and the internal laws of the State of Arizona.

     SECTION 2.7. This Amendment may be executed in two or more counterparts, each of which shall
be considered an original, but all of which together shall constitute the same instrument.

     IN WITNESS WHEREOF, the parties hereto have each caused a duly authorized officer to sign this
Amendment as of the Amendment Effective Date.

	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	ADNEXUS THERAPEUTICS, INC.	 	RESEARCH CORPORATION TECHNOLOGIES, Inc.	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	/s/ Gustav Christensen
	 	By:
	/s/ Gary M. Munsingner	 	 
	 

	 
	 	 	 	 	 
	Name and
Title: Gustav Christensen

                             Chief Executive Officer	 	Name and Title: Gary M.
 Munsingner

                             President	 	 
	 
	 	 	 	 	 	 	 	 
	Date:

	 January 8, 2003
	 	Date:
	 January 14, 2003	 	 

 

 

EXHIBIT B

LICENSE AGREEMENT

     Effective
___ (the “Effective Date”), Research Corporation Technologies, Inc. (“RCT”), a
Delaware nonprofit corporation with offices at 101 North Wilmot, Suite 600, Tucson, Arizona,
85711-3365, and , ___, a ___ corporation with
offices at ___ a
(“Licensee”), agree as follows (fully capitalized terms as used in this Agreement are defined in
ARTICLE 1):

BACKGROUND

     A. RCT and Phylos, Inc. (“Phylos”) are parties to that certain license agreement made
effective July 1, 1999, and amended effective ___(the “Phylos License”), pursuant to
which Phylos obtained a non-exclusive license under the LICENSED PATENTS.

     B. Phylos and Licensee are parties to that certain agreement made effective ___,
concerning the research, development, marketing and commercialization of PHYLOS PRODUCTS.

     C. Under Paragraph 3.3 of the Phylos License, if Phylos and a third party to the Phylos
License have developed a PHYLOS PRODUCT, Phylos may request, in writing, that RCT offer to the
third party a license in the form of that specified in the Phylos License.

     D. Pursuant to Paragraph 3.3 of the Phylos License, Phylos has requested RCT to offer a
license to Licensee. Licensee desires to obtain from RCT, and RCT desires to grant to Licensee, a
limited, non-exclusive license under the LICENSED PATENTS to the extent contained in this
Agreement.

1. DEFINITIONS.

     1.1. “AFFILIATE” means any entity which directly or indirectly controls, is controlled by, or
is under common control with, a party to this Agreement. “Control” shall constitute the right to
cast, or the right to direct the casting of, at least 50% of the votes at a meeting of such owners,
or at a meeting of the entity’s directors or governing body, or the right to designate a majority
of the entity’s directors or members of the entity’s governing body, or the power to direct or
cause the direction of the management or policies of an entity, whether through the ownership of
voting securities, by contract, or otherwise.

     1.2. “CALENDAR QUARTER” means any period of three (3) consecutive months beginning with
January 1, April 1, July 1, or October 1 of each calendar year.

     1.3. “DIAGNOSTIC PRODUCT” means a LICENSED MONOBODY that is intended for USE in: (a) the
diagnosis or monitoring of a disease condition; (b) the determination of the susceptibility of a
patient to a disease or physiological condition; or (c) the determination of protein profiles of
cells from biological sources;.

     1.4. “INSTITUTION” means the University of Rochester.

     1.5. “LICENSED MONOBODY” means a peptide or protein configuration: (a) the manufacture, USE,
or SALE of which infringes, or induces or contributes to the infringement of, a PATENT CLAIM; and
(b) that has been identified, isolated or discovered through the use of the PHYLOS TECHNOLOGY.

     1.6. “LICENSED PATENTS” means:

     (a) the patents and patent applications identified in EXHIBIT A attached to this
Agreement;

     (b) all divisional or continuation, in whole or in part, applications based on any of
the foregoing;

     (c) any and all foreign applications corresponding to the patent applications
described in (a) and (b) above;

 

 

     (d) any and all issued and unexpired patents resulting from any of the applications
described in Paragraph (a), (b) or (c) above; and

     (e) any and all issued and unexpired reissues, reexaminations, renewals or extensions
that may be based on any of the patents described in Paragraphs (a) or (d) above.

     1.7. “NET SALES VALUE” of any PHYLOS PRODUCTS means the gross billings for the SALE or
importation thereof less the deductions identified below.

     1.7.1. Determining Gross Billings. If Licensee or its AFFILIATE SELLS an PHYLOS
PRODUCT:

     (a) To a third party that is not a RELATED PARTY, gross billings shall be
Licensee’s or its AFFILIATE’S actual gross billings, as the case may be;

     (b) To a RELATED PARTY for subsequent SALE by such RELATED PARTY, gross
billings shall be such RELATED PARTY’S actual gross billings for such subsequent
SALE, except to the extent the particular circumstances of such SALE are the
subject of Subsection 3.2.4 in which case the provisions of Subsection 3.2.4 shall
govern; and

     (c) To a RELATED PARTY for USE by such RELATED PARTY gross billings shall be
the gross billings that would result from a hypothetical arm’s length SALE to a
third party (that is not a RELATED PARTY) by Licensee or its AFFILIATE, as the case
may be.

     1.7.2. Allowable Deductions. When factually applicable, the following deductions may
be deducted from gross billings as determined above:

     (a) rebates, volume, quantity, trade or cash discounts, allowed and taken, in
amounts customary in the trade;

     (b) sales taxes and/or use taxes and/or duties imposed upon, and with specific
reference to, particular SALE to the extent included in the amount of gross
billings;

     (c) amounts allowed or credited on returns, rejections or recalls, voluntary
or otherwise (not exceeding the original gross billings); and

     (d) charges for freight, freight allowances, and outbound transportation costs
prepaid to the extent included in such gross billings.

     No other allowance or deduction shall be made including without limitation allowances
or deductions for any commissions or sales fees by whatever name known.

     1.8. “PATENT CLAIM” means a valid claim in an unexpired or pending LICENSED PATENT. A PATENT
CLAIM shall be presumed to be valid unless and until it has been held to be invalid by a final
judgment of a court of competent jurisdiction from which no appeal can be or is taken. For the
purposes of this Agreement, and especially for purposes of earned royalty determination and payment
under this Agreement, any claim being presented in a pending patent application shall be deemed to
be the equivalent of a valid claim of an issued, unexpired patent and in consideration of RCT’s
agreement to grant a license under any patent issuing thereon earned royalties shall be payable in
respect thereto as though it were a valid patent claim.

     1.9. “PHARMACEUTICAL PRODUCT” means a LICENSED MONOBODY that is intended for USE in the
treatment or prevention of a disease or condition.

     1.l0. “PHYLOS PRODUCT” means a PHARMACEUTICAL PRODUCT or a DIAGNOSTIC
PRODUCT, or both, as appropriate in the context.

 

 

     1.11. “PHYLOS TECHNOLOGY” means the [**] molecules are generated with a [**] and wherein peptides
or proteins having a desired binding affinity are [**]. The Phylos Technology, including a
description of [**], is described and [**].

     1.12. “RELATED PARTY” means any one of Licensee, its AFFILIATES, third parties to this
Agreement to which RCT has granted a license under the LICENSED PATENTS, or any person enjoying a
special course of dealing with Licensee or its AFFILIATES. By way of example but not limitation, a
“special course of dealing” includes co-marketing arrangements between Licensee and a third party
wherein the third party may SELL products, arrangements under which a third party will SELL
products under a private labeling arrangement with Licensee, distribution arrangements with third
parties in which Licensee or its AFFILIATE shares, directly or indirectly, in the proceeds from
such distributor’s SALES of an PHYLOS PRODUCT, or barter arrangements in which Licensee exchanges
products for other products in kind. A distributor (other than an AFFILIATE) of Licensee’s product
under Licensee’s name or mark shall not be considered a RELATED PARTY if Licensee (or its
AFFILIATE) does not share, either directly or indirectly, in the proceeds from such distributor’s
sales of Licensee’s product.

     1.13. “SALE” (and any cognate noun form and cognate conjugated verb form thereof) shall mean
to sell, or otherwise part with or dispose of, for value.

     1.14. “USE” (and any cognate noun form and cognate conjugated verb form thereof) shall mean to
use for commercial purposes.

2. GRANT OF LICENSES

     2.1. RCT hereby grants to Licensee a non-exclusive license under the LICENSED PATENTS to make
PHYLOS PRODUCTS, to have PHYLOS PRODUCTS made, to USE LICENSED MONOBODIES in the research and
development of PHYLOS PRODUCTS and in the manufacture of PHYLOS PRODUCTS, to SELL PHYLOS PRODUCTS,
to offer to SELL PHYLOS PRODUCTS, and to import PHYLOS PRODUCTS, free from suit by RCT for
infringement of the PATENT CLAIMS in all countries of the world in which RCT has LICENSED PATENTS.
No right or license is granted under this Agreement to Licensee to USE LICENSED MONOBODIES in the
manufacture of products that do not comprise PHYLOS PRODUCTS. Licensee covenants not to USE
LICENSED MONOBODIES in the manufacture of products that do not comprise PHYLOS PRODUCTS. No other
or further license or right is granted or implied under this Agreement. No license or rights are
granted or implied under any patent application or patent not a LICENSED PATENT. Except as
expressly provided in Paragraph 2.2, Licensee shall have no right or power to grant sublicenses
under the LICENSED PATENTS.

     2.2. At such times as Licensee is not in material default under any of its obligations to RCT
under this Agreement, Licensee shall have the right to extend the licenses granted under Paragraph
2.1 to AFFILIATES. Any such extension shall be in writing and shall be accepted in writing by any
such AFFILIATE. All terms and provisions of this Agreement, except this right to extend and the
obligation to make payments under Paragraph 3.3, shall apply to such AFFILIATE to the same extent
as they apply to Licensee. The operations and action of such AFFILIATE under such extension shall
be deemed to be the operations and actions of Licensee under this Agreement and
Licensee shall be responsible for the performance by such AFFILIATE of all of its obligations
hereunder. Licensee shall notify RCT promptly in writing of any such extension. If an AFFILIATE
ceases to be an AFFILIATE, any license extended to such AFFILIATE under this Paragraph 2.2 shall
terminate concurrently with such AFFILIATE’S ceasing to be an AFFILIATE.

3. PAYMENTS

     3.1. Licensee shall pay to RCT a non-refundable and non-creditable license issue fee of $[**]
payable upon the execution and delivery of this Agreement.

     3.2. Licensee shall pay to RCT earned royalties as follows:

 

 

     3.2.1. Licensee shall pay to RCT an earned royalty equal to [**]% of the NET SALES
VALUE of each DIAGNOSTIC PRODUCT made, SOLD, or imported, by or for Licensee or its
AFFILIATES during the term of this Agreement, including any DIAGNOSTIC PRODUCT made or
imported during the term of this Agreement but SOLD after the termination of this
Agreement.

     3.2.2. Licensee shall pay to RCT an earned royalty equal to [**]% of the NET SALES
VALUE of each PHARMACEUTICAL PRODUCT made, SOLD, or imported, by or for Licensee or its
AFFILIATES during the term of this Agreement, including any PHARMACEUTICAL PRODUCT made or
imported during the term of this Agreement but SOLD after the termination of this
Agreement.

     3.2.3. If an PHYLOS PRODUCT may comprise both a DIAGNOSTIC PRODUCT and a
PHARMACEUTICAL PRODUCT, the earned royalty payable thereon shall be the [**] earned royalty
determined under Paragraph 3.2.1 and 3.2.2 above. Only one earned royalty will accrue and
be paid on a given PHYLOS PRODUCT even if the manufacture of such PHYLOS PRODUCT in one
country is covered by the LICENSED PATENTS and the USE, SALE, or importation in another
country is covered by the LICENSED PATENTS.

     3.2.4. If Licensee SELLS PHYLOS PRODUCTS to a third party that has a license under the
LICENSED PATENTS to make, USE, SELL, offer to SELL, or import products under the LICENSED
PATENTS, the earned royalty on such SALE shall accrue and be paid under such third party’s
license so long as such third party licensee pays such earned royalty. If Licensee
purchases PHYLOS PRODUCTS from a third party that has a license to make, SELL, offer to
SELL, or import products under the LICENSED PATENTS, the earned royalty on such SALE shall
accrue and be paid under this license. Only one earned royalty will accrue and be paid on a
given PHYLOS PRODUCT, even if such PHYLOS PRODUCT is SOLD or transferred between RELATED
PARTIES for subsequent USE or RESALE.

     3.2.5. Earned royalty payments for Licensee’s activities in a given CALENDAR QUARTER
during the term of this Agreement are due on or before the date forty-five days after the
end of such CALENDAR QUARTER. The earned royalty payable on a given PHYLOS PRODUCT shall
not become due until such PHYLOS PRODUCT is SOLD.

     3.3. Licensee shall pay to RCT a non-refundable, non-creditable annual license maintenance fee
of $[**]. Licensee shall pay the first maintenance fee on or before February 14, and shall pay
subsequent maintenance fees on or before February 14 of each year thereafter during the term of
this Agreement.

     3.4. All payments due hereunder are expressed in and shall be paid in United States of America
currency, without deduction of exchange, collection or other charges by wire transfer to: RESEARCH
CORPORATION TECHNOLOGIES, INC., Wells Fargo Bank, N.A., Tucson Main Office, 150 N. Stone Ave., P.O.
Box 1871, Tucson, AZ 85702, ABA & Transit No. 121000248, Acct. 4159-527159—RCT CHECKING; or to the
account of RCT at such other bank as RCT may from time to time designate in writing. Licensee shall
pay the cost of any wire transfer fees. If the amount is $100,000 or less, Licensee may elect to
pay by company check, instead of wire transfer, at the address shown in ARTICLE 13.

     3.5. Licensee agrees to take all reasonable and necessary steps to register this Agreement in
any country of the LICENSED PATENTS where such is required to permit the transfer of funds and/or
payment of royalties to RCT hereunder or is otherwise required by the government or law of such
country to effectuate or carry out this Agreement. In no event shall Licensee be relieved of any
obligations under this Agreement because it failed to register this Agreement in any such country.
If Licensee or an AFFILIATE SELLS any PHYLOS PRODUCT for currency other than United States
currency, Licensee shall determine the earned royalty payable for such PHYLOS PRODUCT in such
currency and then convert the earned royalty into its equivalent in United States currency at the
New York foreign exchange selling rate for such currency for the last business day of the calendar
quarter for which payment is made, as published by the Wall Street Journal. If such rate is not so
published, the conversion shall be at the selling rate for such currency for the last business day
of the calendar quarter for which payment is made, as published by a leading New York, New York
bank chosen by Licensee and reasonably acceptable to RCT. If Licensee is late in making any
payment, the applicable exchange rate obtained from the sources described above shall be the
greater of the rate on the date payment was actually made or the rate on the date on which payment
was due.

 

 

     3.6. If Licensee fails to make any payment required under this Agreement on or before the date
ten days after Licensee’s receipt of RCT’s written notice of such failure, Licensee shall pay
interest on such amount at an annual rate equal to the prime rate, as quoted by Wells Fargo Bank,
N.A., plus 3%, which interest shall accrue on the entire, unpaid amount from the date the payment
not timely manner became due until the date such payment is paid in full. The interest shall be
compounded on the last day of each
CALENDAR QUARTER. If such rate exceeds the rate allowable by applicable law, then the highest
rate allowed by law shall apply. Any payments received shall be applied first to any unpaid,
accrued interest and then to the satisfaction of any unpaid principal.

     3.7. Licensee shall bear all taxes and charges which it is required to withhold from royalty
payments made by Licensee to RCT by a government authority other than the United States or a
political or governmental subdivision thereof, and payments hereunder shall be made undiminished by
any such tax or charge. Such taxes and charges shall not include any U.S. maintenance fees for
keeping in force any issued U.S. patent included under the LICENSED PATENTS. Licensee shall
cooperate with and assist RCT in obtaining any exemption from royalty withholding taxes imposed by
any government (or instrumentality) of any country of the LICENSED PATENTS on payments made by
Licensee to RCT. To that end, Licensee shall ensure that all payments made under this Agreement
from Licensee to RCT shall originate in the United States. If an exemption from royalty withholding
taxes is not available, and if Licensee is unable to originate in the United States payments under
this Agreement, the earned royalty rate provided above (and any payments specified above) shall be
increased by an amount such that the amount actually remitted to RCT after Licensee withholds any
such taxes is equal to the above percentage of the NET SALES VALUE of PHYLOS PRODUCTS. If the
earned royalty rate or a payment is grossed up in the foregoing manner, any refund of such taxes
shall be remitted to Licensee. In such event, RCT shall fully cooperate with Licensee in obtaining,
through ordinary administrative procedures, a refund of such taxes withheld and shall promptly
execute and sign such documents reasonably requested by Licensee to obtain such refund through
ordinary administrative procedures, all without out-of-pocket expense to RCT.

4. RECONDS, REPORTS, AND INSPECTION.

     4.1. Licensee shall render to RCT, at the same time as each of the earned royalty payments
referred to in Paragraph 3.2 are made, a written statement providing the following details:

     (a) the unit quantities of DIAGNOSTIC PRODUCTS and PHARMACEUTICAL PRODUCTS, SOLD by
Licensee or its AFFILIATES, separately stated for each such class of LICENSED MONOBODY,
during the CALENDAR QUARTER covered by the report in each country in which such billing
occurred. The statement shall include the identity of each type of DIAGNOSTIC PRODUCT and
PHARMACEUTICAL PRODUCT SOLD;

     (b) the United States dollar value of the billings on such quantities in (a) above;

     (c) the calculation of NET SALES VALUE of the DIAGNOSTIC PRODUCT and PHARMACEUTICAL
PRODUCT SOLD, separately stated for each class of LICENSED MONOBODY, based on the dollar
value determined in

     (b) above including a detailed accounting of any allowed deductions from the invoice
amounts to arrive at the NET SALES VALUE;

     (d) the computation of earned royalties based on the NET SALES VALUE computed under
(c) above;

     (e) the quantities of such PHYLOS PRODUCTS transferred between RELATED PARTIES or USED
by RELATED PARTIES, the computation of earned royalties thereon, and the total royalties so
computed.

     If no earned royalties are due, Licensee shall so report. On or before the date ninety days
after the end of the CALENDAR QUARTER in which this Agreement is terminated Licensee shall provide
to RCT a written report that complies in all respects with this Paragraph along with a payment of
any amounts to be paid in respect thereof.

 

 

     4.2. Licensee shall keep and maintain records in accordance with generally accepted accounting
principles sufficient to enable RCT to determine the monies payable to RCT by Licensee under the
terms of this Agreement and Licensee’s compliance in other respects with this Agreement. Licensee
shall retain such records for five years after the end of the reporting period to which they
pertain. Licensee shall make such records available to inspection and copying by a certified public
accountant appointed by RCT at RCT’s expense and reasonably acceptable by Licensee, at any
reasonable time during normal business hours, but not more often than once per calendar year, to
the extent necessary for RCT to verify the records and payments due under this Agreement. If any
such inspection discloses an underpayment of earned royalties of 7.5% or more of the amount of
earned royalties actually due for any CALENDAR QUARTER, then Licensee shall promptly pay the
reasonable cost of such inspection after Licensee’s receipt of the bill / invoice for such
inspection.

     4.3. RCT shall maintain the reports made pursuant to Paragraph 4.1 and their content, and any
information obtained or copied pursuant to Paragraph 4.2, in confidence, and shall not disclose,
divulge or otherwise communicate such Confidential Information to others, except to its officers,
employees, consultants and agents. RCT may disclose information pertaining to this Agreement to the
INSTITUTION and the inventors of the LICENSED PATENTS pursuant to RCT’s and the INSTITUTION’S
Agreement for Disclosure, Evaluation, and Commercialization. RCT’s obligations of confidentiality
under this Paragraph 4.3 shall not apply to any information that: (a) at the time of receipt by
RCT, was independently known to RCT from a source other than Licensee or its AFFILIATES; or (b) at
the time RCT discloses it to a third party, is generally known to the public through no fault of
RCT; or (c) at the time RCT discloses it to a third party, has been made available to RCT by a
third party having the lawful right to do so without breaching any obligation of confidentiality to
Licensee; or (d) RCT must disclose to preserve or assert its rights under this Agreement.

5. LIMITATION OF LIABILITY. INDEMINIFCATION. INSURANCE.

     5.1. None of RCT, INSTITUTION or any inventor identified on any LICENSED PATENT, shall be
liable for any damages, whether direct or otherwise, arising out of the use by Licensee, its
AFFILIATE or any third party of information, samples or materials supplied hereunder, or product
made under this Agreement and sold by Licensee or its AFFILIATE. None of RCT, INSTITUTION, or any
such inventor shall be liable for lost or prospective profits or special or consequential damages,
whether or not any one of them has been advised of the possibility of such damages. None of RCT,
INSTITUTION, or any such inventor shall be liable for any claim by a third party against Licensee
except to the extent any such claim is attributable to the gross negligence or willful misconduct
on the part of RCT, INSTITUTION, or such inventor, as the case may be, although those of RCT,
INSTITUTION or such inventor not guilty of such gross negligence or willful misconduct shall not be
subject to this exception and shall continue to benefit from such exclusion of liability.

     5.2. None of RCT, INSTITUTION or any inventor identified on any LICENSED PATENT: (a) shall
have the right to control or will control the manner in which any product licensed under this
Agreement is made or practiced; (b) has provided any know-how or operating instructions or other
information with respect to any such product; and (c) makes any representation or warranty
whatsoever with respect to any such product. In recognition of the foregoing, Licensee agrees to
indemnify and hold harmless RCT, INSTITUTION, any inventor identified on any LICENSED PATENT, and
all directors, officers and employees of RCT or INSTITUTION, (collectively, the “Indemnitees”) from
and against any and all third party claims, demands, actions, liabilities, judgments, costs and
expenses of whatever kind, whether based on contract, negligence, strict liability, product
liability, or statutory liability, and without regard to any contributory negligence on the part of
Indemnitees, including, without limitation, attorney’s fees and cost of defense, arising out of or
related in any way to Licensee’s production, USE or SALE of PHYLOS PRODUCTS. RCT shall ensure that
Licensee is promptly notified of any such claims in which it intends to invoke this Paragraph 5.2.
RCT and its employees shall cooperate fully Licensee and its legal representatives in the
investigation and defense of any action, claim or liability covered by this indemnification at no
out-of-pocket expense to RCT and its employees. The foregoing indemnity shall not be available to
RCT, INSTITUTION, or any such inventor to the extent any claim, damage, or liability arises from
gross negligence or willful misconduct of RCT, INSTITUTION or such inventor, as the case may be, in
the manufacture, use, sale, or importation of an PHYLOS PRODUCT, although those of RCT, INSTITUTION, or such inventor not guilty of such acts shall not be subject to this limitation and shall
continue to benefit from such indemnity.

 

 

     5.3. On or before the earlier of the date Licensee begins clinical trials involving the use of
any PHYLOS PRODUCTS, or marketing of any PHYLOS PRODUCT, Licensee shall obtain and, thereafter
throughout the term of this Agreement, and for a period of 15 years after termination of this
Agreement, maintain in force products liability insurance and other insurance coverages typically
carried by entities engaged in Licensee’s business in amounts not less than Two Million U.S.
Dollars (US$2,000,000) per accident or occurrence. Such insurance policies shall name the
Indemnitees as additional insureds as respects this Agreement. Such policies shall provide or be endorsed to
provide that such insurance is primary and any other insurance carried by any of the Indemnitees
shall be excess and not contributing with the insurance required hereunder. The policies shall
contain Cross Liability and/or Severability of Interests provisions so as to not impair the right
of one insured against another insured. The insurance policies shall provide or be endorsed to
provide that written notice by registered mail shall be given to the Indemnitees at least thirty
days before termination, cancellation, or reduction of coverage. The insurance policies required to
be carried by Licensee under this Agreement shall be with companies that are reasonably acceptable
to, and approved by, RCT. Licensee shall furnish RCT and the INSTITUTION with a certificates of
insurance evidencing coverage and, when requested, a copy of such policy. The requirements of this
Paragraph 5.3 shall survive termination of this Agreement.

6. REPRESENTATIONS AND WARRANTIES. Nothing contained in this Agreement shall be construed
as a representation by RCT that the LICENSED PATENTS can be or will be used to prevent the
importation, SALE or USE by a third party of a product in any country of the LICENSED PATENTS where
such product is placed in commerce under circumstances which applicable laws or treaties preclude
the use of the LICENSED PATENTS to prevent such importation, SALE or USE. Nothing contained in this
Agreement shall be construed as a representation or warranty: (a) as to the scope or validity of
any patent or patent application in the LICENSED PATENTS; or (b) that any performance, or practice
under any patent or patent application in the LICENSED PATENTS is not an infringement of any patent
of others. RCT warrants that it is the owner of the LICENSED PATENTS and that it has the right to
grant the licenses granted under Paragraph 2.1 hereof. Each party represents and warrants to the
other that this Agreement constitutes a valid and binding agreement of the representing and
warranting party, that execution, delivery and performance of this Agreement by the representing
and warranting party are within such party’s corporate power, have been duly authorized by all
necessary corporate action, and that it shall exercise its good faith in performing under this
Agreement. Neither Licensee nor RCT makes any other warranties, express or implied.

7. FORCE MAJEURE. No failure or omission by any party in the performance of any obligation
of this Agreement (except payments hereunder) shall be deemed a breach of this Agreement nor create
any liability if the same shall arise from any cause or causes beyond the control of the party in
question, as the case may be, including, but not restricted to, the following, which, for the
purpose of this Agreement, shall be regarded as beyond the control of the party in question: acts
of God; acts or omissions of any government or any agency thereof; compliance with any governmental
authority or any officer, department, agency or instrumentality thereof; fire; storm; flood;
earthquake; accident; acts of the public enemy; war, declared or undeclared; rebellion;
insurrection; riot; sabotage; invasion; quarantine restrictions; strike; lockout; disputes or
differences with workmen; transportation embargoes or delays in transportation.

8. TERM AND TERMINATION

     8.1. Unless earlier terminated as hereinafter provided, this Agreement shall automatically
expire in each country on the date on which the last to expire of the LICENSED PATENTS that
Licensee is practicing under expires. Licensee may terminate this Agreement at any time by giving
RCT three months’ written notice of Licensee’s election to terminate.

     8.2. If a party defaults under any of the terms, covenants or provisions of this Agreement,
such party shall have thirty days after the giving of written notice of such default within which
to correct such default. If such default is not corrected within such thirty day period, the other
party shall have the right, at its option, and in addition to any other remedy available at law or
equity, to cancel and terminate this entire Agreement and the licenses granted hereunder, including
the licenses extended to AFFILIATES.

     8.3. Termination of this Agreement shall not constitute a termination or a waiver of any
rights of any party against any other party accruing at or prior to the time of such termination.
Without limiting the generality of the foregoing, Licensee’s obligations to pay any amount payable
to RCT under this Agreement, and to report and pay

 

 

royalties to RCT as to any PHYLOS PRODUCT or
LICENSED MONOBODY made before termination of this Agreement or expiration of the pertinent LICENSED
PATENTS (even if such PHYLOS PRODUCT or LICENSED MONOBODY is SOLD or imported after the termination
of this Agreement or expiration of the pertinent LICENSED PATENTS), shall survive such termination
or expiration. In addition to any provision of this Agreement that expressly provides for acts or
obligations to continue beyond the termination of this Agreement, the provisions of ARTICLES 4
(“Reports, Records and Inspection”), 5 (“Limitation of Liability; Indemnity”), 6 (“Representations
and Warranties”), and 12 (“Validity”) and this Paragraph 8.3 shall survive the termination of this
Agreement.

9. INTEGRATION. WAIVERS. This Agreement, and any exhibits attached to this Agreement,
constitute the entire agreement between the parties as to the subject matter of such documents. All
prior and contemporaneous negotiations, representations, warranties, agreements, statements,
promises, and understandings are superseded and merged into, extinguished by, and completely
expressed by such documents. No party shall be bound by or charged with any written or oral
agreements, representations, warranties, statements, promises, or understandings not specifically
set forth in such documents. A party’s express or implied consent or waiver of the other party’s
breach of its obligations hereunder shall not be deemed to be, or construed as, a consent to, or
waiver of, any other breach of the other party. A party’s failure, no matter how long, to: (a)
complain of any act, or failure to act, by the other party; (b) declare the other party in default;
(c) insist upon the strict performance of any obligation or condition of this Agreement; or (d)
exercise any right or remedy consequent upon a breach thereof; shall not constitute a waiver by
such party of its rights, such breach, or any other obligation or condition. A party’s consent in
any one instance shall not limit or waive the necessity to obtain such party’s consent in any
future instance. No single or partial exercise of any right, power or privilege by a party
hereunder shall preclude any other or further exercise thereof or the exercise of any other right,
power or privilege by such party. In any event, no consent or
waiver shall be effective for any purpose hereunder unless such consent or waiver is in writing and
signed by the party granting such consent or waiver.

10. ASSIGNABILITY. This Agreement and any modification thereof shall be binding upon and
shall inure to the benefit of RCT, its assigns and successors in interest. This Agreement and any
modification thereof shall be binding upon and shall inure to the benefit of Licensee and the
successor to its entire business and good will, but shall not otherwise be assigned by Licensee
without prior approval by RCT being first obtained in writing, which approval will not be
unreasonably withheld.

11. LAW. This Agreement shall be governed by and construed according to the laws of the United
States of America, and the internal laws of the state of Arizona, United States of America. The
parties shall make all reasonable efforts to resolve any dispute concerning this Agreement, its
construction, or its actual or alleged breach, by face-to-face negotiations between senior
executives. Should such negotiation fail to resolve the matter, either party may bring judicial
proceedings to resolve the matter in any state or federal court of competent jurisdiction sitting
in the State of Arizona, Pima County. By executing and delivering this Agreement, each party, for
itself and in respect of its property, irrevocably consents and submits to the exclusive
jurisdiction and venue of such courts in any such proceeding and otherwise waives any objection or
defense, including any objection or defense based on forum non conveniens or improper venue, which
it may now or hereafter have to the bringing of any such proceedings in such courts. Each party
further agrees that service of process of notice in any such proceeding shall be effective if in
writing and sent in the manner provided in ARTICLE 13 of this Agreement, or in any other manner
permitted by Arizona law.

12. VALIDITY. Nothing in this Agreement shall be construed to require the commission of any
act contrary to law. If any of the provisions of this Agreement are held to be invalid or
unenforceable, the parties will attempt to replace them with new provisions which have the same
force and effect and the remaining provisions shall not be affected. The parties agree that each
party has reviewed this Agreement and that any rule of construction to the effect that ambiguities
are to be resolved against the drafting party shall not apply to the interpretation of this
Agreement.

13. ADDRESSES. All notices, requests, reports and other communications provided in this
Agreement shall be in writing and shall be deemed to have been made or given: (a) when delivered,
if delivered by hand or sent by facsimile or the like; (b) on the day following deposit with an
overnight courier; or (c) on the date three days following deposit with the United States Mail,
certified or registered:

 

 

If to RCT:

President

Research Corporation Technologies, Inc.

101 N. Wilmot Rd., Suite 600

Tucson, AZ 85711-3365

Fax: 520-748-0025

If to Licensee:

                                        

Fax:                                         

Such addresses may be altered by notice so given. If no time limit is specified for a notice
required or permitted to be given by this Agreement, the time limit therefor shall be three full
business days, not including the day of mailing.

14. INFRINGEMENT AND PATENT PROSECUTION.

     14.1. RCT will protect the LICENSED PATENTS from infringement and prosecute alleged infringers
when, in its sole judgment, such action may be necessary, proper, and justified. Licensee shall
fully cooperate with RCT, as RCT may request, in connection with any such action, at no
out-of-pocket expense to Licensee.

     14.2. At its sole cost and expense, RCT shall maintain and prosecute the LICENSED PATENTS. RCT
does not represent or warrant to Licensee that any patent will issue or be granted based on any
LICENSED PATENT. RCT may, in its sole discretion, abandon any LICENSED PATENT. Should RCT assign
any LICENSED PATENT to the INSTITUTION or any other third party, such assignment shall be subject
to the rights and licenses granted hereunder which shall continue unaffected by any such
assignment. Licensee shall cooperate with RCT in the prosecution of any LICENSED PATENT, and in
RCT’s efforts in seeking any available extension of the term of any LICENSED PATENT at no
out-of-pocket expense to Licensee. To that end, Licensee shall provide RCT with any data,
experimental materials, research or test results in Licensee’s possession or control and that RCT
may reasonably request for its patent prosecution or patent term extension efforts in connection
with the LICENSED PATENTS. In addition, Licensee shall cooperate with RCT, and shall cause its
employees to cooperate reasonably with RCT, in the preparation of any declarations or affidavits
that are to be signed by Licensee or employees of Licensee. RCT agrees to take commercially
reasonable actions to ensure that such any agencies or regulatory bodies to which RCT discloses
such information, materials or samples shall treat the same as confidential.

15. INDEPENDENT CONTRACTOR. In its performance under this Agreement, each party shall be an
independent contractor and neither party (nor its employee or agent) shall be an agent or partner
of the other party.

16. HEADINGS. The headings of the various Paragraph of this Agreement are used solely for
the convenience of the parties, do not form a part of this Agreement, do not affect the
interpretation or meaning of this Agreement, and do not define, limit, extend, or describe its
scope or intent.

17. NO THIRD PARTY BENEFICIARIES. Except for Paragraphs 5.1, 5.2, and 5.3, which shall
also be for the benefit of, and enforceable by, the INSTITUTION and the
inventor of the LICENSED PATENTS, none of the provisions of this Agreement shall be for the benefit
of, or enforceable by, any third-party. The agreements herein contained are made for the sole
benefit of the parties hereto and no other person or entity is intended to or shall have any rights
or benefits hereunder, whether as a third party beneficiary or otherwise.

18. COMPUTATION OF TIME. In computing any period of time pursuant to this Agreement, the
day or date of the act, notice, event, or default from which the designated period of time begins
to run will not be included. The last day of the period so computed will be included, unless it is
a Saturday, Sunday, or national holiday in the country of either party in which event the period
runs until the end of the next day which is not a Saturday, Sunday, or national holiday in the
country of either party.

19. PATENT MARKING. Licensee and its AFFILIATES shall mark all PHYLOS PRODUCTS with a
legible notice indicating that the PHYLOS PRODUCTS are covered by claims in a pending patent
application or an issued LICENSED PATENT, as the case may be, whenever such marking is not
prohibited by applicable law.

 

 

20. NON-USE OF NAMES. Neither Licensee nor its AFFILIATES shall use the name of any
inventor, the INSTITUTION, RCT, or any adaptation of any of them, in any advertising, promotional
or sales literature, without prior written consent obtained from the inventor, the INSTITUTION, or
RCT, as applicable. Nonetheless, either party hereto may publicly announce or disclose the fact of
the parties’ entering into a non-exclusive license under this Agreement but may not publicly
announce or disclose any other terms of this Agreement.

IN WITNESS WHEREOF, the parties hereto have each caused a duly authorized officer to sign this
Agreement to be effective the Effective Date.

	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	[Licensee]	 	Research Corporation Technologies, Inc.	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	 	By:	 	 	 
	 

	 
	 	 	 	 	 
	Name and Title:	 	Name and Title:	 	 
	 
	 	 	 	 	 	 	 	 
	Date:

	 	 	 	Date:	 	 	 	 
	 

	 
	 	 	 	 	 

 

 

EXHIBIT A

LICENSED PATENTS

Inventors: Dr. Shohei Koide

Invention: “Artificial Antibody Scaffolding”

RCT Project No. 060-1710

PATENT APPLICATIONS

	 	 	 	 	 
	Countries	 	Serial No.	 	Filing Date
	United States
	 	096,749	 	June 12, 1998 derived from
Provisional Application
	 
	 	 	 	 60/049,410 filed June 12, 1997
	United States
	 	638,202	 	August 11,2000
	United States
	 	637,614	 	August 11,2000
	United States
	 	165,555	 	June 6, 2002
	United States
	 	174,717	 	June 18, 2002
	United States
	 	190,162	 	July 3, 2002
	 
	 	 	 	 
	Australia
	 	79596/98	 	June 12, 1998
	 
	 	 	 	 
	Canada
	 	2,293,632	 	June 12, 1998
	Japan
	 	11-503195	 	June 12, 1998
	European
	 	98930131.2	 	June 12, 1998
	Austria
	 	 	 	 
	Belgium
	 	 	 	 
	Denmark
	 	 	 	 
	France
	 	 	 	 
	Germany
	 	 	 	 
	Great Britain
	 	 	 	 
	Ireland
	 	 	 	 
	Italy
	 	 	 	 
	Netherlands
	 	 	 	 
	Spain
	 	 	 	 
	Sweden
	 	 	 	 
	Switzerland
	 	 	 	 

 

 

AMENDMENT NO. 2 TO LICENSE AGREEMENT

BETWEEN ADNEXUS THERAPEUTICS, INC. AND RESEARCH CORPORATION TECHNOLOGY

     THIS AMENDMENT NO. 2 (this “Amendment”), effective as of May 2, 2007 (the “Effective Date”),
is by and between Adnexus Therapeutics, Inc. (“Adnexus”) of 100 Beaver Street, Suite 300, Waltham,
MA 02453, and Research Corporation Technologies Inc. (“RCT”) of 101 North Wilmot Road, Suite 600,
Tucson, AZ 85711-3365.

     WHEREAS, Phylos, Inc. (“Phylos”) and RCT entered into a License Agreement effective July 1,
1999, as amended by Amendment No. 1 to the License Agreement, dated January 15, 2003 (as amended,
the “License Agreement”);

     WHEREAS, Adnexus, formerly known as Compound Therapeutics, Inc., became on December 16, 2003
the successor in interest to Phylos under the License Agreement; and

     WHEREAS, the parties desire to amend the License Agreement to replace all references to Phylos
with Adnexus.

     NOW, THEREFORE, in consideration of the mutual covenants contained in the License Agreement
and in this Amendment and other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties hereto agree as follows:

1. Section 14 of the License Agreement (“ADDRESSES”) is amended by replacing the section
beginning “If to Phylos” with the following:

If to Adnexus:

Adnexus Therapeutics, Inc.

100 Beaver Street

Waltham, MA 02421

Fax: 781-209-2302

Attn: Vice President, Business Development

2. The License Agreement (including the Exhibits thereto) is hereby amended by replacing
all references to “Phylos”, whether a capitalized term or not, with “Adnexus” or “ADNEXUS”,
as appropriate (save for any signature blocks). In addition, the preambles to the original
License Agreement and Amendment No. 1 thereto are hereby amended by replacing “Phylos,
Inc., a Massachusetts Corporation, with offices at 128 Spring Street, Lexington, MA
02421-7802” with “Adnexus Therapeutics, a Delaware corporation, with offices at 100 Beaver
Skeet, Waltham , MA 02453”.

3. This Amendment will act to amend the License Agreement, which License Agreement will
otherwise remain in full force and effect. This Amendment will be governed by and
construed according to the laws of the United States of America, and the internal laws of
the state of Arizona, United States of America.

1

 

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their duly
authorized representatives.

	 	 	 	 	 
	 

	 	 	 	 
	ADNEXUS THERAPEUTICS, INC.
	 
	 	 	 	 
	By

	 	/s/ Katrine Bosley	 	 
	 

	 	 	 
	Print Name:

	 	Katrine Bosley	 	 
	Title

	 	VP
Business Development	 	 
	 

	 	 	 	 
	 

	 	duly
authorized
	 	 
	 
	 	 	 	 
	RESEARCH CORPORATION TECHNOLOGIES, INC.
	 
	 	 	 	 
	By

	 	/s/ Shaun A. Kirkpatrick	 
	 

	 	 	 
	Print Name

	 	Shaun A. Kirkpatrick	 	 
	Title

	 	President and CEO	 	 
	 

	 	 	 	 
	 

	 	duly authorized	 	 

 

 

	 	 	 
	

	 	SHAUN A. KIRKPATRICK

President and Chief Executive Officer

101 North Wilmot Road.
Suite 600 Tucson,

Arizona 85711-3365

Phone: (520) 748-4400

Direct: (520) 748-4446

Fax: (520) 748-0208

NOTICE OF ASSIGNMENT

May 31,
2007

By Fax: 781-209-2302

Ms. Katrine Bosley

Vice President, Business Development

Adnexus Therapeutics, Inc.

100 Beaver Street

Waltham, MA 02421

	 	 	 
	Re:

	 	Notice of Assignment of RCT License Agreement
	 

	 	RCT Project No. 060-1710
	 

	 	Artificial Antibody Scaffolding

Dear Ms. Bosley:

Research Corporation Technologies, Inc. (“RCT”) and Adnexus Therapeutics, Inc (“Adnexus”) are
parties to a non-exclusive license agreement made effective as of July 1, 1999, as amended on
January 15, 2003 and May 2, 2007 (the “License Agreement”).

This letter serves as notice to Adnexus that RCT has assigned the License Agreement in its
entirety to Novartis International Pharmaceutical Ltd. (“Novartis”) as of May 29, 2007. As of
that date, RCT has also assigned to Novartis the patent rights that are the subject of the
License Agreement.

Please note that RCT and Novartis are treating both the assignment of the License Agreement
and the patent rights thereunder as strictly confidential. Accordingly, we request that
Adnexus also treat the assignments as confidential information.

Unless notified otherwise by Novartis, Adnexus should send all future reports,
payments, notifications and communications under the License Agreement to:

e-mail: skirkpatrick@rctech.com

http://www.rctech.com

 

 

Page 2
— Letter to Ms. Katrine Bosley — Adnexus Therapeutics, Inc.
 Notice of Assignment of RCT License Agreement

General Counsel

Novartis International Pharmaceutical Ltd.

Hurst Holme

12 Trott Road

Hamilton, HM11

Bermuda

(FAX 441-296-5083)

RCT appreciates the effort Adnexus has made to develop commercial products under the License
Agreement.

Sincerely yours,

	 	 	 
	/s/
Shaun A. Kirkpatrick
 

Shaun A. Kirkpatrick

	 	 
	President & CEO
	 	 

	 	 	 
	C:

	 	Mr. J. Mendlein, President, Adnexus Therapeutics, Inc.
	 

	 	Mr. Jim Moffett
	 

	 	Dr. David Wiersma
	 

	 	Ms. Kieran Fasse

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]